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Chikungunya virus (CHIKV) is a re-emerging arbovirus known to cause chronic myalgia and 
arthralgia with high morbidity and mortality rates.  Responsible for recent epidemics, CHIKV 
is now considered endemic in countries across Asia and Africa.  The tissue tropism of CHIKV 
infection in humans remains, however, ill-defined.  In this study, susceptibilities of various 
cell lines to CHIKV infection were established, and were found to be cell-type and virus-
strain specific.  Furthermore, human skeletal muscle myoblasts (HSMM) were developed as a 
novel human primary cell line that is highly permissive to CHIKV infection, with maximal 
amounts of infectious virions observed at 16 hours post infection.  An siRNA-based library 
screening of host membrane trafficking genes subsequently revealed CHIKV infectious entry 
primarily via macropinocytosis.  Finally, genome-wide microarray profiling analyses were 
performed to identify and map genes that are differentially expressed upon CHIKV infection.  
Infection of HSMM cells with CHIKV resulted in altered expressions of host genes involved 
in skeletal- and muscular-associated disorders, innate immune responses, cellular growth and 
death, host metabolism and virus replication.  Altogether, this study paves the way for further 
analysis of these host genes and their involvement in the various stages of CHIKV replication 
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1.1  Introduction 
 
Chikungunya virus (CHIKV) is an arthropod-borne virus most commonly transmitted 
by Aedes (Ae.) mosquitoes.  First isolated in 1952 in Tanzania, CHIKV transmission begins 
with infection of female mosquitoes via a viraemic blood-meal taken from a susceptible 
vertebrate host and subsequent transmission to another vertebrate host (Solignat et al., 2009).  
Since its first reported case, nearly 2000 scientific articles on various aspects of the disease, 
including pathogenesis, vector transmission and host responses, have been published.  
Majority of these publications were produced following the re-emergence of the virus during 
the 2005 outbreak in islands surrounding the Indian Ocean.   
 
With lower rates of asymptomatic cases as compared to other known arboviral 
infections, more infected patients often require medical attention.  CHIKV-infected 
individuals may suffer from persistent polyarthralgia and myalgia, often resulting in 
significant dips in their quality of life.  Despite the disease having impacted millions around 
the world thus far, no licensed vaccine against CHIKV infection has been commercially 
available, although several vaccine studies are currently under progress.  CHIKV treatment 
remains primarily supportive, with key areas of focus being on management of clinical 
symptoms and prevention of vector transmission.  It is therefore imperative to gain a deeper 











1.2  Alphaviral Biology 
 
1.2.1 Viral Taxonomy 
 
 According to the system of classification based on viral genome composition introduced 
by David Baltimore in 1971, alphaviruses belong to Group IV in the Togaviridae family, 
which also includes viruses from the genus Rubivirus (Enserink, 2006; Powers and Logue, 
2007).  Of these alphaviruses, thirty have been found to be able to infect various vertebrates 
such as humans, rodents, fish, birds and larger mammals such as horses, as well as 
invertebrates.  Three subgroups exist within the Alphavirus genus: the Semliki Forest virus 
(SFV) subgroup, the eastern equine encephalitis virus (EEEV) subgroup and the Sindbis virus 
(SINV) subgroup.  Interestingly, although SINV is known to be geographically restricted to 
the Old World, it is more closely related to the New World-based EEEV subgroup, than it is 
to the SFV subgroup which is also found in the Old World. 
 
 Alphaviruses can yet be antigenically classified within seven different complexes, 
namely: Barmah Forest virus, EEEV, Middelburg virus, Ndumu virus, SFV, Venezuelan 
equine encephalitis virus (VEEV) and Western equine encephalitis virus (WEEV) complexes.  
While SINV is categorised within the WEEV complex, CHIKV along with other well-known 
alphaviruses such as Ross River virus (RRV) and O’Nyong Nyong virus (ONV) is grouped 









1.2.2 Structure & Genetics 
  
 Sensitive to desiccation and temperatures above 58
o
C, CHIKV virions possess a core of 
linear, single-stranded, positive-sense RNA genome of approximately 11.8kb in size, with 
two open reading frames (ORFs) (Khan et al., 2002) (Figure 1.1).  Characteristic of 
alphavirus morphology, electron microscopy analysis of CHIKV revealed an icosahedral-like 
nucleocapsid of about 60-70nm in diameter surrounded by a phospholipid bilayer envelope, 
derived from the plasma membrane of the host cell.  While the structural genes are collinear 
with the 3’ one-third of the genome, the four non-structural proteins – nSPs 1-4, required for 
viral replication – are encoded in the 5’ remaining two-thirds.   
 
 
Figure 1.1 Genomic Structure of CHIKV 
(adapted from Khan et al., 2002) 
 
 The structural proteins are produced by translation of an mRNA that is generated from 
an internal, subgenomic promoter immediately downstream of the non-structural open reading 
frame (Jose et al., 2009).  The polyprotein generated is then processed to produce a capsid 
protein (C) of about 30kDa, two major envelope surface glycoproteins, E1 and E2; as well as 
two small peptides, E3 and 6K (Simizu et al., 1984; Voss et al., 2010).  Responsible for 
membrane fusion and virus attachment, respectively, E1 and E2 proteins each have a 
molecular mass of approximately 50kDa and are anchored in the membrane by conventional 





membrane-spanning anchors located in their C-terminal regions.  The 5’ end of the 
encapsidated genome has a 7-methylguanosine cap, while the 3’ terminal is polyadenylated.    
  
 
1.3  Replication Cycle of Alphaviruses 
 
 The replication cycle of CHIKV is essentially similar to that of other alphaviruses 
(Solignat et al., 2009) (Figure 1.2).  The non-structural proteins (nSP1–4) and their cleavage 
intermediates are involved in RNA replication – which takes place in the cytoplasm with 
close association to the Golgi apparatus - while the five structural proteins (C, E3, E2, 6k, E1) 
and their cleavage intermediates are required for viral encapsidation and assembly (Fros et al., 
2010; Leung et al., 2011).   
 
 
Figure 1.2 Replication Cycle of CHIKV 
(adapted from Leung et al., 2011) 





1.3.1 Viral Attachment 
 
 CHIKV replication is initiated by the attachment of the viral envelope to host cell 
receptors, followed by clathrin-mediated endocytosis of the attached particle, low pH-
mediated membrane fusion and delivery of the viral nucleocapsid into the cytoplasm.  As 
shown in Figure 1.2, entry into target cells is mediated by interaction of the spike E2 
component with protein receptors on the cell surface.  A 67kDa laminin receptor was 
identified as a high-affinity attachment receptor for Sindbis virus (SINV) infection in 
mammalian cells (Wang et al., 1992).  More recently, lectin molecules such as DC-SIGN and 
L-SIGN (Klimstra et al., 2003), as well as heparan sulphate (Byrnes and Griffin, 1998), were 
also shown to function as receptor molecules for SINV.  To date, no CHIKV interacting 
protein has been characterised, but in a very recent study, prohibitin was identified as a 
CHIKV-binding protein expressed by microglial cells (Wintachai et al., 2012). 
 
 Virus fusion with the cell membrane is mediated by the E1 glycoprotein, a class II 
fusion protein.  Cholesterol is essential for several infective events of the alphaviral 
replication cycle, including cell membrane fusion and budding (Solignat et al., 2009).  The 
acidic conditions within the membrane induce a conformational change in the virus envelope 
proteins, resulting in the dissociation of the E2–E1 heterodimers and subsequent E1 
homotrimeric formation.  Following post-translational modifications in the endoplasmic 
reticulum and Golgi apparatus, they are transported to the plasma membrane, where they form 









1.3.2 Infectious Entry 
 
Alphaviral entry has been widely documented to be dependent on clathrin-mediated 
endocytosis and fusion with endosomal membranes.  Nevertheless, the ability of alphaviruses 
to enter host cells via alternative mechanisms has also been reported.  An early study on 
SINV entry showed the translation of viral RNA in the cytosol of cells even upon treatment 
with chloroquine and ammonium chloride, suggesting infection involving acidic endosomes is 
not required (Cassell et al., 1984).  More recently, the infection of various cell lines by SINV 
was shown to progress in the absence of low pH-induced endocytosis, indicative of clathrin-
independent entry (Hernandez et al., 2001; Paredes et al., 2004).  Similarly, Marsh and Bron 
(1997) documented the ability of SFV in infecting BHK efficiently following fusion in either 
endosomes or at the plasma membrane, while Hase and colleagues (1989) determined that 
SFV could be found inside non-coated pits and vesicles.  
 
Indeed, upon siRNA knockdown of clathrin heavy chain, CHIKV infection of both 
HEK293 and HeLa cells was found to be unaffected (Bernard et al., 2010).  Mutants of Eps15 
and Rab5, and endocytic inhibitors only resulted in partial block in CHIKV infection, 
supporting the hypothesis that several pathways are hijacked by CHIKV to penetrate into 
target cells (Bernard et al., 2010). 
 
These clathrin-independent pathways could include caveolae-dependent endocytosis, 
macropinocytosis and dynamin-dependent clathrin- and caveolin-independent endocytosis.  
The caveolar/raft pathway transports internalised virus to neutral-pH caveosomes to be sorted, 
before redistribution and delivery of the cargo to smooth endoplasmic reticulum (sER), 
usually through microtubule-directed movements (Pietiainen et al., 2005).  Viruses known to 





commonly utilise this pathway include SV40, enterovirus 1, filoviruses and polyomaviruses 
(Pietiainen et al., 2005).  
 
 Macropinocytosis uses a non-specific mechanism of internalization that does not require 
any ligand receptor binding.  Instead, the process is triggered in response to cell stimulation to 
internalize large amounts of fluids.  Activation of macropinocytosis occurs when the virus 
binds to a co-receptor, which would result in signal transduction to host cells via cellular 
proteins such as phosphatidylinositol 3-kinase (PI3K), protein kinase C and the Rho GTPase 
Rac1.  Dependent on actin polymerisation, macropinosomes are then formed by closure of 
lamellipodia or membrane ruffles (Marsh and Helenius, 2006). Viruses known to enter via 
this pathway include vaccinia virus (Mercer and Helenius, 2008) and adenovirus 2 (Meier et 
al., 2002). 
 
1.3.3 Viral Genome Replication 
 
Steps in the CHIKV replication cycle have primarily been deduced from data obtained 
with other alphaviruses and strengthened by sequence comparison analyses, indicating that 
amino acid sequences expected to play a major functional role for a typical alphavirus model 
can be found in the corresponding CHIKV protein. 
 
Shortly after infection, negative- and positive-sense RNAs are both transcribed, 
encoding for an open reading frame (ORF) of 7424 nucleotides, which in turn encodes for an 
nsP123 polyprotein precursor of 2474 amino acids.  Individual nsPs would later be produced 
from the polyprotein precursor upon proteolytic cleavage.  Following synthesis and 
maturation, the nsP123 precursor would then complex with the free nsP4 protein and host cell 





proteins to act as a negative-sense RNA replicase catalysing the synthesis of negative-sense 
RNA (Barton et al., 1991).   
 
Together with nsP4, nsP1 catalyses the initiation of the negative-sense RNA synthesis, 
as well as the methylation and capping of the positive-sense RNA (Mi et al., 1989).  An RNA 
replicase, the nsP3 protein facilitates in the transcription of negative strands early in infection 
(Wang et al., 1994).  The RNA-binding capacity of nsP3 also assists in the efficient 
recruitment and synthesis of RNA, and viral pathogenicity (Vihinen et al., 2001). 
 
The fully-cleaved precursor and host cell proteins act as a positive-sense RNA replicase 
to amplify the full-length subgenomic (26S) positive-sense mRNA, with the negative-sense 
RNA as a template (Shirako and Strauss, 1994) and regulated by nsP2.  The nsP2 protein 
functions as a proteinase and helicase, playing a pivotal role in the viral replication process by 
catalysing the cleavage of the precursor polypeptide to yield mature nsP proteins.  
 
The subgenomic positive-sense mRNA of CHIKV (26S) serves as the mRNA for the 
synthesis of the viral structural proteins.  The ORF encoding for the structural proteins is 
composed of 3735 nucleotides and encodes a polyprotein of 1244 residues from which the 
individual structural proteins are formed.  This precursor is processed co-translationally and 
post-translationally into structural proteins C, PE2 and E1, and a small peptide termed 6K, 
which acts as a signal sequence for the translocation of E1.  The cleavage between PE2 and 
6K, catalysed by signalase in the lumen of the endoplasmic reticulum (ER), subsequently 
gives rise to a 6K protein of 61 amino acids long (Strauss and Strauss, 1994). 
 
 





1.3.4 Viral Assembly, Maturation and Release 
 
 To date, the final stages of the CHIKV replication cycle have not been investigated, 
with most assumptions from other alphavirus models remain to be tested.  Virion assembly 
begins with the assembly of the nucleocapsid – consisting of encapsidated viral RNA - in the 
cytoplasm.  The nucleocapsid is characterised by an icosahedral symmetry and is known to 
contain a putative coiled-coil α-helix, essential for core assembly (Perera et al., 2001).  
Nucleocapsid complexes assembled in the cell cytoplasm are thought to diffuse freely to the 
plasma membrane. 
 
As with other alphaviruses, CHIKV buds through the cell membrane.  The cytoplasmic 
nucleocapsids are trafficked to the host cell membrane prior to virions acquiring a lipid 
bilayer envelope containing trimers of the virus-encoded E1 and E2 surface glycoproteins 
(Ekstrom et al., 1994).  The nucleocapsid undergoes a maturation event during the budding 
process, requiring binding to CHIKV E2 structural protein for appropriate targeting to the cell 
membrane (Suomalainen et al., 1992).   
 
At least some of the phosphorylations within the nucleocapsid, E1 and E2 glycoproteins 
(Waite et al., 1974; Liu et al., 1996) are thought to play a role in the assembly and/or post-
assembly steps since the use of protein kinase or phosphatase inhibitors interfere with viral 
maturation (Liu and Brown, 1993).  In addition, the function of CHIKV E3 structural protein 
has yet to be extensively studied, although SINV E3 protein was found to be involved in 
proper folding and disulfide bond formation in the formation of the viral envelope 
glycoprotein spike (Parrott et al., 2009). 
 





1.4  Epidemiology of CHIKV Infection 
  
 CHIKV was first isolated from the serum of a febrile patient in 1952, following an 
outbreak from the Makonde Plateau, along the border between Tanzania (formerly 
Tanganyika) and Mozambique (Robinson, 1955).  The term Chikungunya is derived from the 
Makonde root verb “kungunyala”, meaning “that which bends up” or “to dry up and become 
contorted”, in reference to the stooped and contorted posture developed due to 
rheumatological manifestations of the disease (Lumsden, 1955).  Serogical and antigenic 
characterization of the etiological agent collected during the epidemic - which also affected 
Uganda and Zimbabwe in East and Austral Africa (Mason and Haddow, 1957; Weinbren, 
1958; Weinbren et al., 1958) - ruled out the involvement of dengue but attributed to an 
alphavirus closely related to Mayaro and SFV (Powers and Logue, 2007).  Subsequent studies 
have demonstrated it as a new virus which might have existed in East Africa and maintained 
probably in a non-human primate-sylvatic Aedes mosquito transmission cycle (Powers et al., 
2001).  Retrospective studies have suggested that CHIKV epidemics occurred as early as 
1779 but were documented inaccurately as dengue outbreaks, with the earliest records 
documented as early as 1824 in India [Carey, 1971; World Health Organization (WHO) 
Report, 2006; Ng and Hapuarachchi, 2010]. 
 
 Following the 1952 outbreak, the virus has widely disseminated throughout sub-Saharan 
Africa, India and Southeast Asia, leading to numerous epidemics in the subsequent years 
(Edelman et al., 2000). The virus has become endemic in Africa as evidenced by the frequent 
outbreaks in Angola, Ivory Coast, Uganda, Democratic Republic of Congo, Zimbabwe, 
Senegal, Nigeria, South Africa and Kenya (Filipe and Pinto, 1973; Watts et al., 1994; Diallo 
et al., 1999; Powers and Logue, 2007; Kariuki Njenga et al., 2008).  These outbreaks were 





reported to be unpredictable, with an interval of 7-20 years between smaller individual 
epidemics and 4-5 decades between major epidemics (Powers and Logue, 2007).  Possible 
underlying reasons for the unpredictability could include a variety of ecological, genetic and 
immunological factors, such as the long-lasting immune protection acquired upon CHIKV 
infection.  Indeed, the non-immunised young were observed to be the most at-risk group 
during subsequent outbreaks (Powers and Logue, 2007).   
 
 The first outbreak in Asia was reported from Bangkok in 1958 (Sudeep and Parashar, 
2008), with subsequent epidemics documented in Sri Lanka, Myanmar, Laos, Indonesia, the 
Philippines, Cambodia, Vietnam, Hong Kong and Malaysia (Munasinghe et al., 1966; 
Halstead et al., 1969a,b; Sam and Abu Bakar, 2006).  The first epidemic of CHIKV in India 
was reported from Kolkata (formerly Calcutta), West Bengal in 1963, claiming nearly 200 
lives particularly children (Sarkar et al., 1964). 
 
 Since 2003, there have been outbreaks in the islands of the Pacific Ocean, including 
Madagascar, Comoros, Mayotte, the Seychelles, and Mauritius (Sergon et al., 2007).  In 
2005-2006, La Reunion alone saw more than a third of its total population, or approximately 
267,000 individuals debilitated by the disease (Schuffenecker et al., 2006; Gerardin et al., 
2008), demonstrating the massive impact caused by the dispersing virus.  Forty-four cases of 
mother-to-child transmission were also reported (Economopoulou et al., 2009).  The infamy 
of the disease was yet fortified by late 2005, with massive CHIKV outbreaks in India 
affecting approximately 1.3 million individuals (Kalantri et al., 2006; Lahariya and Pradhan, 
2006; Ravi, 2006).  The re-emergence of CHIKV in Sri Lanka was subsequently confirmed in 
November 2006, after four decades of absence.  An estimated 40,000 individuals were 





affected, with a similar number of infections reported later in 2008 (Hapuarachchi et al., 
2008).   
 
 Thousands of imported cases were documented in Western Europe in 2006.  Several 
European countries – including Belgium, the Czech Republic, France, Germany, Norway, 
Spain, Switzerland and the United Kingdom  - (Bodenmann and Genton, 2006; Cordel et al., 
2006; Frank et al., 2011; Krastinova et al., 2006; Hochedez et al., 2006; Parola et al., 2006; 
Veber et al., 2007), the USA (Lanciotti et al., 2007) and Australia (Bonilauri et al., 2008) 
have since witnessed imported infections, raising serious concerns about the potential burden 
of CHIKV infections.  Nevertheless, until 2007, CHIKV had never been known to circulate in 
Europe.  The first indigenous CHIKV outbreak in Europe was documented in Italy in 2007 
(Rezza et al., 2007).  More recently, two cases of autochthonous transmission of CHIKV was 
confirmed in southeastern France in September 2010 (Gould et al., 2010; Grandadam et al., 




Figure 1.3 Geographical Distribution of CHIKV Infections 
(adapted from www.cdc.gov, as of 23 September 2014) 






 The first CHIK case was not reported until 2006 (Leo et al., 2009), with ten imported 
cases subsequently reported to the Ministry of Health in 2007 (Ministry of Health [MOH] 
Singapore, 2008).  Notably, Taiwan reported a case involving a returning student from 
Singapore in November 2006, suggesting the possibility of autochthonous transmission in 
Singapore (Shu et al., 2008).  Singapore then experienced its first indigenous CHIK fever 
outbreak in January 2008 (Leo et al., 2009; Ng et al., 2009).  During the early 2008 outbreak, 
CHIK infection was confirmed for 13 patients (MOH Singapore, 2008).  CHIKV appears to 
have since become endemic in the city-state, with 1059 individuals were diagnosed with the 
disease in 2013, compared with a total of 60 cases in the three years between 2010 and 2012 
(Figure 1.4).  As of 20 September 2014, a total of 174 infected cases have been diagnosed, 
fewer than the 703 cases reported at the same period in 2013 (Weekly Infectious Disease 
Bulletin, MOH Singapore, 2014).  
 
 
Figure 1.4 CHIKV Infection in Singapore 
(adapted from www.moh.gov.sg, as of 20 September 2014) 
 





1.5  Molecular Epidemiology of CHIKV Infection 
 
 Several distinct phylogroups have been established based on phylogenetic analysis of 
the partial CHIKV E1 viral structural glycoprotein sequence.  With the evolutionary timescale 
of CHIKV estimated to be during the past three centuries, it is believed that sylvatic African 
CHIKV has emerged as a human pathogen during the 18
th
 century while the three epidemic 
genotypes have been estimated to have emerged during the 20
th
 century (Cherian et al., 2009; 
Volk et al., 2010).  Studies conducted thus far have shown the prevalence of these lineages 
with distinct genotypic and antigenic characteristics (Powers et al., 2000; Arankalle et al., 
2007), with the various CHIKV strains circulating in ecologically different regions (De 
Lamballerie et al., 2008b; Volk et al., 2010).  Prior to 2005, two genotypes, namely West 
African – the most genetically diverse genotype - and East, Central, and South African 
(ECSA) genotypes contributed to all African epidemics while the Asian genotype represented 
for the whole of Asia (Powers and Logue, 2007).   
 
 It was, nevertheless found that a newer strain of the ECSA lineage was responsible for 
the emergence of CHIKV in the Indian Ocean during the 2005-2006 epidemic (Schuffenecker 
et al., 2006; Yergolkar et al., 2006).  Kariuki Njenga and co-workers (2008) subsequently 
reported the possible movement of this strain towards the Indian Ocean following CHIKV 
outbreaks in Kenya in 2004.  Several research groups found the viral progenitor to have been 
in existence between 3-9 years prior to the epidemic (Cherian et al., 2009; Volk et al., 2010; 
Lo Presti et al., 2012).   
 
 Although the molecular epidemiology of CHIKV in India has been thoroughly 
described (Yergolkar et al., 2006; Arankalle et al., 2007), the evolutionary relationships of 





CHIKV throughout the rest of the Asian region remain limited and are poorly documented.  
Recent cases reported in Malaysia (Kumarasamy et al., 2006), Singapore (Ng and 
Hapuarachchi, 2010) and Taiwan (Huang et al., 2009) have, however, meant that the Asian 
lineage is still very much in circulation, despite the ECSA genotype predominantly 
responsible for recent Asian outbreaks (Ng and Hapuarachchi, 2010). 
 
Schuffenecker and colleagues (2006) demonstrated a specific change at position 226 of 
the E1 protein with the substitution of alanine with valine (E1:A226V) in the CHIKV isolates 
from the La Reunion outbreak.  This change has been observed in approximately 90% of the 
strains isolated after September 2005, or the latter half of the epidemic.  Such genetic 
alterations were similarly observed in India from CHIKV isolates collected in 2007, although 
the ones in 2006 had not displayed the molecular substitution (Arankalle et al., 2007; 
Santhosh et al., 2008).  These events clearly indicated that the specific mutation occurred with 
the progression of the epidemic in both outbreak areas, and demonstrated the significance of 
these molecular changes in the epidemiology of the virus providing selective advantage for 
effective and rapid transmission by mosquitoes. 
 
 The genetic change in position E1:A226V was speculated to be the primary factor 
resulting in the reduction of the virus’ cholesterol dependence to infect mosquito vectors 
(Schuffenecker et al., 2006).  As mosquitoes often do not have sufficient cholesterol for 
viruses to efficiently infect host cells, the E1:A226V mutation might have assisted in 
replication and transmission of the virus.  Accordingly, Tsetsarkin and co-workers (2007) had 
experimentally demonstrated that the E1:A226V mutation was responsible for the enhanced 
infectivity and efficient transmission to mice by Ae. albopictus and Ae. aegypti mosquitoes.  





Furthermore, they observed an association between cholesterol dependence and increased 
fitness of CHIKV in C6/36 cells. 
 
 
1.6  CHIKV Vectors & Transmission 
 
Substantial evidence has determined that CHIKV is transmitted and dispersed by 
mosquito vectors, particularly Aedes species (spp.) (Weinbren et al., 1958; McIntosh et al., 
1963; Paterson and McIntosh, 1964; Shah et al., 1964; Gilotra and Shah, 1967; Gilotra and 
Bhattacharya, 1968).  Characterised based on its geographical distribution areas, an African 
sylvatic and an Asian urban mosquito-human-mosquito transmission cycles have been defined 
for CHIKV.  The former is similar to the sylvatic cycle of the yellow fever virus, whereby 
virus transmission occurs between forest- or savannah-dwelling mosquitoes and wild non-
human primates or rodents, with occasional viral spillover into neighbouring human 
populations (Diallo et al., 1999; Wolfe et al., 2001).  Meanwhile, CHIKV may also encounter 
domestic or peri-domestic mosquitoes, thus initiating an urban transmission cycle, as typically 
witnessed in Asia, the Indian Ocean, Africa and Europe (Rezza et al., 2007).  These urban 
outbreaks generally resemble the virus transmission cycle of DENV, particularly when Ae. 
aegypti is the predominant vector. 
 
Prior to the 2005-2006 epidemic, the urban and anthropophilic mosquito Ae. aegypti 
(Stegomya aegypti) was the primary vector of CHIKV.  This, and its vector potential in 
CHIKV transmission, was evidenced by the isolation of the virus from the mosquito species 
from various epidemic areas in Tanganyika, India and Southeast Asia (Shah et al., 1964; 
Pavri et al., 1964; Rao, 1964; Yergolkar et al., 2006; Bonilauri et al., 2008; Sang et al., 2008), 





and substantiated by experimental transmission studies (Rao, 1964; Shah et al., 1964; 
Soekiman, 1987).  A cross-sectional seroprevalence study conducted on a representative 
sample of the Kenyan population revealed that 75% of the population presented with anti-
CHIKV antibodies while a similar analysis of the population in Grande Comore island in 
March 2005 reported a seroprevalence of 63% (Sergon et al., 2008; Renault et al., 2012).  
These studies indicated the high levels of CHIKV transmission efficiency by the mosquito 
species.  
 
 However, the major outbreak in 2005-2006 saw the emergence of Ae. albopictus 
(Stegomya albopictus) as the contributing vector of CHIKV transmission in several islands in 
the Indian Ocean as well as in the Indian state of Kerala (Schuffenecker et al., 2006; 
Tsetsarkin et al., 2007; Reiskind et al., 2008; Santhosh et al., 2008).  This was primarily 
attributable to the single mutation in the CHIKV E1 protein, thereby facilitating enhanced 
virus uptake, replication and vector transmission (Tsetsarkin et al., 2011).  Furthermore, the 
mosquito species has been shown to display a remarkable capacity to adapt to peri-domestic 
environments, enabling it to displace Ae. aegypti in some regions and thus emerging as a 
significant vector of CHIKV (Anish et al., 2011).     
 
Additionally, CHIKV has also been isolated from several sylvatic Aedes mosquitoes, 
such as Ae. africanus (Uganda and Bangui), Ae. fulgens, Ae. vittatus, Ae. cordellieri (South 
Africa), Ae. luteocephalus (Senegal), Ae. dalzieli (Senegal), Ae. vigilax, Ae. camptorhyntites, 
Ae. furcifer-taylori (South Africa and Senegal), as well as non-Aedes mosquitoes, including 
Anopheles, Mansonia uniformis and Culex annulirostris (McIntosh et al., 1963; Rao, 1964; 
Diallo et al., 1999; Lam et al., 2001; Yadav et al., 2003).  Outbreaks in rural Africa tend to 





affect small populations and appear to be highly reliant on the sylvatic mosquito population 
densities that proliferate during periods of heavy rainfall (Diallo et al., 1999). 
 
During epidemics, humans act as reservoirs for CHIKV while inter-epidemic periods 
witness several other hosts being implicated including monkeys, rodents and birds (Wolfe et 
al., 2001; Inoue et al., 2003).  Although more details have recently been learnt of CHIKV and 
its vectors and reservoirs, the limited knowledge of its natural history and environmental 
cycle within the African region persists.  Further analyses would need to be performed in 
order to investigate the vector potential of these sylvatic mosquito species - as they have been 
found to be experimentally unable to transmit the virus (Rao, 1964; Shah et al., 1964) – as 
well as putative viral determinants.   
 
 
1.7  Medical Significance of CHIKV 
  
The incubation period of CHIKV ranges from 1-12 days, although it is often 3-7 days 
(Robinson, 1955; Sam and Abu Bakar, 2006).  Attack rates can be as high as 40-85%, 
particularly in susceptible populations.  Prodomal symptoms are very rare, as the proportion 
of CHIKV-infected individuals who develop clinical symptoms is higher than in most other 
arboviral infections (Chastel, 2011).  For instance, only 16.7% of infected cases in La 
Reunion declared no symptoms (Gerardin et al., 2008), while a similar seroprevalence study 
in Kerala, India found that only 3.8% of those with positive serology reported not having 
experienced any clinical symptoms (Kumar et al., 2011). 
 





The disease etiology consists of two phases, namely acute illness and late stage of 
illness, with persistent arthropathy.  Symptoms of acute illness generally include an often 
abrupt and sudden onset of high-grade fever, debilitating polyarthralgia, prolonged myalgia, 
backache, headache and fatigue (Robinson, 1955; Sam and Abu Bakar, 2006).  The fever is of 
short duration and usually resolves within three to four days.  In some patients, a biphasic 
pattern of fever has been described with a febrile episode of four to six days, followed by a 
fever-free period of a few days followed by recurrence of fever (usually 39-41
o
C) lasting a 
few days.  Polyarthralgia represents the most characteristic symptom and is reported in 87-
98% of infected cases.  The viral polyarthropathy is often bilateral and symmetrical and 
involves the peripheral joints including small joints of the hand, wrist and ankles, although it 
may also involve larger joints such as the knees, elbows and shoulders (Robinson, 1955; Sam 
and Abu Bakar, 2006), resulting in severe pain and immobility and sleeping disorders.  
Moreover, myalgia has been observed primarily in the limbs without myositis, and was 
reported in 46-59% of infected cases in prospective studies, with a much higher prevalence of 
93% documented in retrospective studies. 
 
The infection is also commonly associated with cutaneous manifestations, characterised 
by a maculopapular or petechial rash, typically on the extremities, neck trunk and ear lobes 
(Figure 1.5; Bandyopadhyay and Ghoush, 2010).  Reported in 40-50% of CHIKV-infected 
cases, the skin lesions are transient and typically appear within 2-5 days upon disease onset.  
Various other skin and mucous membrane lesions, such as hypermelanosis, 
hyperpigmentation, exfoliative dermatitis, photosensitivity, erythema nodosum-like lesions 
and vasculitic lesions, as well as exacerbation of pre-existing dermatoses including psoriasis 
and mucosal ulceration, have also been documented.  
 







Figure 1.5 Mucocutaneous Manifestations of CHIKV Infections 
(adapted from Bandyopadhyay and Ghoush, 2010) 
 
Additionally, digestive symptoms including diarrhoea, vomiting, nausea and abdominal 
pain can occur during acute CHIKV illness, involving 15-47% of infected cases.  Albeit 
typically mild, the illness can result in limited normal activity and tiredness, with patients also 
feeling depressed and demoralised due to their inability to perform daily routine tasks. 
 
Although rheumatological manifestations feature less frequently in children, they may 
experience other atypical and at times, severe clinical symptoms such as peripheral cyanosis, 
vomiting, abdominal pain and constipation.  Dermatological manifestations, such as 
vesiculobullous lesions and generalised erythema, as well as neurological complications, 
including acute encephalopathy, encephalitis, meningeal syndrome and febrile seizures, are 
also highly prevalent in infant cases (Robin et al., 2008; Sebastian et al., 2009; 
Valamparampil et al., 2009).    
 
Vertical mother-to-child transmission was unprecedentedly reported during the 2005-
2006 La Reunion epidemic (Pialoux et al., 2007; Mavalankar et al., 2008).  Gerardin and 
colleagues (2008) observed severe illness in 53% of newborns, of which 44% experienced 





encephalopathy with persistent disabilities.  Cardiological (myocardial hypertrophy, 
pericarditis, ventricular dysfunction), neurological, haemorrhagic and dermatological 
complications were also reported (Ramful et al., 2007; Nair, 2008; Rao et al., 2008). 
 
A wide range of other atypical clinical manifestations have been reported during acute 
CHIK fever, including conjunctival suffusion, pericarditis, persistent conjunctivitis, 
iridocyclitis, neuroretinitis, dry cough, myocarditis, nephritis, pneumonia, lymphadenopathy, 
hepatitis and pancreatitis (Borgherini et al., 2007; Mirabel et al., 2007; Renault et al., 2007; 
Rezza et al., 2007; Simon et al., 2007; Mahendradas et al., 2008; Simon et al., 2008; 
Staikowsky et al., 2009; Rajapakse et al., 2010; Win et al., 2010; Rose et al., 2011; Nair et 
al., 2012).  An estimated 0.3% of all symptomatic cases presented with these symptoms 
during the outbreak in La Reunion in 2005-2006, of which 36% were considered to be severe 
(Economopoulou et al., 2009).  The epidemic also witnessed unprecedented CHIKV-
associated fatalities (Pialoux et al., 2007; Mavalankar et al., 2008).  Albeit being rarely life-
threatening, the CHIKV outbreaks in La Reunion and India resulted in approximately 200 
deaths, with a case-fatality ratio of approximately 1 in 1000 (Josseran et al., 2006; 
Manimunda et al., 2011).   
 
While CHIK is a self-limiting disease, and the joint pains typically resolve in one to 
three weeks, 12 per cent of CHIKV-infected patients experience arthritis persisting for up to 
three years after the onset of illness (Brighton et al., 1983; McGill, 1995).  Musculoskeletal 
pains including arthralgia are the most common symptoms experienced during late-stage 
CHIKV illness, with spondylarthopathy, rheumatoid arthritis (RA) and other non-classified 
rheumatism being associated with the disease.  Other less-frequently reported long-term 
symptoms include neuropathic pain syndromes, cerebral disorders, sensorineural 





impairments, dysesthesia and/or paraesthesia, tunnel syndromes, digestive disorders, skin 
rash, alopecia, pruritus, erythermalgia, joint stiffness, bursitis, tenosynovitis and synovitis.  A 
cross-sectional study conducted based on the La Reunion outbreak revealed 53% of patients 
suffering from chronic CHIKV disease, with an average of 128 days after the onset of the 
illness.  Similarly, 66% of infected cases reported arthralgia, myalgia and/or asthenia a year 
after the epidemic in Italy.  Interestingly though, the Gabon outbreak in 2010 witnessed a 
83% complete recovery rate within 30 days of disease onset, while only 12% of patients still 
suffered from musculoskeletal pain a year after the 2006 epidemic in West India.  The 
widespread occurrence of the disease has nevertheless caused substantial morbidity, as well as 
inflicted enormous social burden and economic loss on affected communities (Figure 1.6; 
Bettadapura et al., 2013).   
 
Figure 1.6 Pathogenesis of CHIKV-Induced Polyarthritis 
(adapted from Bettadapura et al., 2013) 
 






Unlike DENF, haemorrhagic and neurological manifestations are uncommon in CHIKV 
infections, although they have been known to occur since the 1960s.  When present, they are 
mild and are more frequently encountered in Asian compared with African patients 
(Robinson, 1955; Sam and Abu Bakar, 2006).  These manifestations include epistaxis, 
bleeding from the gums, positive Hess test, subconjunctival bleed and petechial spots or 
purpuric rash, as well as meningoencephalitis in rare cases.  Other complications observed in 
CHIKV-infected patients also include ophthalmic involvements, hypokalemic paralysis, 
sensorineural hearing loss, encephalomyeloradiculitis, Guillain Barre Syndrome and acute 
flaccid paralysis (Lalitha et al., 2007, Mittal et al., 2007a, b; Rampal et al., 2007; Bhavana et 
al., 2008).   
 
Couderc and co-workers (2008) reported that certain groups of individuals were more at 
risk of lengthened illness as well as developing atypical and/or severe complications from the 
disease including death, namely the elderly and immunocompromised, such as adults 
suffering from diabetes, impaired renal function and alcoholic hepatopathy.  Pre-existing or 
underlying conditions, such as joint pain, osteoarthritis, hypertension, cardiac disorders and 
respiratory diseases are also linked to an increased risk of persistent symptoms as well as 
hospitalisation and disease severity.   
 
While CHIK fever affects all age groups, with both genders being equally at risk of the 
viral infection, females have been found to be linked with a longer duration of illness and 
persistent symptoms.  However, no similarly distinct association has been reported between 
females and more severe illness.  
 





 Thiberville and colleagues (2013) identified two stages of CHIKV disease, namely the 
viral stage at days 1-4 upon disease onset – typically linked with a rapid decrease of viraemia, 
followed by speedy improvement of clinical presentation – and the convalescent stage at days 
5-14, with no detectable viraemia and slow clinical presentation.  The acute stage of 
chikungunya fever is characterised by elevated viraemic loads with a median duration of 
viraemia of 6 days and accompanying abnormalities such as marked lymphopenia and 
thrombocytopenia.  It was prospectively discovered that during the Reunion island outbreak 
in 2006, 79% of infected patients presented with lymphopenia, of which 39% were severe and 
more pronounced manifestations were associated with enhanced viraemic loads.  Moreover, 
moderate thrombocytopenia was observed in 40–50% of patients. Other less common 
biological abnormalities have been documented such as leukopenia, hypocalcemia, anemia 
and escalated liver enzymes, creatinine and creatinine kinase. 
 
Although viral load has been associated with persistent symptoms during the La 
Reunion outbreak, the outbreak in Singapore found no relationship between both factors.  A 
strong early Immunoglobulin G3 (IgG3) response triggered by a high viral load was also 
proposed to protect against chronic effects of CHIKV infection.  Conversely, a positive 
association between high titres of CHIKV-specific IgG antibodies and persistent arthralgia 
was recently observed (Moro et al., 2012; Gerardin et al., 2013).  Furthermore, Win and 
colleagues (2010) reported significantly lower peak creatinine levels in patients with 
persistent arthralgia. 
 
Similarly, at the acute severe stage of CHIKV disease, immunological markers such as 
creatinine, C reactive protein (CRP), hypocalcemia, elevated IL-1b or IL-6 and liver enzyme, 
as well as decreases in RANTES or early CHIKV-specific IgG3, have been postulated to be 





linked with disease severity.  While several studies documented enhanced viral loads in 
severely-infected patients, others did not reveal significant association between viraemic 
loads and clinical presentation (Borgherini et al., 2007; Rezza et al., 2007; Simon et al., 2007; 
Taubitz et al., 2007; Queyriaux et al., 2008; Staikowsky et al., 2009; Bandyopadhyay and 
Ghosh, 2010; Riyaz et al., 2010; Win et al., 2010; Chow et al., 2011; Nkoghe et al., 2012; 
Thiberville et al., 2013). 
 
Relapse of infection or persistent symptoms are often experienced by CHIKV-infected 
individuals.  The clinical description and risk factors of late-phase CHIKV infection have 
recently garnered heightened interest as evidenced by several studies (Simon et al., 2007; 
Borgherini et al., 2008; Bouquillard and Combe, 2009; Hoarau et al., 2010; Win et al., 2010; 
Gerardin et al., 2011; Moro et al., 2012; Nkoghe et al., 2012; Ribera et al., 2012; Thiberville 
et al., 2013). 
 
 
1.8  Pathogenesis of CHIKV Infection 
  
In animal models, CHIKV was detected in the cytoplasm of numerous mononuclear 
cells in the spleen and lymph nodes, with the sinusoidal endothelium of the liver and 
macrophages identified as primary cellular reservoirs during late CHIKV infection in a 
macaque model (Labadie et al., 2010).  
 
Prior to the use of mouse models, non-human primates were already found to be 
susceptible to CHIKV infection, probably due to them being natural reservoir hosts in Africa 
and Asia (McCrae et al., 1971; Marchette et al., 1978; Peiris et al., 1993; Inoue et al., 2003).  





The first experimental CHIKV infection was achieved in rhesus and bonnet macaques in 
1967, although only the former showed episodes of fever within a few days of virus 
inoculation (Binn et al., 1967; Paul and Singh, 1968).  
 
Labadie and colleagues (2010) recently infected cynomolgus macaques with CHIKV 
strains from La Reunion Island and found high viremic and detectable replication levels in 
target tissues, similar to those in human infections.  CHIKV was reported to replicate in 
several cell types during the acute infective phase (Higgs and Ziegler, 2010; Labadie et al., 
2010) but was subsequently predominantly detectable in macrophages. Similar viral 
replication profiles were thereafter recorded in rhesus macaques (Akahata et al., 2010; Chen 
et al., 2010). 
 
The use of mice defective in various genes of the IFNα pathway enabled mechanisms of 
the innate immune responses specific to CHIKV to be deciphered (Couderc et al., 2008; 
Schilte et al., 2010; Werneke et al., 2011; Gardner et al., 2012; Schilte et al., 2012), thereby 
implicating roles for ISG15, IRF-3, MYD88 and RSAD2 (viperin) (Teng et al., 2012).  
Fibroblasts constituted the primary target cells of CHIKV infection in joint, muscle and 
dermal tissues, while CHIKV was rarely present in satellite cells of skeletal muscles.  
Similarly, choroid plexus epithelial cells and ependymocytes were found to be infected in the 
central nervous system as opposed to microglial cells, astrocytes and microvascular 
endothelial cells (Couderc et al., 2008; Couderc and Lecuit, 2009). 
 
Currently, mouse models are primarily used in in vivo screening of drugs targeting acute 
CHIKV infection.  As yet, no mouse model is able to truly depict the persistent chronic 
arthralgic features found in approximately 60% of the CHIKV-infected patients, although 





CHIKV-induced arthritis in a mouse model was found to significantly resemble with 
rheumatoid arthritis in humans (Nakaya et al., 2012).  A possible reason could be due to the 
inability of young mice to exhibit severe forms of the disease, thereby rendering them 
incompatible to investigate mechanisms of neurological disease.  
 
Nevertheless, Gardner and colleagues (2010) provided a model of CHIKV-induced 
rheumatic disease in 6-week-old C57BL/6J mice by shifting the site of injection to the dorsal 
side of the footpad, thus demonstrating acute and persistent arthritis, tenosynovitis and 
myositis at the infected footpad, similar to that reported in RRV-infected mice (Rulli et al., 
2009; Rulli et al., 2011).  Severe CHIKV disease was further analysed by Rudd and co-
workers (2012), who showed that inadequate IFNα/β responses upon CHIKV infection 
resulted in the induction of haemorrhagic fever and shock. 
 
Unlike in mouse models, CHIKV was detected in human muscle satellite cells whereas 
myotubes were essentially refractory to infection (Ozden et al., 2007).  Upon analyses of 
skeletal muscle, joint and skin biopsies, CHIKV antigens were also detected but appeared to 
be confined to fibroblasts of the joint capsule of skeletal muscle fascia and of the dermis 
(Couderc et al., 2008; Couderc and Lecuit, 2009, Schwartz and Albert, 2010).  Early 
leukopenia was observed in humans (Borgherini et al., 2007; Borgherini et al., 2009; Akahata 
et al., 2010; Labadie et al., 2010), along with markers of antiviral inflammation and cell 
immune activation (Higgs and Ziegler, 2010; Labadie et al., 2010).  
 






Figure 1.7 Pathogenesis of CHIKV Infection 
(adapted from Schwartz and Albert, 2010) 
 
 
1.9  Cell-Type Specific Responses to Alphaviral Infection 
 
 In recent times, cell susceptibility to CHIKV replication has been extensively studied, 
with the use of a panel of immortalised primary human cells.  Human epithelial and 
endothelial cells, primary fibroblasts and monocyte-derived macrophages were found to be 
susceptible to CHIKV infection whereas no replication was detected in lymphoid and 
monocytoid cell lines, primary lymphocytes and monocytes, or monocyte-derived dendritic 





cells (Sourisseau et al., 2007).  Solignat and colleagues (2009) also showed that several blood 
cells such as H9 - a CD4
+
 T lymphoid cell line - as well as the monocytoid U937 and TPH-1 
cell lines and primary dendritic cells, are resistant to CHIKV infection.   
 
 Furthermore, CHIKV has also been isolated in numerous continuous or diploid cell 
lines, including mammalian cells (Vero, BHK21, HEK-213T, BGM), amphibian cells (XTC) 
and mosquito cells (C6/36, Ae, A20).  The cervical carcinoma epithelial cell line HeLa, the 
kidney epithelial cell line HEK293T, the hepatocarcinoma epithelial cell line HUH7, and the 
neuroblastoma cell line SH-SY5Y have been found to exhibit cytopathic effects and syncytia 
formation upon CHIKV exposure (Solignat et al., 2009).  In addition, BEAS-2B, Hs 789.Sk 
skin cells, dividing and non-dividing MRC5 lung cells and endothelial cell lines (TrHBMEC 
and hCMEC/D3) were also susceptible to CHIKV (Sourisseau et al., 2007).  More recently, it 
was reported that the syncytiotrophoblastic cell line BeWo, as well as A549 alveolar epithelial 
cell line, is refractory to CHIKV infection (Couderc et al., 2008).  
 
 
1.10  Laboratory Diagnosis of CHIKV Infection  
 
Since no effective vaccines or therapeutics are currently available, early detection and 
proper diagnosis remain primary measures towards effective control of the disease.  Infant 
mice inoculation and serological techniques such as haemagglutination, haemagglutination 
inhibition assay, complement fixation and neutralization test, were used effectively in the 
identification and characterization of viruses (Clarke and Casals, 1958; Pavri, 1964).  The 
development of immunoglobulin M (IgM) antibody-capture enzyme-linked immunosorbent 
assay (MAC-ELISA) provided a rapid and reliable technique for arboviral diagnosis (Gadkari 





and Shaikh, 1984; Bodenmann and Genton, 2006).  Indirect immunofluorescent antibody 
technique is another reliable technique for detection and identification of viral antigens from 
clinical samples (Yergolkar et al., 2006). 
 
In the event of a viral outbreak, the situation warrants for rapid detection and 
identification of the etiological agent.  Reverse transcription polymerase chain reaction (rt-
PCR) with the use of primers designed for structural and non-structural domains has been 
found to be useful in the rapid diagnosis of CHIKV (Pastorino et al., 2005).  In addition, the 
combination of RT-PCR/nested PCR has also proved efficient for specific detection and 
genotyping of CHIKV (Hasebe et al., 2002; Pfeffer et al., 2002) while quantitative real time 
rt-PCR (qRT rt-PCR) has revolutionised the field with its rapidity, sensitivity, reproducibility 
and reduced risk of contamination and is now routinely being used for detection and 
quantitation of viruses (Parida, 2008).  To that end, a recent study utilised 2,7-diamino-1,8-
naphthyridine derivative (DANP)-labeled primers to develop a novel single-step molecular 
platform with which to diagnose early CHIKV infection, with high specificity and sensitivity 
rates achieved (Chen et al., 2013).     
 
 
1.11 Vaccines & Antivirals against CHIKV Infection 
 
With no specific antiviral against CHIKV infection currently available, supportive 
treatment for the symptoms, including analgesics, antipyretics and anti-inflammatory agents, 
is generally administered.  However, the efficacy of these symptomatic therapeutics has not 
been thoroughly evaluated.  Nonetheless, acetaminophen, codeine, tramadol and non-steroidal 
anti-inflammatory drugs (NSAIDs) have been recommended for infected patients without 





polyarthritis, although aspirin and systemic corticosteroids should be avoided due to risks of 
bleeding and rebound effects (Ali Ou Alla and Combe, 2011; Simon et al., 2011; Singh and 
Unni, 2011; Burt et al., 2012; Ribera et al., 2012).     
 
Disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate, 
hydroxychloroquine or sulphasalazine have also been proposed to treat severe chronic 
arthritis (Bouquillard and Combe, 2009), particularly with a diagnosis of long-term defined 
inflammatory polyarthritis (Ribera et al., 2012).  Furthermore, patients diagnosed with post-
CHIK rheumatoid arthritis have been effectively treated with anti-tumour necrosis factor 
antibodies (Bouquillard and Combe, 2009), although they were later found to be associated 
with exacerbated disease in mouse models during early CHIKV infection (Zaid et al., 2011). 
 
The increasingly global spread of CHIKV has stimulated renewed interest in developing 
new antiviral agents.  Although several drugs have been found to be effective against CHIKV 
when tested in vitro, no recognised antiviral treatment is currently available. 
 
Immunoglobulin G (IgG) extracted from the sera of monkeys immunised with a CHIKV 
virus like particle (VLP)-based vaccine candidate was administered passively to mice, which 
were then infected with CHIKV.  Akahata and colleagues (2010) subsequently observed that 
the immune IgG succeeded in protecting the mice from infection by CHIKV.  Similarly, 
Couderc and co-workers (2009) reported high prophylactic and therapeutic levels of efficacy 
of human immunoglobulins purified from the convalescent plasma of CHIKV-infected 
patients upon CHIKV infection in mice, whilst also exhibiting a high in vitro neutralising 
activity.  More recently, human recombinant monoclonal antibodies exhibited strong and 
specific neutralising activity in vitro when tested against various CHIKV strains and were 





able to substantially delay the CHIKV-driven lethality in AGR129 mice (Warter et al., 2011; 
Fric et al., 2013). 
 
Interferons (IFN), along with interferon-induced genes, have been found to be capable 
of inhibiting virus infections in the absence of adaptive immunity.  These genes encode for 
enzymes, such as dsRNA-dependent protein kinase R (PKR), 2’-5’-oligoadenylate synthetase 
(OAS) and MxA (Randall and Goodbourn, 2008), and have been adapted for antiviral therapy 
at the chronic stage of viral infections, such as HCV and HBV (Heim, 2012).  Nevertheless, 
IFN therapy has also been proposed for acute viral infection such as SARS or influenza 
(Wang and Fish, 2012).  While IFN has been known to inhibit the growth of several 
alphaviruses (Pinto et al., 1990; Lukaszewski and Brooks, 2000), the efficacy of IFN therapy 
in treating CHIKV infections in vivo still remains undetermined.  
 
While ribavirin is known to inhibit various RNA viruses in vitro, it is less effective in 
vivo (Smee et al., 1988; Ho et al., 2010).  Nevertheless, it has been used to treat Lassa fever 
and severe respiratory syncytial virus (RSV) infections, and is currently being used in 
combination with IFNα to treat HCV infections (Crotty et al., 2002).  Indeed, Briolant and 
colleagues (2004) showed the synergistic antiviral in vitro effect of the IFNα-ribavirin 
combination therapy against two alphaviruses, namely CHIKV and SFV.  Furthermore, 
Ravichandran and Manian (2008) observed in vivo antiviral activity of ribavirin during 
CHIKV in a human cohort study, although the lack of a large number of participants resulted 
in unattainable statistical analysis.  Hence, the effectiveness of ribavirin in humans as an 
antiviral against CHIKV infection remains to be ascertained.  
 





Chloroquine has long been established as an antiviral drug against numerous virus 
infections (Inglot, 1969), but its therapeutic potential against alphavirus infections has yet to 
be evaluated.  In fact, Maheswari and colleagues (1991) reported enhanced SFV replication in 
mice upon chloroquine treatment.  Nevertheless, it was previously observed to be effective for 
chronic CHIK-induced arthritis (Brighton, 1984) and in vitro inhibition of CHIKV replication 
by chloroquine has since been documented (Delogu and de Lamballerie, 2011), although a 
more recent randomised human cohort trial yet observed insignificant levels of efficacy of 
chloroquine against CHIK fever and rather enhanced post-CHIK arthralgic symptoms in 
infected patients (de Lamballerie et al., 2008a).  Additionally, Ozden and co-workers (2008) 
observed stronger inhibition of CHIKV infection upon immediate addition of an irreversible 
furin-inhibiting peptide (decanoyl-RVKR-chloromethyl ketone [dec-RVKRcmk]), which 
prevented cleaving of glycoprotein precursors by furin-like proprotein convertases thereby 
inducing defects in viral production.  Indeed, a chloroquine-dec-RVKRcmk co-treatment 
induced an additive effect, with enhanced inhibitory levels yet reported upon pre-treatment 
(Ozden et al., 2008). 
 
Arbidol (ARB) has been observed to be clinically active against respiratory viruses 
including influenza A and B viruses and respiratory syncytial virus (RSV), as well as HCV 
(Brooks et al., 2012).  Delogu and de Lamballerie (2011) recently reported the effectiveness 
of ARB against CHIKV in vitro, with the former interfering with early CHIKV infection by 
targeting the cellular membrane. 
 
The recent spur of in-depth analysis of crystal structures of the replicative proteins of 
alphaviruses, including CHIKV, (Lampio et al., 2000; Russo et al., 2006; Malet et al., 2009; 
Voss et al., 2010), has paved the way for the development of structure-based, specific 





inhibitors against these viral infections.  Based on a homology model of the crystal structure 
of VEEV nsP2 protein, Singh and colleagues (2012) identified four lead compounds that 
could potentially inhibit CHIKV nsP2 protease.  Similarly, a yet-unidentified natural 
compound (ID1452-2) was found to inhibit CHIKV replication in vitro by interfering with 
nsP2 activity (Lucas-Hourani et al., 2013). 
 
Other nature-based compounds found to inhibit CHIKV replication in vitro include 
Trigocherrins - found in both New Caledonia and Vietnam (Allard et al., 2012a; Allard et al., 
2012b; Bourjot et al., 2012a) - and leaf extracts of the Madagascan plant Anacolosa 
pervilleana (Bourjot et al., 2012b; Bourjot et al., 2012c).  More recently, Kaur and colleagues 
(2013) identified a cephalotaxine alkaloid named harringtonine, amongst a highly-purified 
natural product compound library, that exhibited potent inhibitory levels of CHIKV infection, 
affecting CHIKV RNA production as well as viral protein expression while maintaining 
minimal cytotoxicity. 
 
Modern research and technology has enabled for the development of such DNA- and 
RNA-based compounds as peptide-conjugated phosphorodiamidate morpholino oligomers 
(PPMO) and small interfering RNA (siRNA) to combat virus infections.  The former - single-
stranded DNA-analogues acting as steric-blocking antisense agents through stable duplex 
formation with complementary RNA (Stein, 2008) – has been observed to greatly decrease 
viral titres and thereby reduce viral replication of poliovirus, coxsackievirus B3, DENV, West 
Nile virus, influenza A virus, RSV, Ebola virus and VEEV (Paessler et al., 2008; Stein, 
2008).  Meanwhile, the latter - induced by double-stranded RNA and specifically prevent 
infection evoked by viruses by selectively shutting off post-transcriptional mRNA expression 
(Tan and Yin, 2004; Cullen, 2006) - has been successfully utilised to inhibit replication of 





many RNA and DNA viruses, including influenza, HIV, Japanese encephalitis virus, West 
Nile virus, foot and mouth disease virus, HBV, and HSV, as well as alphaviruses such as 
VEEV and SFV (Dash et al., 2008).  Dash and colleagues (2008) also noted substantial levels 
of CHIKV inhibition upon addition of siRNAs binding to the CHIKV nSP3 and E1 genomic 
domains.  Similarly, CHIKV replication was significantly diminished upon siRNA-based 
inhibition of Beclin-1, an autophagic protein (Krejbich-Trotot et al., 2011).  More recently, 
plasmid-based small hairpin RNA (shRNA) against the E1 region of the CHIKV genome has 
resulted in significant inhibition of infectious virus production in vitro and sustained anti-
CHIKV protection in suckling mice pre-treated with shRNA E1 (Lam et al., 2012). 
 
Recurrent CHIKV epidemics resulting in severe morbidity and tremendous economic 
and social burden have necessitated the need for an efficient and effective vaccine.  Initial 
attempts to develop a formalin-inactivated vaccine were first reported in late 1960s (White et 
al., 1972), but its immunogenicity levels were moderate and effects limited (Harrison et al., 
1971).  The US Army subsequently established a live, attenuated vaccine (TSI-GSD-218), 
based on an Asian 1970s strain (Levitt et al., 1986; Hoke et al., 2012), although it was also 
shelved after being associated with several adverse events including arthralgia.  The 
importance of IFNs in regulating the vaccine strain was nevertheless analysed further, thereby 
demonstrating its ability in eliciting neutralising antibody responses that confer short- and 
long-term protection against wildtype (wt) CHIKV-La Reunion virus challenge (Partidos et 
al., 2011).  Indeed, arthritogenic disease in mice infected with wt CHIKV, but not with the 
vaccine strain, was exacerbated with IFNα/β deficiency (Couderc et al., 2008; Gardner et al., 
2010; Gorchakov et al., 2012).  
 





Recently, large-scale codon re-encoding was introduced as a strategy to attenuate 
viruses, in which numerous synonymous mutations were inserted in order to modify the 
nucleic acid composition of large coding regions without modifying the encoded proteins 
(Burns et al., 2006; Mueller et al., 2006; Coleman et al., 2008; Mueller et al., 2010).  
Nougairede and colleagues (2013) then applied the novel method via reverse genetics to the 
LR2006 CHIKV strain and found that the large number of synonymous mutations resulted in 
significantly diminished levels of replicative fitness of CHIKV in both primate and arthropod 
cells while exhibiting a stable phenotype with minimal reversion of mutations.  Whilst the 
immunogenic potential of vaccine candidates designed based on this attenuation strategy 
would still need to be evaluated in animal model studies, it represents a potentially cost-
effective and highly efficacious alternative to other vaccine types. 
 
Recombinant protein-based and whole-virus inactivated vaccines have also been 
developed in the attempt to combat CHIKV infection.  For instance, a recombinant vaccine 
based on the Indian CHIKV strain succeeded in eliciting a balanced Th1/Th2 response with 
virus-neutralising antibodies in BALB/C mice (Khan et al., 2012).  Similarly, Kumar and co-
workers (2012) observed complete protection of infected adult BALB/c mice upon 
immunisation with alum-adjuvanted recombinant CHIKV E2 protein-based, as well as whole-
virus inactivated vaccine candidates. 
 
Design of VLP-based vaccines has gained intense momentum in the past decade.  
Akahata and colleagues (2010) observed substantially increased antibody responses in 
BALB/c mice upon immunisation as compared with the use of a DNA vaccine based on the 
same subgenomic RNA sequence (C–E3–E2–6k–E1).  Protection was also induced in mice 
and non-human primates upon subsequent CHIKV challenge, although VLP production was 





minimal.  Production of functional VLPs was nevertheless later enhanced by an improved 
method, whereby a specific domain of the CHIKV E2 protein was found to be responsible for 
particle formation in cells (Akahata and Nabel, 2012).  Similarly, Metz and co-workers (2011) 
recently established a VLP-based mouse model system using chimeric baculovirus and have 
performed preliminary vaccination studies. 
 
A chimeric alphavirus vaccine candidate – containing VEEV or EEV non-structural and 
CHIKV structural protein coding sequences, along with an encephalomyocarditis virus 
internal ribosome entry site (IRES) - efficiently induced protective immune responses in 
IFNα/β-deficient A129 mice against CHIKV infection (Wang et al., 2011b) and was also able 
to provide cross-protective immunity in these mice as well as adult IFNα/β/c-deficient AG129 
mice, against alphaviruses of the SFV antigenic complex (Partidos et al., 2012).  Wang and 
colleagues (2011a) also tested a recombinant adenovirus vaccine candidate containing the 
CHIKV structural domain and found the antibody neutralisation titres to be favourable and 
fully protective against subsequent CHIKV challenge.  More recently, chimeric 
vesiculo/alphavirus candidates were also observed to be capable of protecting adult C57BL/6 
mice upon immunisation with the vaccine, in which the entire CHIKV envelope polyprotein 
was expressed (Chattopadhyay et al., 2013).  
 
Additionally, Mallilankaraman and co-workers (2011) found that CHIKV neutralising 
antibodies were significantly enhanced, along with high CHIKV-specific cellular responses, 
upon electroporative vaccination of a CHIKV envelope-containing plasmid into 8-week-old 
female BALB/c mice.  The vaccination strategy was subsequently advanced to include rhesus 
macaques, whereby variable neutralising antibody and specific T cell responses were 
detected.   






It is clearly evident that an effective and efficient vaccine against CHIKV infection is 
greatly desired, although questions remain as to which vaccine type will be able to meet a 
wide range of safety and cost criteria.  For instance, inactivated vaccines are unlikely to 
provide strong and long-lasting immunity, and will almost certainly require multiple doses, 
thereby reducing their cost effectiveness.  Meanwhile, DNA vaccines have proved to be less 
effective in humans than in other mammals.  Currently, live attenuated vaccine candidates 
appear to be most likely to result in the design of an efficacious vaccine with long-lasting 
immunity against CHIKV infection.  
 
 
1.12  Genomic Profiling of CHIKV 
 
 Several CHIKV-based profiling studies have recently been conducted to gain deeper 
understanding of CHIKV and its interactions with its host.  Saxena and colleagues (2013) 
utilised microarray technology to establish the miRNA, snoRNA and mRNA signature of 
CHIKV-induced host responses upon CHIKV infection, with regulation of 152 miRNAs 
observed.  Genes were found to be differentially expressed along three major pathways, 
namely TGF-b, endocytosis and the cell cycle pathways.  Proteomic profiling of serum 
samples from CHIKV-infected patients was also performed to identify 63 differentially 
expressed molecules involved in lipid metabolism, immune response, transport, signal 
transduction and apoptosis (Puttamalesh et al., 2013). 
 
 Furthermore, Nakaya and co-workers (2012) generated a consensus CHIKV arthritis 
gene expression signature and showed common inflammatory features between rheumatoid 





arthritis and CHIKV disease.  Similarly, a comprehensive analysis of immune response genes 
expression in target tissue of a CHIKV mouse model was conducted using a cytometric bead 
array with the aim of understanding pathogenesis of CHIKV-induced disease (Patil et al., 
2012). 
 
 Vector-based profiling studies were also recently established.  Lee and colleagues 
(2013) identified mosquito host genes differentially regulated during the infectious entry 
process of CHIKV infection on C6/36 mosquito cells, with the use of a customized gene 
expression microarray of approximately 19,000 transcripts known to target Aedes mosquito 




1.13  RNA Interference 
 
 RNA interference (RNAi) is a post-transcriptional gene silencing pathway first 
discovered in Caenorhabditis elegans in 1998, involving the degradation of target mRNA 
mediated by double-stranded RNA (dsRNA) (Fire et al., 1998).  Produced through ATP-
dependent processive cleavage of long dsRNAs by the enzyme Dicer, 21- to 23-nucleotide 
short interfering RNAs (siRNAs) form the effector molecules.  The antisense strand of the 
siRNA is then incorporated into an RNA-induced silencing complex (RISC) and is used to 
target perfectly complementary mRNA species.  RISC subsequently cleaves the target 
mRNA, resulting in gene silencing (Bernstein et al., 2001).   
 





 Sequence-specific gene-silencing by siRNA-mediated RNAi has now been widely used 
and accepted as a powerful genetic tool to inhibit gene expression and to investigate the 
immediate effects of inhibiting specific genes in mammalian cell cultures.  Dash and co-
workers (2008) first tested the RNAi mechanism in inhibiting CHIKV replication in 
mammalian cells.   
 
 On a much more extensive scale, RNAi can also be used to conduct genome-wide or 
subset library screening of genes required for specific mechanisms of interest.  For instance, 
Kolokoltsov and colleagues (2007) utilised a subset of the human membrane trafficking 
library to screen for endocytic genes involved in respiratory syncytial virus (RSV) infection.  
Numerous candidate mammalian genes were also found to be important for the co-localisation 
of SINV capsid protein with autophagolysosomes (Orvedahl et al., 2011).  Similarly, Panda 
and colleagues (2013) identified several conserved regulators involved in SINV entry.  More 
recently, a genome-wide siRNA screen was performed to identify novel host proteins 




1.14  Aims & Objectives 
 
 Since the isolation of CHIKV in 1952 and its re-emergence in 2005, extensive studies 
have been conducted in an effort to gather knowledge of its pathogenesis as well as to monitor 
its epidemiological characteristics.  Although several cell types and cell lines have been found 
to be permissive to CHIKV infection, it remains imperative to establish a cellular model that 
truly represents the tissue tropism of the disease.  Furthermore, it is equally paramount to 





identify host factors essential in various processes of the CHIKV replication cycle, including 
entry and egress.  This is to enable the development of effective strategies in limiting and 
preventing the extent of CHIKV infection in individuals and the community at large. 
 
 Therefore, the objectives of this study were as follows: 
 
1 To develop susceptibility profiles of various cell lines upon CHIKV infection 
2 To establish and characterise a novel primary human cellular model for CHIKV 
infection 
3 To determine host factors that mediate the infectious entry processes of CHIKV in 
HSMM cells 
4 To perform genomic profiling of host factors involved in CHIKV infection and 
investigate the interactions between CHIKV and its host   
 
 Establishment of growth kinetics of several CHIKV strains across various cell lines was 
first performed, via infectious viral plaque assays and indirect immunofluorescence 
microscopy.  These assays, along with transmission electron microscopy (TEM) studies, were 
also used to develop a primary human cellular model for CHIKV infection.  An siRNA-based 
library screening and genome-wide microarray profiling were performed to investigate the 
interactions between CHIKV and its host.  Techniques used in the validation of screening and 
profiling data included qRT rt-PCR, siRNA-based gene-specific knockdown and drug 
inhibitory assays.  Chapter 2 describes the experimental approaches undertaken in this study. 
 
 Chapter 3 presents the results of CHIKV growth profiles as observed in various cell 
lines tested.  Also described are results of immunofluorescence assays and TEM analyses 





performed on selected cell lines.  Sequencing analyses of the three virus strains used in this 
chapter were also presented. 
 
 Chapter 4 presents the results of establishing a novel primary human cellular model for 
CHIKV infection.  Data discussed include those of immunofluorescence assays and TEM 
analyses across various infection time-points.  TEM studies and apoptotic assays to study the 
egress and apoptotic mechanisms of CHIKV in host cells were also presented. 
 
 Chapter 5 discussed the membrane trafficking library screening study to determine host 
factors involved in the infectious entry of CHIKV into cells.  Drug inhibitory assays and 
siRNA-based gene knockdown and qRT rt-PCR analyses of genes of selected putative hits 
were also described in detail. 
 
 Chapter 6 discussed the genome-wide microarray profiling study performed to 
investigate CHIKV interactions with host factors.  Randomly selected genes of several 
biological pathways were analysed further via siRNA-based gene knockdown and qRT rt-
PCR analyses, and the results of these downstream experiments were presented. 
 
 The results and observations in this study are summarised in Chapter 7, along with 
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2.1  Eukaryotic Cell Culture 
 
 Where necessary, cell culture media and solutions were prepared with reverse osmosis 
water in sterile conditions in Class II biosafety cabinets (ESCO Class 2 Type A2).  All 
eukaryotic tissue culture was carried out under sterile conditions in Class II biosafety 
cabinets, with cells routinely tested for mycoplasma using the MycoAlert Mycoplama 
Detection Kit (Cambrex).    
 
2.1.1 Cell Lines 
Table 2.1 List of Cell Lines Used in Study 
CELL LINE ORIGIN SOURCE MORPHOLOGY 
HEK293A Human Life Technologies adherent, epithelial 
HEK293FT Human Life Technologies adherent, epithelial 
Baby Hamster Kidney-21 
(BHK-21) 
Hamster ATCC CCL-10 adherent, fibroblast 
C2C12 Mouse ATCC CRL-1772 adherent, myoblast 
Aedes albopictus C6/36 Mosquito ATCC CRL-1660 adherent, epithelial-like 
Chinese Hamster Ovary 
(CHO-K1) 
Hamster ATCC CCL-61 adherent, epithelial-like 
HeLa Human ATCC CRM-CCL-2 adherent, epithelial 
HepG2 Human ATCC HB-8065 adherent, epithelial 
Human Skeletal Muscle 
Myoblast (HSMM) 
Human Lonza adherent, myoblast 
HUH7 Human 
Dr. P. Yang, Harvard 
Medical School, U.S.A. 
adherent, epithelial 
HUH7.5 Human 
Dr. Y. Suzuki, National 





Human ATCC CCL-136 adherent, spindle-shaped 
SJCRH30 Human ATCC CRL-2061 adherent, fibroblast 
SK-N-SH Human ATCC HTB-11 adherent, epithelial 
Vero Green African Monkey ATCC CCL-81 adherent, epithelial 
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2.1.2 Maintenance of Primary Cell Lines 
  
 Human skeletal muscle myoblast (HSMM; Clonetics, Lonza Group Ltd, Switzerland) 
cells were grown at 37°C in Skeletal Muscle Myoblast Cell Growth Medium (SkGM-2; 
Clonetics) supplemented with 10% FCS, dexamethasone, GA-1000, rhEGF and L-glutamine 
(Clonetics).  HSMM cells are isolated from normal donors, from post-gestational tissue 
typically from the quadriceps or psoas tissue.  Cells were passaged in T75 flasks at 50-60% 
confluency, with fresh media added twice weekly. 
 
2.1.3 Maintenance of Immortal Cell Lines 
  
 Cells were maintained as monolayers in sterile 75cm
2
 (T75) and 25cm
2
 (T25) cell 
culture flasks (Corning Inc., U.S.A.) in appropriate growth media (Roswell Park Memorial 
Institute [RPMI-1640, Sigma-Aldrich Corp., U.S.A.] or Dulbecco’s Modified Eagle’s Media 
[DMEM; Thermo Scientific
TM
]) supplemented with 10% filtered fetal calf serum (FCS; 
Hyclone, U.K.) and sodium bicarbonate (Merck). Cells were incubated in a 37
o
C incubator 
humidified with 5% CO2/95% air and subcultured every 3-7 days as necessary. 
  
2.1.4 Cell Line Storage and Thawing  
 
 In order to prepare cells for long-term storage in liquid nitrogen, growth media was 
firstly removed from flasks containing the incubated cells.  After washing with PBS, the cells 
were then trypsinised for 5 mins at 37
o
C with 5% CO2.  After incubation, appropriate growth 
media was then added to neutralise the trypsin and cells were aspirated with gentle pipetting.  
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which the cell pellet was resuspended in growth media containing 10-20% dimethyl sulfoxide 
(DMSO).  In order to maximise cell preservation, the cells were then placed in a Mr. Frosty
TM
 
freezing container (Thermo Scientific) – designed to achieve a cooling rate of -1oC per minute 
- at -80
o
C overnight, prior to storage in liquid nitrogen. 
 
 To rescue frozen cells for subsequent culture, the cells were removed from liquid 
nitrogen storage and after thawing at 37
o
C, were then placed into a flask filled with 
appropriate growth media and supplements.  The cells were incubated overnight at 37
o
C with 
5% CO2, before unattached cells were removed and fresh growth media added. 
 
2.1.5 Preparation of Coverslips for Cell Culture 
 
 Glass coverslips of 13mm diameter were first rinsed with reversed osmosis water.  The 
coverslips were then soaked in 70% denatured ethanol, before being rinsed twice with 
reversed osmosis water. The coverslips were subsequently left to dry at 60ºC and placed into 
clean glass petri dishes.  The coverslips were then sterilized by baking at 160ºC for 2 hrs. 
 
2.1.6 Cell Culture 
 
 Upon determining cell confluency levels, DMEM growth media was removed from 
flasks containing incubated cells.  After washing with PBS, the cells were then trypsinised for 
5 mins at 37
o
C with 5% CO2.  After incubation, appropriate growth media was then added and 
cells were aspirated with gentle pipetting.  Further cell passages were maintained by 
establishing appropriate dilutions with the addition of the growth media, and cells were 
incubated at 37
o
C with 5% CO2 until desired confluency levels were met. 
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 Cell numbers were determined by pipetting the cell suspension into the chamber of a 
Neubauer haemocytometer and counting them in accordance with conventions.   
 
2.1.6.1 Seeding in Tissue Culture Flasks 
 
 Cells were cultured as mentioned in Section 2.1.5, and cell numbers were determined.  
The cells were then diluted accordingly with appropriate growth media.  For instance, 1 x 10
6
 
cells were required for a 25 cm
2
 
sterile cell culture (T25) flask, with 5mL cell-media mix 
seeded into each flask.  Similarly, 10mL of 5 x 10
6









2.1.6.2 Seeding in Tissue Culture Plates 
 
 Cells were cultured as mentioned in Section 2.1.5, and cell numbers were determined.  
The cells were then diluted accordingly with appropriate growth media.  For instance, 1.5 x 
10
4
 – 2 x 104 cells were required for a 96-well plate, with 100µL cell-media mix seeded into 
each of the wells.  Similarly, 7 x 10
4
 – 1 x 105 cells were required for a 24-well plate, with 
1mL cell suspension seeded into each well, and 5mL of 5 x 10
5
 cell suspension was seeded 
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2.1.6.3 Seeding on Coverslips 
 
The coverslips were first placed into the wells of a 24-well cell culture plate using a pair 
of sterile forceps under sterile conditions in the class II biosafety cabinet.  Cells were cultured 
as mentioned in Section 2.1.5, and cell numbers were determined.  The cells were then diluted 
accordingly with appropriate growth media.  One millilitre of 7 x 10
4
 – 1 x 105 cell 




2.1.7 Cell Viability Assays 
 
2.1.7.1 Alamar Blue Assay 
 
 The alamarBlue® assay was used to assess cell viability upon treatment with 
biochemical agents, such as siRNAs and chemical inhibitors.  Living cells maintain a 
reducing environment within the cytosol.  Resazurin, the active ingredient of alamarBlue® 
reagent, is a non-toxic, cell-permeable compound that is blue in colour and virtually non-
fluorescent.  Viable cells continuously convert resazurin to resorufin - a red and highly 
fluorescent compound, thereby increasing the overall fluorescence and colour of the 
surrounding media.   
 
Cells were seeded in 96-well cell culture plates and incubated overnight at 37°C with 
5% CO2.  Upon treatment with respective drugs for 3 hrs (Section 2.7) or siRNAs for 48 hrs 
(Section 2.5.7.2), 10μL alamarBlue® reagent was added to each well, before incubation at 
37°C with 5% CO2 for 4 hrs.  The resulting fluorescence was read on an ELISA plate reader 
(Bio-Rad) at a peak excitation wavelength of 570nm and a peak emission wavelength of 
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585nm.  Fluorescence results were finally analysed by plotting fluorescence intensity against 
compound concentration.   
 
2.1.7.2 Terminal Deoxynucleotidyltransferase-Mediated dUTP Nick End Labelling 
(TUNEL) Assay 
 
 The In Situ Cell Death Detection Kit, Fluorescein (Roche, U.S.A.) was used to measure 
and quantitate cell death via apoptosis by enzymatic labelling of the free 3’-OH termini - from 
the resultant DNA strand breaks – with the use of modified nucleotides and enzymes such as 
DNA polymerase and terminal deoxynucleotidyl transferase (TdT).  Subsequent detection of 
the DNA strand breaks in individual cells could then be performed by fluorescence 
microscopy. 
 
 Cells were seeded onto coverslips and incubated overnight at 37°C with 5% CO2.  Upon 
infection with CHIKV, the cells were fixed with 4% paraformaldehyde/PBS and 
permeabilised with 0.1% Triton-X/0.1% sodium citrate solution at appropriate time-points.  
Negative (without TdT) and positive (treated with 1µM staurosporine for 2 hrs and harvested 
at 8 hrs post-infection [h.p.i.]) labeling controls were included, along with mock-infected 
controls.  Samples were then subjected to labeling with the TUNEL reaction mixture prior to 
imaging analysis.  Cell nuclei were counter-stained with DAPI.  The specimens were then 
viewed with Olympus IX81 motorized inverted epifluorescence microscope (Olympus, Japan) 
with appropriate
 
excitation and emission wavelengths for TUNEL at the GFP channel (490nm 
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2.2  Viruses 
  
2.2.1 Virus Strains 
  
 CHIKV strain (Singapore/07/2008 strain; designated as CHIKV-0708 throughout the 
thesis) was obtained from Dr Raymond Lin (National Public Health Laboratory, Ministry of 
Health, Singapore) and propagated in BHK-21 cells.  CHIKV strains LK(EH)CH6708 and 
SGEHICHID122508 (designated as CHIKV-6708 and CHIKV-122508, respectively) were 
obtained from Environmental Health Institute (EHI), National Environment Agency (NEA) 
(Singapore) and propagated in C6/36 cells.  All CHIKV strains were previously isolated from 
individual patients during the Singapore CHIKV outbreak in 2008.  All experiments involving 
the use of the CHIKV strains were performed in Biosafety Level 2 facilities.  
 
2.2.2 Viral Infection of Cells 
 
2.2.2.1 Infection in Tissue Culture Flasks 
 
Cells were cultivated on tissue culture flasks as described in Section 2.1.6.1 and allowed 
to grow to confluent monolayers.  Upon discarding the spent medium and washing the cells 
with PBS, the appropriate amount of virus was added to the cells at a multiplicity of infection 
(M.O.I) of 10 and subsequently incubated for 1.5 hrs in the humidified 37ºC incubator with 
5% CO2, with gentle rocking every 15 mins.  The virus was then discarded and the flasks 
were washed thrice with PBS to remove excess unbound virus.  Appropriate maintenance 
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media, enriched with 2% FCS and sodium bicarbonate, was added into each flask.  The flasks 
were then incubated in the humidified 37ºC incubator with 5% CO2
 
for the desired period. 
 
2.2.2.2 Infection in Tissue Culture Plates and Coverslips 
 
Cells were cultivated on tissue culture plates and coverslips, as described in Section 
2.1.6.2 and 2.1.6.3, respectively, and allowed to grow to 75% confluency.  Upon discarding 
the spent medium and washing the cells with PBS, the appropriate amount of virus was added 
to the cells at an M.O.I of 10.  For instance, 20µL virus was added into a 96-well plate, while 
100µL and 500µL virus was dispensed into each well of a 24- (including coverslips) and 6-
well plate, respectively.   The plate was subsequently incubated for 1.5 hrs in the humidified 
37ºC incubator with 5% CO2, with gentle rocking every 15 mins.  The virus was then 
discarded and the wells were washed thrice with PBS to remove excess unbound virus.  
Appropriate maintenance media, enriched with 2% FCS and sodium bicarbonate, was added 
into each well.  The plates were then incubated in the humidified 37ºC incubator with 5% CO2
 
for the desired period. 
 
2.2.3 Production of Viral Stocks 
 
Confluent monolayers of BHK-21 cells in T75 flasks were first washed with PBS and 
infected with CHIKV-0708 at an M.O.I of 10.  Similarly, confluent monolayers of C6/36 cells 
were infected with CHIKV-6708 or CHIKV-122508 at an M.O.I of 10.  The infected cells 
were then incubated in the 37ºC incubator with 5% CO2, with gentle rocking every 15 mins.  
Thereafter, the flasks were topped up to 10mL of appropriate maintenance media prior to 
further incubation at 37ºC with 5% CO2 or 28ºC without 5% CO2.  The infected flasks were 
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monitored daily under the light microscope to observe for cytopathic effects induced by the 
virus.  The cell-virus suspension in the flasks was harvested when approximately 80% of the 
cells lifted off, via centrifugation at a speed of 800x g for 15 mins.  The virus-containing 
supernatant was harvested and aliquoted into 1mL cryovials before being placed in the -80ºC 
freezer for long-term storage.  The virus titres were subsequently determined by viral plaque 
assay (Section 2.2.4). 
 
2.2.4 Determination of Viral Titres by Viral Plaque Assay 
 
Viral plaque assays were performed on BHK-21 cells to quantitate infectious virus 
titers, calculated following the method of Dulbecco (1952).  Briefly, BHK-21 cells were 
grown in 24-well tissue culture plates as described in Section 2.1.6.2 and incubated to 
approximately 75% confluency.  Each virus sample was subjected to ten-fold serial dilutions 
using appropriate maintenance media, with triplicate wells being allocated to each dilution.  
Upon discarding the spent media, each of the triplicate wells was then inoculated with 100µL 
virus sample and incubated at 37ºC with 5% CO2
 
for 1.5 hrs, with gentle rocking every 15 
mins.  Thereafter, the wells were then washed thrice with PBS, prior to the addition of 1mL 
overlay medium (RPMI supplemented with 1% carboxymethyl cellulose [CMC] and 2% 
FCS) and further incubation for three days at 37ºC with 5% CO2.   
  
 Upon observation of plaques, the overlay medium was removed and replaced with 
500μL crystal violet staining solution.  The tissue culture plate was stained overnight with 
gentle shaking prior to being washed thoroughly allowed to air dry.  The number of plaques in 
each well was counted and expressed as plaque forming unit per millilitre (PFU/mL).  The 
serial dilution with 50-100 countable plaques was averaged out to give the final virus titre. 
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2.2.5 Establishment of CHIKV Growth Kinetics 
  
Cell monolayers grown overnight in 24-well tissue culture plates (1 x 10
5
 cells per well) 
were infected with CHIKV at a multiplicity of infection (M.O.I) of 10 for 1.5 hrs at 37
o
C with 
5% CO2. Inoculated cells were then washed three times with PBS and overlaid with 1mL 
maintenance medium per well.  Cells and supernatants were collected every 6 hrs for 24 hrs, 
and subsequently daily for 5 days, with the first time-point (time 0) collected immediately 
after the addition of the maintenance medium to account for excess non-specific virus 
binding.  Infectious virus titres of the supernatants collected were determined by viral plaque 
assay, as previously mentioned.   
 
Viral RNA was also extracted (Section 2.4.1) from viral supernatants obtained from 
parallel experiments conducted, and titrated by quantitative real-time reverse transcriptase 
PCR (qRT rt-PCR).  Additionally, differential interference contrast (DIC) images of were 
taken using an inverted fluorescence microscope (IX81 Olympus) at 100x magnification at 
each infection time-point to observe the cytopathic effects of the CHIKV-infected cells. 
 
 
2.3 Transmission Electron Microscopy (TEM) Studies 
 
 To track CHIKV infectious processes into host cells at various time points p.i, CHIKV-
infected cells were fixed with 2.5% glutaraldehyde (Agar Scientific, U.K.) at 4ºC for 20 mins, 
followed by scraping of the cells and further subjecting them to fixation at 4ºC overnight.  
The following day, cells were centrifuged and the pellets were washed with PBS and 
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deionized water.  Cell pellets were post-fixed with 1% osmium tetroxide (Ted Pella, Redding, 
U.S.A.) and 1% potassium ferro-cyanide for 2 hrs, followed by dehydration in an ascending 
graded series of ethanol and acetone, i.e. 25%, 50%, 75%, 95% and 100% for 10 mins at each 
concentration.  Cells were then infiltrated with resins by passing them through three changes 
of mixture, comprised of a combination of acetone, ethanol and araldite.  
 
 The following day, cells were infiltrated with four changes of absolute embedding 
media with 1 hr incubation each at room temperature, 40ºC, 45ºC and 50ºC.  After a final 
spin, cell pellets were resuspended in 100-200µL araldite.  The mixture was subsequently 
embedded using the BEEN capsule (size 3) and was incubated at 60ºC for 24 hrs to enable 
polymerization.  The samples were trimmed with an ultramicrotome (Reichert-Jung, U.S.A.) 
and the sections were stained with 2% uranyl acetate and fixed with lead citrate.  The stained 
sections were viewed under the transmission electron microscope Philip EM 208 and images 
were captured digitally with a dual view digital camera (Gatan, U.S.A.). 
 
 
2.4 Microarray Genome Profiling 
 
2.4.1 Total RNA Isolation and Amplification, Hybridisation, Labelling and 
Scanning 
 
A total of 5 x 10
5
 HSMM cells were seeded in 6-well tissue culture trays (Nunc) 
overnight - as described in Section 2.1.6.2 - before being infected in triplicates with CHIKV-
DSO at an MOI of 10 or mock-infected with an equal volume of concentrated conditioned 
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growth medium, as described in Section 2.2.2.2.  At 6, 12, 24, and 48 h.p.i., total RNA was 
extracted using TRIzol reagent according to manufacturer’s instructions (Invitrogen).   TRIzol 
lysates were subsequently purified with the RNeasy Mini Kit (Qiagen) and quality tested 
using the Agilent RNA 6000 Nano Kit on an Agilent bioanalyzer (Agilent Technologies Inc., 
Germany).   
 
The RNA samples were then used for probe synthesis of streptavidin-Cy3-labeled 
cRNA using the Illumina® TotalPrep RNA Amplification Kit (Illumina Inc., U.S.A.) prior to 
hybridization onto Illumina HumanHT-12 v4 Expression BeadChip gene expression 
microarray chips (Illumina), which targets 47,231 transcripts derived from the National 
Center for Biotechnology Information Reference Sequence (NCBI) RefSeq Release 38 
(November 7, 2009) and legacy UniGene content.  Hybridization was carried out at 65
o
C for 
18 hrs in an Illumina hybridization oven at 10x g.  After hybridization, the microarray chips 
were washed before scanning on Illumina BeadArray Reader.  Raw signal data was extracted 
from the TIFF images with GenomeStudio Data Analysis Software (Gene Expression 
Module; Illumina). 
 
2.4.2 Microarray Data Analysis 
 
Raw microarray expression data were processed and analyzed using Partek Genomics 
Suite (Partek; U.S.A.) to generate values representing fold changes in gene expression. An 
average of the triplicate values was used to calculate fold change, and each value was then 
assessed for its statistical significance, using analysis of variance (ANOVA).  Host genes 
demonstrating at least a 1.5- and 2-fold change in expression and a > 95% probability of 
being expressed differentially (P < 0.05) were selected for further investigation.   
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Pathway analysis was subsequently detailed with Ingenuity Pathway Analysis (IPA) 9.0 
(Ingenuity Systems 2011, U.S.A.) and differentially regulated genes involved in various 
pathways were selected for pathway mapping.  STRING 9.1, an online software containing a 
database of known and predicted protein interactions – both direct/physical and 
indirect/functional – was also utilised to map associations among selected protein hits. 
 
 
2.5 RNA and DNA Manipulation Studies 
  
2.5.1  Isolation of Viral RNA 
 
 Viral RNA was extracted using the QIAampR Viral RNA Mini kit (Qiagen, Germany), 
in accordance with manufacturer’s instructions.  Briefly, 140µL viral stock was added to 
560µL Buffer AVL-carrier RNA and mixed by pulse-vortexing for 15 secs.  The sample was 
then incubated at room temperature for 10 mins, after which 560µL of 100% ethanol was 
mixed to the sample.  The lysate was pipetted into the QIAamp Mini spin column and 
centrifuged at 6000x g.  After all lysates had been drawn through the column, membrane-
bound RNA was washed consecutively with 500µL Buffer AW1 and 500µL Buffer AW2.  
After the final wash, the column was centrifuged for 3 mins at 20,000x g to remove any 
excess buffer.  Viral RNA was finally eluted from the column by the addition of 60µL Buffer 
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2.5.2  Isolation of Total RNA 
 
 Total RNA was extracted using Qiagen RNeasy Mini Kit, according to manufacturer’s 
instructions.  Briefly, the plasma membrane of the cells was lysed with the addition of Buffer 
RLT and mixed by vigorous vortexing.  100% ethanol was subsequently added prior to 
transferring the sample to an RNeasy spin column and centrifuging at 8000x g for 15 secs.  
The centrifugation steps were then repeated after the addition of wash buffers RW1 and RPE.  
The total RNA was eluted with RNase-free water and centrifugation at 8000x g for 1 min. 
 
2.5.3  Isolation of Plasmid DNA 
 
  GFP-tagged plasmid constructs of Dyn2 (wild-type dynamin 2) and its dominant 
negative mutant K44A (inhibits cell spreading and lamellipodia formation) were kindly 
provided by Dr. M. McNiven, Mayo Clinic, Arizona, U.S.A.  Plasmid constructs of CtBP1 
(phosphorylation target of PAK1) and its dominant negative mutant S147A (phosphorylation-
defective) were kindly provided by Dr. U.F. Greber, Universitat Zurich, Zurich, Switzerland.  
Plasmid constructs of BST2 were kindly provided by Dr. N. Yamamoto, National University 
of Singapore, Singapore.  The plasmids were grown up to sufficient amounts prior to DNA 
transfection into host cells. 
  
2.5.4  Determination of RNA and DNA Quality 
 
 Concentration of the purified DNA was determined by the use of Nanodrop
TM
 ND-
1000 spectrophotometer (Thermo Scientific).  With appropriate settings (set to Nucleic Acids; 
Chapter 2 
Materials and Methods 
61 
 
RNA: 40, dsDNA:50) in place, 1µL DNA sample was pipetted onto the pedestal and analysis 
was performed using the integrated Data Viewer programme (http://www.nanodrop.com). 
 
2.5.5  Quantitative Real-Time Reverse Transcriptase Polymerase Chain 
Reaction (qRT rt-PCR) 
 
One-step quantitative real-time reverse transcription-PCR (qRT rt-PCR) assays were 
performed using the ABI PRISM 7500 RT-PCR system (Applied Biosystems, Life 
Technologies Corporation, U.S.A.).  Twenty-five-microliter reaction mixtures were set up 
according to manufacturer’s instructions.  Briefly, for quantification of viral gene expression, 
samples were assayed with a final concentration of 250nM of each CHIKV nsP2 primer in a 
1x final concentration of SYBR Green Taq Ready Mix for Quantitative RT-PCR (1x Taq 
DNA polymerase, 10mM Tris-HCl, 50mM KCl, 3mM MgCl2, 0.2mM dNTPs, stabilizers) and 
1x reference dye (Sigma Aldrich, U.S.A.), and Moloney Murine Leukemia Virus reverse 
transcriptase (M-MLV RT) (Promega).  CHIKV nsP2 primer sequences are available in 
Appendix B.   
 
Similarly, for quantification of host gene expression, samples were assayed with a final 
concentration of 200nM of each gene primer in a 1x final concentration of Maxima
TM
 SYBR 
Green/ROX qPCR Master Mix (Hot Start Taq DNA polymerase, KCl, (NH4)2SO4, dNTPs, 
stabilizers) (Fermentas, Thermo Fisher Scientific Inc., U.S.A.) and M-MLV RT (Promega).  
Primer sequences are available in Appendix B.  
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Reaction conditions consist of a 20-min reverse transcription step at 44°C, followed 
by 2 mins of Taq polymerase activation at 94°C, 40 cycles of PCR at 94°C for 15 secs per 
cycle (denaturation) and finally 1 min at 60°C (annealing and extension).  Following the 
amplification, a melting curve analysis was performed to verify the melting temperature of 
PCR products amplified by the primer pairs.  Amplification graphs were checked for the Ct 
value of the PCR product. The Ct value represented the cycle by which the fluorescence of a 
sample increased to a level higher than the background fluorescence in the amplification 
cycle.  β-actin acts as the normalizing housekeeping gene.  For quantification of host gene 
expression, the comparative threshold cycle (CT) method was used to calculate the fold 
change in gene expression, with β-actin as the normalizing control gene.   
 
2.5.6  Sequencing and Sequence Analysis 
 
 DNA fragments of CHIKV strains were amplified via rt-PCR with the use of viral RNA 
extracted, as described in Section 2.5.1, and SuperScript III reverse transcriptase (Invitrogen).  
PCR amplification was subsequently performed using Q5 high-fidelity Taq DNA Polymerase 
(New England Biolabs).  Reaction conditions consist of an initial denaturation at 98°C for 30 
secs followed by 40 cycles of PCR with each cycle consisting of stages at 98°C for 10 secs, 
70°C for 30 secs and 72°C for 3 mins, before a final extension phase for 2 mins at 60°C.  The 
expected PCR products were cleaned up and extracted via the QIAquick Gel Extraction Kit 
(Qiagen) prior to determining the purity and concentration by NanoDrop. 
 
 The nucleotide sequences of the purified PCR products were determined by next 
generation sequencing with the use of the Ion Torrent platform and performed by AITbiotech.  
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Analysis of DNA chromatograms was performed with variant calling in Ion Sequencing Data 
TVC3.6. 
 
2.5.7  Transfection Assays 
 
2.5.7.1 siRNA-Based Library Screening 
 
 The human genome siRNA subset library targeting the endocytic and membrane 
trafficking genes (Dharmacon, RTF H-005500) was used in this study.  A smartpool approach 
of incorporating four siRNAs targeting each gene was utilised.  The list of 122 targeted 
human genes and isoforms is presented in Appendix D. 
 
A high-throughput platform for the specific detection of CHIKV infection in the 384-
well plate format via immunofluorescence staining was employed for the library screening 
assay.  A 1.2% (vol/vol) stock solution of the transfection reagent (DharmaFECT-4) was 
prepared in DCCR cell culture buffer (Dharmacon) and incubated at room temperature for 10 
mins.  From this stock, 8μL was added to the lyophilised siRNA in each well of the 384-well 
plate and incubated at room temperature for 30 mins to allow the siRNAs to rehydrate and 
form siRNA-lipid complexes. Subsequently, 5 x 10
3
 HSMM cells in 42μL complete growth 
medium were added.  The siRNA-cells mixture was then incubated at 37
o
C for 48 hrs to 
ensure effective gene knockdown by the siRNAs, prior to CHIKV infection, as described in 
Section 2.2.2.2.  The final concentration of pooled siRNAs was 50nM per well, with 
individual siRNA duplexes at a concentration of 6.25pmol per well.  
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After 16 h.p.i., CHIKV-infected cells were then fixed with cold absolute methanol 
(Sigma) for 15 mins at -20
o
C before being subjected to immunofluorescence staining using 
primary anti-Alphavirus antibodies (Santa Cruz), followed by FITC-conjugated secondary 
antibodies (Invitrogen).  Cell nuclei were counter-stained with DAPI (100nM; Invitrogen) 
prior to collation of image data by the ArrayScan VTI HCS automated fluorescence 
microscope Reader system (Cellomics) with appropriate excitation and emission wavelengths 
for FITC (495nm and 520nm, respectively) and DAPI (358nm and 461nm, respectively).  
Data collection and autofocusing parameters were pre-determined using Cellomics Target 
Activation Bioapplication (Cellomics).  A generic segmentation tool function was used to 
identify the two different stains (DAPI and FITC) with intensities above background staining 
and data collection was obtained by logging the measurements.   
 
 Data analysis following image acquisition was carried out using CellProfiler 2.1.0 
(Broad Institute, U.S.A.).  DAPI-stained nuclei were counted to determined total cell 
populations while FITC-stained cytoplasm was scored to determine the number of virus-
infected cells.  An average of at least 50% total inhibition rate – therefore a less than 50% 
infection rate - among the triplicate samples, was used as the cut-off criteria for positive 
screening hits.  Three independent screening assays were performed. 
 
Controls included in individual sets of experiments were the use of transfection reagent 
(DharmaFECT-4) alone, a non-targeting siRNA  (Dharmacon), a green fluorescent non-
specific siRNA (siGLO, Dharmacon), RISC-free siRNA (Dharmacon) and siRNA smartpools 
targeting cyclophilin B duplex, glyceraldehyde-3-phosphate dehydrogenase and lamin A/C 
(Dharmacon). These siRNAs served as negative controls for non-specific effects of siRNA 
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and/or transfection reagents on cell viability and virus infection.  In addition, cell viability 
was observed and monitored by visual inspection via the use of phase-contrast microscopy. 
 
2.5.7.2 siRNA Transfection 
 
Different siRNAs targeting various host genes involved in endocytic and viral exit 
processes were selected to perform reverse transfection assays in HSMM cells, in order to 
validate microarray and library screening findings.  The list of siRNA-based genes used in the 
study is shown in Table 2.2. 
 
Specific gene-targeting siRNAs were dissolved in DEPC-treated reverse osmosis water 
to a final stock concentration of 100mM, and incubated at room temperature for 30 mins with 
gentle agitation. Different siRNAs were diluted to desired working concentrations of 25nM 
and 50nM with serum-free media (Lonza) and transfection reagent (Dharmafect-1, 
Dharmacon).  The specific individual siRNAs that were directed against each of the 
respective genes were then transfected into HSMM cells prior to being subjected to CHIKV 
infection after 48 hrs post-transfection.  The supernatants were then harvested 16 h.p.i for 













Table 2.2 Gene List of siRNAs Used in Study 
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2.5.7.3 Plasmid DNA Transfection 
 
Transfections were performed by using Lipofectamine LTX reagents according to 
manufacturer’s recommendation (Invitrogen).  Briefly, HSMM cells were grown on 
coverslips in 24-well tissue culture plates, as described in Section 2.1.6.3.  Subsequently, 5µg 
plasmid DNA was complexed with 5µL Plus reagent in 250µL OPTI-MEM medium (Gibco, 
New York, U.S.A.).  The mixture was then added to 50µL OPTI-MEM containing 4µL 
Lipofectamine LTX (Invitrogen, USA) in a 1:1 ratio.  After incubation for 5 mins at room 






2.6 Bioimaging Analyses 
 
2.6.1 Indirect Immunofluorescence Microscopy 
 
Coverslips were prepared as described in Section 2.1.5 and the cells were cultivated on 
the coverslips as described in Section 2.1.6.3.  The cells were then either pre-treated with 
drugs or transfection agents before infection with CHIKV.  The coverslips were fixed with 
ice-cold absolute methanol for 15 mins at -20
o
C and washed three times with cold PBS.   
 
The cells were then subjected to immunofluorescence staining using appropriate 
antibodies and/or fluorescent dyes, such as primary anti-Alphavirus mouse monoclonal 
antibodies (Santa Cruz Biotechnology) or customised rabbit polyclonal antibodies targeted 
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against CHIKV E2 proteins (ProSci Inc., U.S.A.), followed by secondary antibodies 
conjugated to fluorescein isothiocyanate (FITC; Invitrogen) and Texas Red (TR; Invitrogen) 
for 1 hr per antibody.  Cell nuclei were counter-stained with 4’, 6’-diamidino-2-phenylindole 
(DAPI; 100nM) fluorescent dye (Invitrogen) for 15 mins in the dark (Table 2.3).    
 
The coverslips were then mounted onto glass slides and visualized using a motorised 
inverted epifluorescence microscope (IX81 Olympus) with appropriate
 
excitation and 
emission wavelengths for FITC (490nm and 525nm, respectively), TR (596nm and 615nm, 
respectively) and DAPI (350nm and 470nm, respectively) at 100x, 200x and 1000x 
(immersion oil) magnification.  
 
Table 2.3 Antibodies and Fluorescent Dyes Used in Study 
TYPE OF 
ANTIBODIES/DYES 




Anti-Alphavirus (Santa Cruz) 








Anti-Mouse FITC (Invitrogen) 
Anti-Rabbit FITC (Invitrogen) 










2.6.2 Infectious Entry Bioimaging Studies 
 
HSMM cells were first incubated at 4ºC for 30 mins and then washed with ice-cold 
PBS, prior to infection with CHIKV at an M.O.I of 10.  The infected cells were further 
incubated at 4ºC for 1 hr immediately after virus addition to enable virus binding before the 
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temperature was shifted rapidly to 37
o
C for virus internalisation.  CHIKV-infected HSMM 
cells were subsequently processed for immunofluorescence assay and microscopic imaging at 
appropriate time-points of the early infective stages: 0, 5, 10, 15, 30, 45, 60 and 90 mins.  
Supernatants were harvested from transfected cells and plaque assays were performed.  
 
 
2.7 Drug Inhibitory Studies 
 
Drugs used in this study were prepared according to the recommendations given in the 
product sheet under sterile conditions within the biosafety cabinets (ESCO Class 2 type A2).  
All drugs (Table 2.4), obtained from Sigma Aldrich, were freshly diluted to their respective 
working concentrations with growth media.   
 
HSMM cells were seeded into 24-well plates, as described in Section 2.1.6.2, and 
incubated overnight prior to drug inhibitory assays.  Pre-treatment drug assays were 
performed in favour of co- and post-treatment studies, in order to ensure that potential 
CHIKV inhibition is most likely to occur at the entry step, as opposed to downstream 
infective phases, such as viral replication. 
 
Hence, to determine the effects of the drugs used to inhibit the CHIKV entry, HSMM 
cells were pre-treated with drugs at various concentration ranges (Table 2.4) for 3 hrs at 37
o
C. 
The pharmacological inhibitors were then removed and cell monolayers were washed twice 
with PBS, in order to eliminate the possibility of exposure of the virus to the inhibitors.  This 
is to ensure minimal risk of the inhibitors directly influencing the viability of the virus and its 
subsequent entry into the cells.  After 1.5 hrs of virus infection at an M.O.I. of 10, the cells 
Chapter 2 
Materials and Methods 
70 
 
were washed thrice with PBS, replaced with fresh growth media and incubated for another 16 
hrs. Supernatants from the CHIKV-infected cells were subsequently harvested for viral 
infectious plaque assays.  Three independent experiments were carried out for each 
concentration set of drugs used.  
 





Bafilomycin A1 Vacuolar H+-ATPase inhibitor 0.01, 0.05, 0.1, 0.5, 1 (µM) 
Concanamycin A 
Inhibits acidification of 
organelles and perforin-
mediated cytotoxicity 
20, 40, 60, 80, 100 (nM) 
Cytochalasin B Inhibits actin polymerization 0.2, 1, 2, 3, 4, 5, 10 (µg/mL) 
Dynasore Dynamin-specific inhibitor 





Selective blocker of Na+/H+ 
antiport 
10, 25, 50, 100, 150, 200 
(µM) 
Filipin 
Inhibitor of caveolae-dependent 
endocytosis  
0.5, 1, 1.5, 2, 3 (µg/mL) 
Methyl-β-Cyclodextrin 
(MβC) 
Inhibits synthesis of lipid rafts 




Inhibitor of receptor-mediated 
endocytosis 





1, 5, 10, 15, 20 (µM) 
Nystatin 
Inhibitor of caveolae-dependent 
endocytosis  
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2.8 Statistical Analysis 
 
Where applicable, analyses of statistical significance were performed on repeated 
measurement using the one-tailed Student’s t test in GraphPad Prism 5 Online Statistical 
Software Package version 5.02 (SPSS Inc.; http://www.graphpad.com).  Unless otherwise 
noted, statistical significance was defined as follows: * denotes a p-value of less than 0.1 (p < 
0.1), ** denotes a p-value of less than 0.05 (p < 0.05) and *** denotes a p-value of less than 



















CHAPTER 3  
SUSCEPTIBILITY OF VARIOUS 
CELL LINES TO CHIKV 


















3.1  Introduction 
 
 Several studies have demonstrated susceptibility of various cell lines to CHIKV 
infection, with the rapid induction of apoptosis observed (Sourisseau et al., 2007; Solignat et 
al., 2009).  Epithelial cells, endothelial cells, primary fibroblasts and monocyte-derived 
macrophages were found to be permissive to infection (Sourisseau et al., 2007; Solignat et al., 
2009).  Skeletal muscle progenitor cells or satellite cells were also found to sustain CHIKV 
antigens, possibly resulting in the recurrent myalgia experienced by infected individuals 
(Couderc et al., 2008).  Moreover, in vivo murine studies suggest fibroblasts as the primary 
cellular target for CHIKV infection, confirming previous in vitro findings and accounting for 
CHIKV muscular and arthralgic tropism (Nakaya et al., 2012).  Consistent with reports of 
neurological involvement, neurons and glial cells are also observed to be susceptible to 
CHIKV infection (Das et al., 2010).  In a non-human primate model, persistent infection of 
liver tissues, as well as significant levels of hepatocyte cell death implicates the involvement 
of hepatocytes in the disease (Labadie et al., 2010).   
 
 Nevertheless, this study aims to ascertain susceptibility of a wide panel of mammalian 
and mosquito cell lines to CHIKV infection.  Determining the cell types to which CHIKV can 
attach and productively infect is crucial in understanding the pathophysiology of CHIKV 
infection in humans.  Furthermore, this study also aims to establish growth kinetics of various 
CHIKV strains available and determine whether susceptibility of these cell lines to CHIKV 







3.2  Various CHIKV Strains Contain Important Amino Acid 
Differences 
 
 To establish growth kinetics of various CHIKV strains presently available in our 
laboratory, sequencing of these virus strains were first performed.  As already mentioned in 
Section 2.2.1, CHIKV strain CHIKV-0708 was obtained from Dr Raymond Lin (National 
Public Health Laboratory, MOH, Singapore) and propagated in BHK-21 cells while CHIKV 
strains CHIKV-6708 and CHIKV-122508 were obtained from EHI, NEA (Singapore) and 
propagated in C6/36 cells.  All CHIKV strains were previously isolated from individual 
patients during the Singapore CHIKV outbreak in 2008.   
 
 Upon genome-wide sequencing of the three CHIKV strains, it was observed that 
CHIKV strain CHIKV-0708 was very similar to the prototypic African CHIKV Ross strain, 
which was of the early-phase ECSA lineage (Appendix C).  Meanwhile, CHIKV strains 
CHIKV-6708 and CHIKV-122508 were found to be evolutionally closer to the latter-stage 
ECSA lineage, which was found to be responsible for the 2008 outbreak in Singapore, 
although the former was isolated during the early stages of the outbreak, while the latter was 
isolated in the final phases.  The genomic sequences of all three CHIKV strains are shown in 
Appendix C. 
 
 Several amino acid differences among the three virus strains are listed in Table 3.1.  It 
was observed that CHIKV strains CHIKV-6708 and CHIKV-122508 were much more similar 
as compared to CHIKV-0708, with fewer amino acid differences between them (data not 
shown). CHIKV strain CHIKV-0708 was distinctly different from the other two strains, and 





amino acid at position 1937 of the nsP4 protein encodes for highly similar proteins in 
CHIKV-6708 and CHIKV-122508 strains (threonine and alanine, respectively), CHIKV-0708 
encodes for aspartic acid (Table 3.1).  Also, at position 577 of the structural E2 protein, highly 
similar amino acids lysine and glutamine were encoded in CHIKV-6708 and CHIKV-122508 
strains, respectively, while CHIKV-0708 encodes for valine (Table 3.1).  Of particular 
interest, is the amino acid difference among the three strains at position 1035 of the E1 
protein.  Alanine was encoded for CHIKV-6708 while CHIKV-122508 encodes for valine 
(Table 3.1). Previous studies have shown that this amino acid change facilitated the ability of 
the virus to efficiently infect host cells.  It could possibly explain the enhanced susceptibility 
profiles observed by majority of the cell lines tested in this study upon infection of the 
CHIKV-122508 strain.    
 





0708 6708 122508 
nSP4 1937 d t a 
E2 503 r h r 
E2 577 v k q 
E2 677 i l p 




3.3  Susceptibility of Human-Based Cell Lines to CHIKV Infection 
 
 A total of eight human-based cell lines were tested against the various strains of CHIKV 





line graph depicts that of CHIKV-0708, while the blue-line and green-line graphs display 
those of CHIKV-6708 and CHIKV-122508, respectively. 
 
 HUH7 is a well differentiated hepatocyte derived cellular carcinoma cell line that was 
originally taken from a liver tumour in a 57-year-old Japanese male in 1982.  It is an immortal 
cell line of epithelial-like tumorigenic cells.  HUH7.5 is a cell clone of the human hepatoma 
HUH7 cells, with a mutation in RIG-I.  As shown in Figures 3.1a and 3.1b, the growth 
kinetics of both CHIKV-0708 and CHIKV-6708 followed similar trends in both cell lines.  
However, CHIKV-122508 showed a consistently elevated increase in infectious viral particle 
production in HUH7 cells from 12 h.p.i. to 72 h.p.i., as opposed to that in HUH7.5 cells, 
which remained relatively flatter throughout. 
 
 Similar susceptibility trends can be observed in both 293FT and 293A cells.  The 293A 
cell line is a subclone of the 293 cells and has a relatively flat morphology.  It contains a 
stably integrated copy of the E1 gene that is typically used to supply the E1 proteins required 
to generate recombinant adenovirus.  Meanwhile, 293FT is a fast-growing, highly 
transfectable clonal isolate of the 293 cells, derived from human embryonal kidney cells 
transformed with the SV40 large T antigen.  While growth kinetics of all three CHIKV strains 
remained relatively plateaued throughout all infection time-points in 293FT cells (Figure 
3.1c), infectious titres of CHIKV-6708 and CHIKV-122508 peaked at 24 h.p.i. and 48 h.p.i. 
respectively, in 293A cells (Figure 3.1d). 
 
 HepG2 is an epithelial cell line derived from the liver tissue of a 15 year-old Caucasian 
American male with a well-differentiated hepatocellular carcinoma.  The RD cell is a muscle 





Caucasian female with rhabdomyosarcoma.  While the growth kinetics of CHIKV-0708 and 
CHIKV-6708 followed similarly flat trends as with previous cell lines, the infectious titre of 
CHIKV-122508 steadily increased to peak at 48 h.p.i. and 72 h.p.i. in HepG2 and RD cells, 
respectively (Figures 3.1e and 3.1f). 
 
 Amongst the various human-based cell lines tested, SK-N-SH and in particular, 
SJCRH30 exhibited the most favourable susceptibility profiles across all the CHIKV strains.  
Both derived from the metastatic site of the bone marrow, SK-N-SH is a brain epithelial cell 
line isolated from a 4 year-old female with neuroblastoma while SJCRH30 is a muscle 
fibroblastic cell line isolated from a 17 year-old Caucasian male with rhabdomyosarcoma.  As 
observed in Figure 3.1g, the infectious titres of all CHIKV strains were progressively 
increased, although the peak infection time-point for CHIKV-122508 was at 24 h.p.i., while 
those of CHIKV-0708 and CHIKV-6708 were at 48 h.p.i.  Similar growth trends could be 
seen for all CHIKV strains in SJCRH30 cells, with CHIKV-122508 infectious titre peaking 
earlier, as compared to the other two strains (Figure 3.1h).  However, it can also be observed 
that the peak infectious titres of all CHIKV strains in SJCRH30 cells were much higher as 
opposed to all other human-based mammalian cell lines, at 10
14



































































































































































































































































































































































































































































































































 CHIKV replication in host cells was analysed by performing an immunofluorescence 
assay on randomly selected cell lines. As shown by representative images in Figure 3.2 (upper 
panels), approximately 80-100% infection rates were achieved by 24 h.p.i. for all cell lines 
tested, including HUH7.5, RD, SK-N-SH and SJCRH30 cells.  At a higher magnification 
level, the cellular location of the CHIKV envelope protein within the host cells can be 
observed.  At 24 h.p.i., CHIKV viral proteins were observed to be accumulating within the 
cytoplasm and towards the plasma membrane, as shown by the red arrows (Figure 3.2, lower 
panels).  Figure 3.2 depicts immunofluorescence images of infection of CHIKV-strain 
CHIKV-122508 on the cell lines and are representative of all three CHIKV strains tested, 
taken at the 24 h.p.i. time-point. 
 
 SJCRH30 cells were subsequently chosen for further analysis via TEM studies.  This 
was due to the high infectability rates of all three CHIKV strains on the cells.  Furthermore, 
these cells were being shown, for the first time, to be highly susceptible to CHIKV infection.  
As shown by representative images in Figure 3.3, ultrastructural analysis of CHIKV-infected 
host cells revealed viral budding at early infective phases of 24 h.p.i. (red arrows; Figure 
3.3a).  Mature virions were subsequently observed to be budding into cytopathic vesicles-II 
(CPV-II) (red arrows; Figure 3.3b), ultimately resulting in massive exocytosis at later 
infective stages of 48 h.p.i. (red arrows; Figures 3.3c).  Figure 3.3 depicts TEM images of 
infection of CHIKV-strain CHIKV-122508 on the selected cell line and is representative of 





































































































































































































































































































































































































































































































































(a) Viral Budding @ 24 h.p.i. 
 
(b) Formation of CPV-IIs @ 24-48 h.p.i. 
 
(c) Exocytosis @ 48 h.p.i. 
 
 
Figure 3.3 CHIKV Infection Modes in SJCRH30 Cells 
                    (a) Ultrastructural analysis of CHIKV-infected host cells revealed viral budding at 24 
h.p.i. (red arrows).  (b) Mature virions were subsequently observed to be budding into 
CPV-IIs (red arrows), with (c) massive exocytosis by 48 h.p.i. (red arrows). PM: plasma 





3.4  Susceptibility of Non-Human Mammalian Cell Lines to 
CHIKV Infection 
 
 To investigate the susceptibility of non-human mammalian cells to CHIKV infection, a 
total of four different cell lines were utilised.  CHO cells were first derived in the 1960s from 
the ovary of the Chinese hamster while Vero was first isolated from kidney epithelial cells 
extracted from an African green monkey in 1962.  Similar to the human-based mammalian 
cell lines, growth profiles for CHIKV-0708 and CHIKV-6708 remained relatively flat 
throughout in CHO (Figure 3.4a) and Vero (Figure 3.4b) cells.  Conversely, CHIKV-122508 
infectious titres in both cells peaked at 48 h.p.i. 
 
 BHK21 is an adhesive fibroblastic cell line derived in 1961 from the kidneys of 
newborn Syrian golden hamsters while C2C12 is a mouse myoblast cell line originally 
obtained through serial passages of myoblasts cultured from the thigh muscle of C3H mice.  
Both cell lines were observed to be highly susceptible to all CHIKV strains, with peak 




 pfu/mL at 48 h.p.i. for CHIKV-6708 and CHIKV-
122508, respectively in C2C12 cells (Figure 3.4c).  In particular, more than 10
14
 pfu/mL was 
observed at 24 h.p.i. for CHIKV-122508 in BHK21 cells (Figure 3.4d).  Similarly high peak 
titres were seen for CHIKV-0708, albeit at a later infection time-point of 48 h.p.i., while 
CHIKV-6708 peaked at 48 h.p.i. in BHK21 cells, with approximately 10
8











    
















































































































































































































































































 CHIKV replication in non-human mammalian cells appeared similar to that in human-
based cells.  As shown by representative images in Figure 3.5 (upper panels), an almost-
complete infection rate was achieved within 24 h.p.i. in BHK21 cells (Figure 3.5a), while 
lower rates were observed in Vero (Figure 3.5b) and C2C12 (Figure 3.5c) cells.  At a higher 
magnification level, CHIKV viral proteins were observed to be accumulating within the 
cytoplasm and towards the plasma membrane (red arrows; Figure 3.5, lower panels).  Figure 
3.5 depicts immunofluorescence images of infection of CHIKV-strain CHIKV-122508 on the 














































Figure 3.5 CHIKV Replication in Non-Human Mammalian Cell Lines 
 Images shown are representative of infection of CHIKV strain CHIKV-122508 on 
selected cell lines, taken at 24 h.p.i.  High infection rates were observed, as depicted by 
the green fluorescence (upper panels).  CHIKV viral proteins were also observed to be 
accumulating within (a and b) the cytoplasm and towards the plasma membrane (red 
arrows, lower panels), as well as (c) the perinuclear region (red arrowheads, lower                   








3.5  Susceptibility of Mosquito Cell Lines to CHIKV Infection 
 
 Susceptibility of mosquito cell lines to CHIKV infection was also tested, with the use of 
C6/36 cells, derived from the whole larvae of Ae. albopictus (Asian tiger) mosquitoes.  
Progressively increasing growth profiles could be observed for all CHIKV strains, albeit with 
peak infectious titres at differing time-points.  CHIKV strains CHIKV-0708 only peaked at 72 
h.p.i., while the other two strains peaked earlier at 48 h.p.i., with approximately 10
8
 pfu/mL 
(Figure 3.6a).  Immunofluorescence studies to analyse CHIKV replication in C6/36 cells 
revealed approximately 100% infection rate by 24 h.p.i. (Figure 3.6b, left panel), with cellular 
localisation of viral envelope proteins to the ER and plasma membrane (red arrows; Figure 
3.6b, right panel).  Figure 3.6 depicts immunofluorescence images of infection of CHIKV-
strain CHIKV-122508 on the cell lines and are representative of all three CHIKV strains 
tested, taken at the 24 h.p.i. time-point. 
 
 Results of the wide range of cell lines tested and their susceptibility profiles against the 
































Figure 3.6 Susceptibility of Mosquito Cell Lines upon CHIKV Infection 
 (a) Cells were infected with different CHIKV strains across various timepoints.  CHIKV 
strains CHIKV-0708, CHIKV-6708 and CHIKV-122508 are represented by the red (    ), 
blue (    ) and green (    ) line-graphs, respectively. (b) Images shown are representative of 
infection of CHIKV strain CHIKV-122508 on selected cell lines, taken at 24 h.p.i.  High 
infection rates were observed, as depicted by the green fluorescence (left panel).  CHIKV 
viral proteins were also observed to be accumulating within the cytoplasm and towards 














0708 6708 122508 
HUH7 X X √ 
HUH7.5 X X √ 
HEK293A X √ √ 
HEK293FT X X X 
HepG2 X X √ 
RD X X √ 
SK-N-SH √ √ √ 
SJCRH30 √ √ √ 
CHO X X √ 
Vero X X √ 
C2C12 √ √ √ 
BHK21 √ √ √ 


























CHAPTER 4  
ESTABLISHMENT OF A NOVEL 
PRIMARY HUMAN CELLULAR 

















4.1  Introduction 
 
 Although several human cell lines have previously been shown to be permissive to 
CHIKV infection, these cell lines do not, however, address the tissue tropism observed during 
the infection in humans, and a human cellular model that provides a true reflection of the 
infection is lacking.  Human skeletal muscle myoblasts (HSMM) would therefore be an ideal 
cellular model, as it would accurately reflect the clinical manifestations observed in humans, 
including myositis, myalgia and arthritis.   
 
 In this study, we identified and characterised HSMM cells as a novel human primary 
cell line that is highly permissive to CHIKV infection.  The infective processes of CHIKV in 
its natural site of infection were therefore able to be thoroughly investigated. 
 
 
4.2  HSMM Cells are Permissive to CHIKV Infection 
 
Susceptibility of HSMM cells to CHIKV infection, via growth kinetics, was first 
established.  As shown in Figure 4.1a, progressive CHIKV infection was observed upon 
infection at an m.o.i. of 10 on HSMM, peaking at 16 h.p.i. with approximately 10
6
 pfu/ml 
before subsequently plateauing at later infection time-points.  
 
Validation of CHIKV infectability on HSMM cells was performed via morphological 
assessment and qRT rt-PCR analysis.  The amount of viral RNA was found to increase over 
time post-infection (Figure 4.1b), with an approximately ten-fold increase over 24 hrs, and 





the HSMM cells have been killed due to the infection.  As compared to the fibroblastic nature 
of uninfected cells, drastic cytopathic effects were induced upon CHIKV infection by 48 
h.p.i., displaying a highly unhealthy morphology (Figure 4.1c).  These results indicate that 
subsequent CHIKV infection studies can be effectively conducted with the use of these 






























Figure 4.1 Permissibility of HSMM Cells to CHIKV Infection 
(a) Growth kinetics of CHIKV strain CHIKV-0708 on HSMM cells; plot shown is 
representative of three independent experiments (b) Table showing qRT-PCR analysis of 
CHIKV infection on HSMM cells across various infection timepoints (c) Cytopathic 
effects observed upon CHIKV infection by 48 h.p.i.  Mock-infected HSMM cells 
displayed typical fibroblastic features. 
12 h.p.i. Mock-Infected 





4.3  HSMM Cells are Myoblastic in Nature and Transfectable 
 
PAX7 staining was performed to confirm the myoblastic characteristics of HSMM cells.  
Indeed, green fluorescence within the cell nuclei accounted for the presence of PAX7, thus 
suggesting that most of the cells retained their myoblastic features throughout the study 
(Figure 4.2a).  Additionally, transfectability of HSMM cells was tested with the use of siGLO 
as the fluorescent oligonucleotide duplex and a high proportion of the cells were observed to 
be transfected well with DharmaFECT-4 (Dharmacon) (Figure 4.2b).  This ensures that 














Figure 4.2 Investigating Myoblastic and Transfectability Characteristics of HSMM Cells 
(a) HSMM cells were stained with nucleus-centric PAX7 to confirm its myoblastic nature 
(green fluorescence, FITC) (b) HSMM cells were treated with siGLO to confirm its 









4.4  CHIKV Replication in HSMM Cells 
 
 CHIKV replication in HSMM cells was analysed by performing an 
immunofluorescence assay.  As shown in Figure 4.3, the production of the FITC-stained 
CHIKV envelope protein could be observed by 12 h.p.i., with about 20% infection rate.  
Approximately 80% of the cells were infected within 48 h.p.i. and an almost-complete 
infection rate was achieved by 72 h.p.i. (Figure 4.3).  
 
 At a higher magnification level, the cellular location of the CHIKV envelope proteins 
within the HSMM cells can be observed.  In the early stages of infection of up to 12 h.p.i., the 
viral antigens could be observed within the perinuclear region of the cell (red arrows; Figure 
4.4).  As infection progressed, the viral proteins were observed to be accumulating within the 







































Figure 4.3 Analysis of CHIKV Replication in HSMM Cells 
At 100x magnification, production of CHIKV envelope protein (green fluorescence; 
FITC) could be observed by 12 h.p.i., with almost-complete infection observed by 72 
h.p.i.  Cell nuclei were counterstained with DAPI. 
4 hpi 8 hpi 
12 hpi 16 hpi 
20 hpi 24 hpi 






























Figure 4.4 Cellular Localisation of CHIKV Viral Proteins in HSMM Cells 
At 1000x magnification, CHIKV viral antigens (green fluorescence; FITC) could be 
observed along cellular periphery by 24 h.p.i. (red arrows).  Cell nuclei were 
counterstained with DAPI. 
 
4 hpi 8 hpi 
12 hpi 16 hpi 





4.5  CHIKV Undergoes Dual Mode of Egress from Host Cells 
 
Ultrastructurally, normal uninfected cells displayed long fibroblastic structures, with a 
large nucleus (denoted N in red) seen (Figure 4.5a), along with numerous actin/myosin 
filaments (denoted F in red) (Figure 4.5b).  Upon CHIKV infection, virus-induced structures 
such as replication complexes could be observed.  During early infective stages of between 6 
to 12 h.p.i., spherules - postulated to form the site of viral transcription (Froshauer et al., 
1988) - were observed within CPV-Is (Figure 4.5c).  The CPVs were closely associated with 
rough endoplasmic reticulum (rER), which has been posited to be the site of viral translation 
(Stephens et al., 2005).  Viral budding also occurred at the plasma membrane during the early 
infection phase (red arrows; Figure 4.5d).   
 
CPV-IIs were formed in later infective stages of between 24 to 48 h.p.i., with viral 
nucleocapsids aligning themselves along the vesicles (red arrows) prior to budding to form 
mature virions (red arrowheads) (Figure 4.5e).  The exocytotic vesicles (EV) containing the 
numerous mature virions were subsequently shuttled out of the apoptotic cell (Figure 4.5f).  
The significance of the dual mode of CHIKV egress – budding during early infective phase 
and exocytosis during late infective phase – remains to be seen, although it could provide an 


















































































































































































































































































































































































































































































































































































































































4.6  CHIKV Induces Apoptosis in Host Cells 
 
Previous studies have shown that CHIKV can induce apoptosis in infected cells 
(Krejbich-Trotot et al., 2011; Dhanwani et al., 2012).  In order to determine whether CHIKV 
induces apoptosis in infected HSMM cells, TEM analysis was also performed at late infection 
time-points.  Intense nuclear condensation (red arrows; Figure 4.6a, left panel) and 
widespread vacuolation (red arrowheads; Figure 4.6a, right panel), classical features of 
cellular apoptosis, were observed by 2 d.p.i.   
 
A TUNEL assay to detect in situ cell death further confirmed the apoptotic action 
induced upon CHIKV infection of HSMM cells, whereby the number of apoptotic cells 
increased as infection progressed (Figure 4.6b, upper panels and table).  It should be noted 
that with increasing cell death and degradation of cellular components, the number of 
TUNEL-stained apoptotic cells decreased due to lifting off of these cells.  This was 
particularly true towards the latter phases of CHIKV infection in HSMM cells (days 4-5), 
whereby the percentage of TUNEL-stained apoptotic cells decreased in relation to the total 
number of remaining cells (Figure 4.6b, table).  At a higher magnification level, the TUNEL-
stained cell nucleus could be seen to be much reduced in size, as compared to that of a mock-
infected cell.  Staurosporine-treated and mock-infected cells served as positive and negative 
controls, respectively (Figure 4.6b, lower panels).  These novel findings strongly suggest that 

























Figure 4.6 CHIKV Induces Apoptosis in HSMM Cells 
(a) Apoptosis of CHIKV-infected HSMM cells with nucleolar degradation (red arrows, 
left panel) and massive vacuolation (red arrowheads, right panel) by day 2 p.i. (b) 
TUNEL assay showed the increase in the number of apoptotic cells as infection 
progressed, as depicted by the green fluorescence (upper panels and table).  At 1000x 
magnification, the cell nuclei were observed to be shrunk.  Staurosporine-treated and 
mock-infected cells served as positive and negative controls, respectively (lower panels).  
Cell nuclei were counterstained with DAPI. 
 
        1 d.p.i.    2 d.p.i.           3 d.p.i.     4 d.p.i.           5 d.p.i. 





















CHAPTER 5  



















5.1  Introduction 
 
 In order to investigate the roles played by host genes in CHIKV infectious entry, 
screening of the human membrane trafficking gene library was also performed.  As shown in 
Appendix D, an siRNA-based library of 122 human genes, known to be involved in 
membrane trafficking functions, was used on HSMM cells.  Screening controls included in-
plate controls such as siCONTROL
TM
 non-targeting siRNA pool, RISC-free
TM
 siRNA and 
GAPDH SMARTpool
TM
 siRNA (Appendix D), as well as positive controls of genes known to 
inhibit CHIKV infection such as prohibitin (PHB) (Wintachai et al., 2012) and purinergic 
receptor P2X, ligand-gated ion channel 6 (P2RX6) (previously established in our laboratory, 
unpublished data).  As can be seen, both PHB and P2RX6 controls displayed an 
approximately two-log decrease in CHIKV infection upon siRNA knockdown of the genes, at 
25nM and 50nM, respectively (Figure 5.1a). 
 
 To assess the screening data, CellProfiler 2.1.0, a cell image analysis software was 
utilized.  Data collection and autofocusing parameters were pre-determined and a generic 
segmentation tool function was used to identify the two different stains (DAPI and FITC) 
with intensities above background staining.  An average of at least 50% total inhibition rate – 
therefore a less than 50% infection rate - among the triplicate samples, was used as the cut-off 
criteria for positive screening hits.  Figure 5.1b showed representative images of a positive 
infected/mock-transfected control (left panel), a negative mock-infected/mock-transfected 
control (middle panel) and a positive screening hit, that is a sample displaying an 
approximately 50% total inhibition rate (right panel). 

















      
Figure 5.1 siRNA-Based Library Screening of Membrane Trafficking Genes  
(a) Both positive controls displayed an approximately two-log decrease in CHIKV 
infection upon siRNA knockdown of the genes, with PHB at 25nM and P2RX6 at 
50nM. (b) Representative images of a positive infected/mock-transfected control 
(left panel), a negative mock-infected/mock-transfected control (middle panel) 
and a positive screening hit, that is a sample displaying an approximately 50% 











5.2  Screening Data Reveals CHIKV Infectious Entry via 
Clathrin-Mediated Endocytosis and Macropinocytosis 
   
 Based on these analysis criteria, a total of 36 putative genes were found to result in 
decreased CHIKV infection levels upon siRNA-based gene knockdown (Appendix E).  Genes 
involved in the clathrin-dependent endocytic pathway as well as macropinocytosis appeared 
to be the dominant players in enabling the infectious entry of CHIKV into host cells.  These 
genes were subsequently mapped onto STRING, an online software depicting functional 
known and predicted protein interactions.  As expected, majority of the proteins are known to 
interact with one another, with the main players being amphiphysin (AMPH), dynamin 2 
(DNM2), phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma (PIK3CG) 























Figure 5.2 Protein Interaction Network of siRNA-silenced Genes Resulting in Inhibition 
of CHIKV Infection 
A total of 36 putative genes were found to result in decreased CHIKV infection 
levels upon siRNA-based gene knockdown.  These genes were found to be 










5.3  Validation of Library Screening Data 
 
5.3.1 qRT rt-PCR 
 
In order to evaluate the screening findings, several different techniques were utilised 
such as qRT rt-PCR, siRNA-based gene-specific knockdown of selected putative hits and 
drug inhibitory assays. 
 
Twelve genes from the list of positive screening hits were randomly selected for qRT rt-
PCR validation.  As shown in Table 5.1, majority of the selected genes exhibited enhanced 
mRNA levels upon CHIKV infection at both 6 h.p.i. and 24 h.p.i., albeit with varying degrees 
of fold change relative to mock-infected samples and β-actin as the normalising housekeeping 
control.   
 
Sorting nexins (SNX) are involved in intracellular trafficking and endosomal sorting.  In 
particular, SNX5 is a known regulator of macropinocytosis, being recruited onto newly-
formed macropinosomes (Lim et al., 2008; Lim et al., 2012) and  SNX9 has also been found 
to be associated with the formation of early-stage macropinosomes (Wang et al., 2010).  
While SNX5 was observed to be only very slightly upregulated at both infection time-points, 
SNX9 was enhanced nine-fold during early CHIKV infection (Table 5.1). 
 
RAB7B controls vesicular trafficking from the endosomes to the trans-Golgi network 
and was recently found to be required for cargo trafficking during macropinocytic entry of 
human papillomavirus 16 (HPV16) into host cells (Day et al., 2013).  Krieger and colleagues 





endocytosis and cell motility - in echovirus 1 entry into polarised Caco-2 cells.  Both genes 
did not, however, displayed significant fold changes upon CHIKV infection in HSMM cells. 
 
Protein kinase C and casein kinase substrate in neurons 1 (PACSIN1) plays a role in the 
reorganisation of the microtubule and actin cytoskeleton and was found to regulate the 
TLR7/9-mediated type I interferon response in plasmacytoid dendritic cells (Esashi et al., 
2012).  Found to be involved in the macropinocytic entry of respiratory syncytial virus (RSV) 
into host cells (Krzyzaniak et al., 2013), p21 protein (Cdc42/Rac)-activated kinase 1 (PAK1) 
– which plays an important role in various cellular processes such as cytoskeleton dynamics, 
cell adhesion and vesicle-mediated transport – was also shown to be directly activated upon 
entry of African swine virus into cells (Sanchez et al., 2012).  Associated with cytoplasmic 
surfaces of synaptic vesicles, amyphiphysin (AMPH), Neuvonen and co-workers (2011) 
found that viral RNA replication was promoted upon SH3 domain-mediated recruitment of 
host cell amphiphysin (AMPH) by alphavirus nsP3 while hepatitis C virus (HCV) NS5A 
phosphorylation was impacted through its interaction with AMPH-II (Masumi et al., 2005).  
While the upregulation of PACSIN1 upon the early phase of CHIKV infection was 
significant, it was even more significant for both PAK1 and AMPH, with approximately five- 
and 84-fold upregulation upon infection, respectively. 
 
A pro-apoptotic tumour suppressor, the SH3 domain of bridging interior 1 (BIN1) was 
also shown to interact with HCV NS5A protein (Feuerstein et al., 2012).  Carter and 
colleagues (2011) found that HIV-I infects macrophages via an endocytic route dependent on 
Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein) (RAC1), 
which is also known to be involved in the regulation of cellular responses including the 





beta 1 subunit (AP1B1) mediates the recruitment of clathrin to the membrane and was found 
to be associated with persistent HCV viremia (Saito et al., 2004).  While both BIN1 and 
AP1B1 were both observed to be insignificantly regulated upon CHIKV infection, RAC1 was 
highly expressed with increasing fold changes over time of CHIKV infection. 
 
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma (PIK3CG) is 
an important modulator of extracellular signals, such as cell-cell adhesion, and its signalling is 
known to be involved in the chemokine-induced migration of macrophages (Weiss-Haljiti et 
al., 2004).  Similarly, ezrin (EZR) plays a major role in cell surface structure adhesion, 
migration and organisation, and has been shown to be associated with the infectivity of 
various viruses such as HIV-I (Bregnard et al., 2013), SARS coronavirus (Millet et al., 2012) 
and HCV (Bukong et al., 2013).  Both PIK3CG and EZR did not exhibit increased expression 
upon early CHIKV infection, although the former was subsequently significantly upregulated 
in the latter stages of the infection. 
 
In general, while many of the clathrin-associated genes such as BIN1 and AP1B1, did 
not display differential expression upon CHIKV infection, several genes known to be related 
to the macropinocytic pathway, including SNX9, PAK1 and RAC1, exhibited enhanced 
expression levels.  It can therefore be suggested that CHIKV utilises macropinocytosis as a 
















SNX5 intracellular trafficking, endosomal sorting and 
macropinocytosis 
0.199 0.224 
SNX9 9.311 0.220 
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reorganization of the microtubule and actin 
cytoskeleton; cellular transport 
3.745 0.062 
BIN1 
interaction with dynamin, synaptojanin, 
endophilin and clathrin 
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PAK1 
intracellular signaling pathways; reorganization of 
the actin and tubulin cytoskeleton 
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regulation of cellular responses eg. growth-factor 
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mediates recruitment of clathrin to membrane and 
recognition of sorting signals within cytosolic tails 






5.3.2 siRNA-Based Gene-Specific Knockdown of Putative Hits 
 
 In order to further confirm previous findings, siRNA-based gene-specific knockdown of 
several putative hits was conducted.  Four genes – namely SNX9, RAC1, PIK3CG and 
DNM2 - were selected to investigate their effects on CHIKV infection.  As observed in Figure 
5.3, relative to positive controls, CHIKV infection was significantly inhibited by between 
one- to 1.5-log upon siRNA knockdown of the genes at both concentrations of siRNAs.  PTC 
denotes positive tranfection and infection control while PC denotes positive infection control 
only.  Similarly, TC denotes positive transfection/negative infection control while NC denotes 
negative transfection and infection control.  The results suggested the importance of these 

































































































































































































































































































































































































































































  Although significant, the decreases in CHIKV infection upon siRNA knockdown of 
the genes were not complete.  To ascertain whether clathrin-mediated endocytosis could prove 
to play an equally major role in CHIKV infectious entry, siRNA knockdown of clathrin heavy 
chain (CLTC) was performed.  Indeed, a significant one-log decrease in CHIKV infection 
was observed (Figure 5.4).  This suggests the possibility of an alternative entry pathway for 





Figure 5.4 Knockdown of CLTC siRNA 
Significant one-log decreases in CHIKV infection were observed at both concentrations 
of CLTC siRNA.  PTC: positive tranfection and infection control; PC denotes positive 
infection control only; TC: positive transfection/negative infection control; NC: negative 
transfection and infection control.  Asterisks indicate significant p values by one-tailed 









5.3.3 Drug Inhibitory Assays 
 
Drug inhibitory assays were also conducted, with HSMM cells being pre-treated with 
specific known inhibitors of the various endocytic pathways.  Figures 5.5 to 5.13 show the 
results of pre-treatment assays performed, with 0.1% DMSO as the solvent control.  SC 
denotes solvent control (infected) while PC and NC denote for positive and negative infection 
controls, respectively.  Cell viabilities of above 70% were observed across the various 
concentration ranges of all inhibitors tested. 
 
Monodansylcadaverine (MDC), a commonly used agent of receptor-mediated 
endocytosis, was observed to induce a significant albeit non-dose dependent decrease of 
approximately one-log in CHIKV infection (Figure 5.5).  
 
Figure 5.5 Pre-Treatment Assays with Inhibitor Affecting Receptor-Mediated 
Endocytosis 
Significant but non-dose dependent decreases in CHIKV infection upon MDC 
treatment (blue bar graph) were observed.  Cell viabilities of above 90% were also 
observed across all concentrations tested (red line graph). SC: solvent control 
(DMSO); PC positive infection control; NC: negative infection control. Asterisks 
indicate significant p values by one-tailed Student’s t test, with * p < 0.1, *** p < 0.01 
relative to SC. 




























 Similarly significant levels of inhibition of CHIKV infection were seen upon pre-
treatment with dynasore (Figure 5.6), a GTPase inhibitor that targets dynamin and blocks 
endocytosis, particularly clathrin-mediated endocytosis.  Due to the non-dosage dependency 
of the inhibition of CHIKV infection, it cannot therefore be concluded with certainty the use 




Figure 5.6 Pre-Treatment Assays with Inhibitor Affecting Clathrin-Dependent 
Endocytosis 
Significant but non-dose dependent decreases in CHIKV infection upon dynasore 
treatment (blue bar graph) were observed.  Cell viabilities of above 90% were also 
observed across all concentrations tested (red line graph). SC: solvent control 
(DMSO); PC positive infection control; NC: negative infection control. Asterisks 


































To ascertain the role of caveolae-mediated endocytosis in CHIKV infection, filipin – an 
inhibitor of caveolae-dependent endocytosis – was utilised.  CHIKV infectious viral titres 
upon filipin pre-treatment were similar to that of MDC and dynasore – significant but non-
dose dependent (Figure 5.7), thus eliminating the possibility of caveolae-mediated endocytic 




Figure 5.7 Pre-Treatment Assays with Inhibitor Affecting Cavoelae-Dependent 
Endocytosis 
Significant but non-dose dependent decreases in CHIKV infection upon filipin 
treatment (blue bar graph) were observed.  Cell viabilities of above 100% were also 
observed across all concentrations tested (red line graph). SC: solvent control 
(DMSO); PC positive infection control; NC: negative infection control. Asterisks 


































5-(N-ethyl-N-isopropyl)amiloride (EIPA), a specific inhibitor of macropinocytosis, was 
also used to investigate its role in CHIKV infectious entry.  As observed in Figure 5.8, a dose-
dependent reduction in CHIKV infection was seen upon EIPA pre-treatment, with significant 
decreases of up to four log units at 200µM EIPA.  These results suggest that macropinocytosis 




Figure 5.8 Pre-Treatment Assays with Inhibitor Affecting Macropinocytosis 
Significant and dose-dependent inhibition in CHIKV infection was observed upon EIPA 
treatment (blue bar graph), with a four-log unit decrease in infectious viral titres at 
200µM EIPA.  Cell viabilities of above 90% were also observed across all concentrations 
tested (red line graph). SC: solvent control (DMSO); PC positive infection control; NC: 
negative infection control. Asterisks indicate significant p values by one-tailed Student’s t 


































Cholesterol, confined in lipid rafts, has long been shown to be a crucial component 
required by numerous viruses in attaining entry into host cells (Goluszko and Nowicki, 2005).  
Previous studies have analysed the dependence of CHIKV on cholesterol to facilitate its entry 
into several mammalian and insect cells (Bernard et al., 2010; Gay et al., 2012).  To ascertain 
the role of cholesterol in CHIKV infection on HSMM cells, nystatin – a cholesterol-
sequestering agent – were utilised.  Pre-treatment with nystatin resulted in a dose-dependent 
decrease in CHIKV infection (Figure 5.9), suggesting the possibility of cholesterol 




Figure 5.9 Pre-Treatment Assays with Inhibitor Affecting Cholesterol 
Significant and dose-dependent inhibition in CHIKV infection was observed upon 
nystatin treatment (blue bar graph), with a 2.5-log unit decrease in infectious viral titres at 
40µM.  Cell viabilities of above 90% were also observed across all concentrations tested 
(red line graph). SC: solvent control (DMSO); PC positive infection control; NC: 
negative infection control. Asterisks indicate significant p values by one-tailed Student’s t 
test, with *** p < 0.01 relative to SC. 
 
 




























Acidic pH has been found to induce the fusion activity of alphaviruses, including SFV 
and SINV (Glomb-Reinmund and Kielian, 1998).  Vacuolar-ATPases (V-ATPase), in 
particular, are responsible for cell pH homeostasis and endosomal acidification, and its 
inhibitors have been commonly used to inhibit infection by viruses known to require low pH 
membrane fusion (Hunt et al., 2011).  Indeed, dose-dependent reductions in CHIKV levels 
were also observed upon pre-treatment with concanamycin A and bafilomycin A1, specific 
inhibitors of V-ATPase, with a three-log unit decrease in CHIKV infection seen at 60nM in 
the former (Figure 5.10) and a four-log unit reduction at 1 µM in the latter (Figure 5.11).  




Figure 5.10 Pre-Treatment Assays with Specific Vacuolar ATPase Inhibitor  
Significant and dose-dependent inhibition in CHIKV infection was observed upon 
concanamycin A treatment (blue bar graph), with a 3-log decrease in infectious viral titres 
at 60nM.  Cell viabilities of approximately 80% were also observed across all 
concentrations tested (red line graph). SC: solvent control (DMSO); PC positive infection 
control; NC: negative infection control. Asterisks indicate significant p values by one-
tailed Student’s t test, with *** p < 0.01 relative to SC. 
 




































Figure 5.11 Pre-Treatment Assays with Inhibitor Affecting Endosomal Acidification 
Significant and dose-dependent inhibition in CHIKV infection was observed upon 
bafilomycin A1 treatment (blue bar graph), with a 4-log decrease in infectious viral 
titres at 1µM.  Cell viabilities of above 80% were also observed across all 
concentrations tested (red line graph). SC: solvent control (DMSO); PC positive 
infection control; NC: negative infection control. Asterisks indicate significant p values 



































Spuul and colleagues (2010) observed that transport of SFV replication complexes from 
the plasma membrane to modified lysosomes was dependent on the cytoskeleton network, 
particularly actin and microtubules.  In order to investigate whether the same is true for 
CHIKV infection in HSMM cells, specific inhibitors of the cytoskeleton were utilised.  Pre-
treatment with nocodazole – an inhibitor of microtubule polymerisation – did not lead to 
reductions in CHIKV levels (Figure 5.12).  Meanwhile, pre-treatment with cytochalasin B – 
an inhibitor of actin polymerisation - caused CHIKV infection levels to dip by approximately 
two log units at 5 µg/mL (Figure 5.13), although the cytotoxicity levels decreased 
correspondingly, suggesting that the reduction in CHIKV infection might not be a direct result 
of inhibitory action by cytochalasin B.  It can therefore be suggested that both microtubule 
and actin polymerisation are non-essential events during CHIKV infectious entry. 
 
 
Figure 5.12 Pre-Treatment Assays with Inhibitor Affecting Microtubule Polymerisation 
No significant inhibition in CHIKV infection was observed upon nocodazole treatment 
(blue bar graph).  Cell viabilities of above 80% were also observed across all 
concentrations tested (red line graph). SC: solvent control (DMSO); PC positive 
infection control; NC: negative infection control. 
 
 


































Figure 5.13 Pre-Treatment Assays with Inhibitor Affecting Actin Polymerisation 
Inhibition of CHIKV infection was observed upon cytochalasin B treatment, with a 2-
log unit decrease at 5µM and 10µM (blue bar graph).  However, cell viability levels at 
these concentrations were also observed to decrease correspondingly, to approximately 
70% (red line graph). SC: solvent control (DMSO); PC positive infection control; NC: 
negative infection control. Asterisks indicate significant p values by one-tailed 















































CHAPTER 6  
CHANGES IN HOST GENE 


















6.1  Introduction 
 
 In order to better understand the pathogenesis of CHIKV infection, the effect of CHIKV 
infection on host gene expression was subsequently investigated by performing human 
genomic microarray profiling across four different time-points of CHIKV infection in HSMM 
cells – 6, 12, 24 and 48 h.p.i.  Total RNA extracted from cells was hybridized to Illumina 
HumanHT-12 v4 Expression BeadChips (Illumina Systems) for gene expression analysis. 
 
6.2 CHIKV Infection Regulates HSMM Cell Gene Expression 
 
6.2.1 Gene Regulation is A Result of CHIKV Infection on HSMM Cells 
 
As shown in Figure 6.1, the log2 expression data, represented by a heatmap, indicated 
distinct separation between mock and infected triplicate samples, regardless of infection time-
points.  Sample grouping was initially assessed with the use of the sources of variation and 
principal component analysis (PCA) plots (Partek Genomics Suite 6.6 Beta, Partek Inc.) 
(Figures 6.2a and 6.2b, respectively).  As shown in Figure 6.2a, infection time-points, in 
particular, was observed to be the main player in the variation amongst the various samples, 
as opposed to that between mock-infected and infected samples.  In addition, similar to 
findings in Figure 6.1, PCA mapping showed distinct separation between mock and infected 
samples, with the first three principal components – namely infection time, infection type and 
a combination of the former two factors - successfully accounting for 76.5% of the variation 
amongst the samples, thereby reducing the possibility of variation due to error (Figure 6.2b).  
These data further confirmed that the differences in gene regulation were indeed a result of 



























Figure 6.1 Whole Genome Profiling of CHIKV Infection on HSMM Cells 
Heatmap displaying differential regulation in gene expression between CHIKV-infected 
and mock samples displayed distinct separation between the two sample sets, regardless 


































































Figure 6.2 Assessment of Sample Grouping 
(a) Pie-chart displayed the various sources of variation amongst the samples, and 
infection time-point was found to primarily result in the sample variation (b) PCA plot 
showing distinct separation between mock (blue) and CHIKV-infected (red) samples, 
with infection time-point, infection type and a combination of both factors accounting for 


































PC #1 63.3% 





6.2.2 Determining Criteria for Differential Regulation in Gene Expression 
 
Initially, absolute fold change and p-value criteria were set at more than 1.5 and less 
than 0.05, respectively.  However, as shown in Figure 6.3a, genes that were commonly 
observed across all infection time-points were too large in numbers, with 921 differentially 
expressed genes.  Typically, the number of differentially expressed genes should ideally fall 
within 100 to 200 genes, thereby ensuring more efficient and effective downstream analyses.  
Hence, the absolute fold change cut-off criteria was increased to more than 2, while 
maintaining the p-value cut-off (Figure 6.3b).  This set of criteria resulted in a list of 148 
differentially regulated genes, which fall within the ideal number range.  As comparison, 5112 



















(a) -1.5 < Fold Change > 1.5 
 
(b) -2 < Fold Change > 2  
 
(c) No Fold Change Cut-Off 
 
 
Figure 6.3 Venn Diagrams Displaying Number of Differentially Expressed Genes with 
Varying Fold Change Cut-Off Criteria 
24 h.p.i. (5778) 12 h.p.i. (5487) 
6 h.p.i. (2564) 48 h.p.i. (2017) 
24 h.p.i. (1246) 12 h.p.i. (1011) 
6 h.p.i. (599) 48 h.p.i. (802) 
24 h.p.i. (11740) 12 h.p.i. (10866) 





As such, throughout the microarray analyses, differential regulation in gene expression 
is defined as absolute fold-changes of more than 2, denoting biological significance, as well 
as p values of less than 0.05, denoting statistical significance.  As shown in the volcano plot in 
Figure 6.4a, while majority of genes were expectedly biologically and/or statistically 
insignificant, there were a good proportion of genes that fell within the criteria set for 
significance and were hence good candidates for further analyses.     
 
The total number of differentially expressed genes (DEGs) between CHIKV-infected 
and mock-infected samples at each time-point is shown in Figure 6.4b.  The highest number 
of DEGs was observed at 24 h.p.i., which coincides with the peak of CHIKV infection in 
HSMM cells, thus suggesting that a maximal number of host genes were regulated during this 
period, either due to host defence or as a means of providing aid to the virus.    
 
A total of 148 genes – 143 upregulated and 5 downregulated across all four infection 
time-points – were subsequently selected for further analyses into the various pathways that 
may have been involved in causing these differences during CHIKV infection (Figure 6.4c).  
The complete list of differentially expressed genes and the fold changes across various 
































Figure 6.4 Comparison Analyses of CHIKV Infection on HSMM Cells 
(a) Volcano plot showing selection criteria for DEGs, with absolute fold changes of more 
than 2 and p value of less than 0.05 (boxed in red) (b) Table displaying the total number 
of DEGs between mock and CHIKV-infected sample sets across various infection time-
points (c) Venn diagram exhibiting the total number of DEGs across various infection 
time-points, with 148 genes selected for downstream analyses (boxed in red).    
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6.3 Gene Ontology Analysis of Expression Data 
 
Gene ontology analysis of the microarray expression data was performed with Ingenuity 
Pathways Analysis [IPA] 9.0 software (Ingenuity Systems).  Host genes with altered 
expression levels during CHIKV infection were involved in a range of biological processes, 
and a total of nine functional pathways were subsequently selected (Figure 6.5).  Genes 
chosen for further investigation included those involved in pathways regulating host defence 
(e.g. inflammation, cell death), host metabolism (e.g. lipid and carbohydrate metabolism, 
protein synthesis) and virus replication.  Many of the host genes significantly regulated by 
infection were also involved in processes such as vision, taste and embryogenesis.  These 
processes were not considered relevant to the study and were therefore excluded from the 
analysis. 
 
6.3.1 CHIKV Infection Alters the Expression of Host Genes Involved in 
Skeletal and Muscular Disorders 
 
As determined by IPA, skeletal and muscular disorders, such as arthritis and rheumatoid 
arthritis, were identified as the disease group most closely associated with CHIKV infection.  
This is hardly surprising as infection by CHIKV often results in persistent myalgia and 
polyarthralgia in infected patients.  The expression profiles for 38 skeletal-muscular 
associated genes regulated by CHIKV infection are represented by heat map diagrams in 
Figure 6.5a.  
 
Among the differentially expressed genes in this group are guanylate binding protein 1 
(GBP1), signal transducer and activator of transcription 1 (STAT1), CXC chemokine ligand 





2009).  Additionally, GBP1 was previously found to be associated with fibromyalgia (Smith 
et al., 2012), while an increased expression of transporter 1, ATP-binding cassette (TAP1) 
was observed in juvenile dermatomyositis (Tezak et al., 2002). 
 
6.3.2 CHIKV Infection Alters the Expression of Genes Involved in Host 
Defence Mechanisms 
 
Many of the genes regulated following CHIKV infection were involved in host defence 
mechanisms in order to protect the cell against the infection and ensure survival. The 
expression profiles for the cellular defence genes regulated by CHIKV infection are 
represented by heat map diagrams in Figure 6.5. 
 
6.3.2.1 Proinflammatory Antiviral Response Genes 
 
Increases in expression levels in 23 genes associated with innate immune responses 
were observed upon CHIKV infection (Figure 6.5b) including those involved in type I and II 
interferon responses (e.g. IRF1, IRF9, and MX1 genes), type III interferon responses (e.g. 
interleukin-29 [IL-29]) and the production of proinflammatory chemokines and cytokines 
(e.g. IL-6, GBP2, CCL3 and -5, and CXCL9, -10 and -11 genes).  Increased expression of 
genes encoding negative regulators of the interferon response was also observed (e.g. IL18BP 
gene). 
 
6.3.2.2 Genes Controlling Cellular Survival 
 
The expression of 31 genes controlling apoptosis and cell cycle arrest was significantly 






























Figure 6.5 Heatmaps Displaying Various Biological Pathways of Interest 
Host genes with altered expression levels during CHIKV infection were involved in a 
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cell cycle arrest were observed.  These included an increase in the expression of genes that 
induce apoptosis, such as those involved in p53 and transforming growth factor beta (TGFβ) 
signaling (e.g. IFI16 gene), an increase in the expression of pro-apoptotic genes (e.g. 
PMAIP1, CASP1, TNFSF10 and XAF1 genes) and a decrease in the expression of anti-
apoptotic genes (e.g. TNFRSF10D gene).  At the same time, increased expression levels were 
also observed in genes promoting inhibition of the apoptotic machinery (e.g. BIRC3 and 
TNFAIP3 genes) as well as genes promoting cellular survival and proliferation (e.g. 
TNFSF13B and PLSCR1 genes), demonstrating that conflicting transcriptional changes 
occurred following CHIKV infection. 
 
6.3.3 CHIKV Infection Alters the Expression of Host Genes Involved in 
Cellular Functions 
 
Genes involved in typical cellular functions were differentially expressed in spite of 
CHIKV infection to ensure continuous survival, including those associated with cell-cell 
signalling and interaction, molecular transport and host metabolism.  The expression profiles 
for the cellular function genes regulated by CHIKV infection are represented by heat map 
diagrams in Figure 6.5. 
 
6.3.3.1 Genes Controlling Cell-Cell Signalling and Molecular Transport 
 
Significant increases in the expression levels of 23 cell-cell signalling related genes 
were observed (Figure 6.5d).  These genes included those involved in the IL-1 and TLR 
signalling pathways such as toll-like receptor 3 (TLR3) and myeloid differentiation primary 
response 88 (MYD88), while eukaryotic translation initiation factor 2-alpha kinase 2 





insulin pathways.  Conversely, ral guanine nucleotide dissociation stimulator (RALGDS), 
known to be an effector of Ras-related GTPases that participate in signalling for a variety of 
cellular processes, was found to be down-regulated upon CHIKV infection. 
 
Ten genes mediating molecular transport in host cells were also found to exhibit 
increased expression levels following CHIKV infection (Figure 6.5e).  For instance, MYD88 
has been shown to activate the expression of interferon regulatory factor 1 (IRF1) resulting in 
its rapid migration into the nucleus.  Other genes associated with molecular transport include 
TRIM21, CCL5, TLR3 and CXCL11. 
 
6.3.3.2 Host Metabolism Genes 
 
Several genes differentially expressed upon CHIKV infection were involved in host 
metabolic processes in order to ensure continual survival of the cell.  A total of eight highly-
regulated genes, which are more known for their inflammatory properties, are involved in 
calcium metabolism (Figure 6.5f).  These genes include CXCL11, IL6, TLR3, TRIM21, 
CCL3 and CXCL9.  In particular, CXCL10 was found to be upregulated by approximately 
100-fold while CCL5 expression was increased about 55-fold following CHIKV infection. 
 
Increases in expression levels in six genes associated with protein systhesis were also 
observed upon CHIKV infection (Figure 6.5g).  For instance, expression of EIF2AK2, known 
to inhibit viral replication via inhibition of translation resulting in shutdown of both cellular 
and viral protein synthesis, was found to be enhanced by three-fold following CHIKV 
infection.  Thought to be part of a pioneering group of proteins in evolution due to its central 





tRNA synthetase (WARS) was similarly observed to be highly expressed by five-fold upon 
CHIKV infection.  
 
Significant increases in the expression levels of seven lipid and carbohydrate 
metabolism-related genes were observed (Figure 6.5h).  These genes included tumour 
necrosis factor, alpha-induced protein 6 (TNFAIP6) and phospholipid scramblase 1 
(PLSCR1).  The former, known to be involved in extracellular matrix stability and cell 
migration via its hyaluronan-binding domain, was observed to increase by approximately 
five-fold during CHIKV infection.  Interestingly, enhanced levels of TNFAIP6 have 
previously been found in patients with osteoarthritis and rheumatoid arthritis (Stove et al., 
2000; Jiang et al., 2011; Ramos et al., 2014), thus further substantiating the CHIKV-induced 
levels observed in the microarray data.  Meanwhile, known to mediate transbilayer 
phospholipid migration resulting in loss of phospholipid asymmetry in the plasma membrane, 
PLSCR1 was found to be enhanced by 4.5-fold upon CHIKV infection. 
 
6.3.4 CHIKV Infection Alters the Expression of Host Genes Involved in 
Virus Replication 
 
As determined by IPA, 19 genes associated with viral replication were found to be 
regulated by CHIKV infection and are represented by Figure 6.5i.  Among the highly 
expressed genes in this group include RARRES3, DDX58, BST2, MYD88 and MX1.  In 
particular, radical S-adenosyl methionine domain containing 2 (RSAD2), or more commonly 
known as viperin, was found to be largely enhanced by 50-fold upon CHIKV infection.  
Known to inhibit a wide range of DNA and RNA viruses, such as human cytomegalovirus 





A virus (Waheed and Freed, 2007), Sindbis virus (SINV) (Chan et al., 2008), West Nile virus 
(WNV) and dengue virus (DENV) (Jiang et al., 2010), RSAD2 has even been previously 
found to restrict CHIKV replication and pathology (Teng et al., 2012), thus strengthening the 
findings in this study.   
 
 
6.4  Validation of Microarray Expression Data 
 
6.4.1 qRT rt-PCR 
 
In order to evaluate the microarray findings, several different techniques were utilised 
such as qRT rt-PCR and siRNA-based gene-specific knockdown of selected putative hits. 
 
Eight genes from the list of positive screening hits were randomly selected for qRT rt-
PCR validation and subsequent comparison against the microarray data.  As shown in Figure 
6.6, in line with the microarray results, all selected genes exhibited enhanced mRNA levels 
upon CHIKV infection across all infection time-points, albeit with varying degrees of fold 
changes relative to mock-infected samples and β-actin as the normalising housekeeping 
control.  The blue line graphs depict microarray data while qRT rt-PCR results are 
represented by the red line graphs.  Both sets of results were taken from triplicate independent 
samples.   
 
A cytoplasmic RNA helicase, retinoic acid receptor responder (tazarotene induced) 3 
(RARRES3), also known as retinoic acid inducible protein I (RIG-I), is thought to act as a 





the central regulator of antiviral cytokines expression induced by influenza A virus, while 
Tasaka and co-workers (2007) subsequently found that cellular expression of type I IFNs in 
response to HCV infection was mediated by RIG-I.  It was also later shown to result in severe 
inhibition of ebolavirus replication (Spiropoulou et al., 2009).  With the exception of the 6 hr 
infection time-point, the differential expression levels across all infection time-points were 
very similar for both the microarray and qRT-PCR data, with approximately 11-fold and 12-
fold upregulation at 12 h.p.i., respectively (Figure 6.6a). 
 
Characterised by its ability to specifically bind guanine nucleotides, guanylate binding 
protein 1, interferon-inducible (GBP1) mediates an IFN-induced antiviral effect against VSV 
and encephalomyocarditis virus (EMCV) (Anderson et al., 1999).  Itsui and colleagues (2006) 
has further shown that knockdown of GBP1 resulted in an increase in HCV replication while 
it was also found to be significantly upregulated upon chronic active EBV infection (Ito et al., 
2008).  While GBP1 levels were increased almost ten-fold at 24 h.p.i. in the microarray 
genomic profiling, it was only enhanced three-fold upon qRT-PCR validation (Figure 6.6b).   
 
Chemokine (C-X-X motif) ligand 10 (CXCL10), or interferon-inducible protein-10 (IP-
10), is one of several chemokines of the CXC subfamily, and was found to be expressed at 
prolonged and enhanced levels upon herpes simplex virus type 1 (HSV-1) infection (Su et al., 
1996).  Increased expression levels of IP-10 were also shown in tissues with necrosis and 
vascular damage resulting from Epstein-Barr virus- (EBV-) positive lymphomatoid 
granulomatosis (Teruya-Feldstein et al., 1997).  As shown in Figure 6.6c, although 
microarray expression levels of CXCL10 only reached to approximately 240-fold 
upregulation, qRT-PCR validation levels were immensely enhanced to more than 3000-fold 






Known for its antiviral, anti-bacterial and anti-cancer activities, interferon beta 1, 
fibroblast (IFNβ1), along with other IFN-stimulated genes, was induced upon influenza A 
virus infection thereby inhibiting viral replication (Hillesheim et al., 2014).  Similarly, 
mediated by ISG15, IFNβ1 was induced in response to dengue virus (DENV) and West Nile 
virus (WNV) infection (Dai et al., 2011).  From Figure 6.6d, it can be seen that microarray 
expression levels of IFNβ1 showed a similar downward trend from 12 h.p.i. to 48 h.p.i., albeit 
at much higher levels for the qRT-PCR data. 
 
Caspase 1, apoptosis-related cysteine peptidase (CASP1) is involved in the signal 
transduction pathways of apoptosis, necrosis and inflammation and was initially found to be 
inhibited by serpin, a specific inhibitor of the gene encoded by cowpox virus (Ray et al., 
1992).  Similarly, Kettle and colleagues (1997) showed that vaccinia virus also encodes for a 
serpin that can inhibit CASP1, while Sloand and co-workers (1997) subsequently showed that 
CASP1 induction plays a significant role in the apoptotic depletion of CD4
+
 cells during HIV 
infection.  As shown in Figure 6.6e, differential expression levels of CASP1 at 12 h.p.i were 
very similar for both the microarray and qRT-PCR data, with approximately 3.9-fold and 3.2-
fold upregulation, respectively. 
 
Facilitating the activation of latent RNase L and resulting in viral RNA degradation and 
subsequent inhibition of viral replication, 2’-5’-oligoadenylate synthethase 1, 40/46kDa 
(OAS1) was induced in response to infection with Sendai and influenza A viruses 
(Melchjorsen et al., 2009).  Lim and colleagues (2009) also showed that genetic variation in 
OAS1 is a genetic risk factor for initial WNV infection while Mashimo and co-workers 





as other diseases including type 1 diabetes and multiple sclerosis.  OAS1 exhibited highly 
similar upward trend of upregulated expression levels for both data sets across all infection 
time-points, albeit at much enhanced levels for the qRT-PCR data (Figure 6.6f).  
 
Although more commonly known to function as an essential signal transducer in the IL-
1 and TLR signalling pathways, MYD88 has also been shown to mediate inhibition of 
Hepatitis B virus (HBV) replication via activation of the NFκB signalling pathway and 
downregulation of viral transcription (Xiong et al., 2004).  Lund and colleagues (2004) 
further illustrated that responses to infection with vesicular stomatitis virus (VSV) were 
limited due to MYD88 deficiency.  As can be seen in Figure 6.6g, similar to OAS1, the 
expression levels and trend of MYD88 were very similar for both sets of data, although the 
qRT-PCR validation data showed insignificant upregulated levels from 12 h.p.i. to 48 h.p.i. 
 
One of numerous IFN-stimulate genes (ISGs), receptor transporter protein 4 (RTP4) has 
not been extensively investigated upon but was previously tested for its inhibition against 
yellow fever virus (YFV) and VSV, although dose-dependent inhibitory levels were only 
observed in the former (Schoggins et al., 2011).  The upward trend of upregulated expression 
levels of RTP4 was observed in both sets of data from 12 h.p.i. to 48 h.p.i., with similar 
































































































































































































































































































































































































































































































































































































































6.4.2 siRNA-Based Gene-Specific Knockdown of Putative Hits 
 
 To further confirm previous findings, siRNA-based gene-specific knockdown of several 
putative hits was conducted.  Several genes from four biological pathways – namely skeletal 
and muscular disorders, apoptosis, viral replication and viral egress - were selected to 
investigate their effects on CHIKV infection.  PTC denotes positive tranfection and infection 
control while TC denotes positive transfection/negative infection control.  Results shown 
were analysed based on three independent experiments performed, with 50nM siRNA used.   
 
 In Figure 6.7a, relative to positive controls, significant inhibitory levels of CHIKV 
infection were only observed upon siRNA knockdown of TAP1.  Knockdown of other genes 
associated with skeletal and muscular disorders, including GBP1, GCA, TRIM22, CXCL10 
and RALGDS, did not result in significant changes in CHIKV infection compared to the PTC 
control.  TAP1 was previously found to be down-regulated by human EBV-encoded IL-10 
protein (Zeidler et al., 1997).  However, as observed in the microarray findings in Appendix 
E, CHIKV infection resulted in increased expression levels of TAP1.  It is therefore 
unsurprising to observe reduced CHIKV titres upon siRNA knockdown of TAP1 (Figure 
6.7a). 
 
 Similarly, in Figure 6.7b, only IL6 knockdown resulted in significantly decreased 
CHIKV infection levels while other apoptotic genes such as OAS1, CASP1, IFNβ1 and BTC 
exhibited similar CHIKV titres as the PTC control.  Cytokines have been widely shown to 
modulate HIV infection, with IL6 found to enhance its replication (Lai et al., 1991).  Hence, 





upon CHIKV infection (Appendix F) and validated by decreased CHIKV infection upon 
siRNA knockdown of IL6 (Figure 6.7b). 
 
 Several genes known to be involved in viral replication were selected for further 
analysis, including BST2, MX1, MYD88 and DDX58.  However, with the exception of bone 
marrow stromal cell antigen 2 (BST2), which displayed a significant decrease in CHIKV 
levels upon its knockdown, inhibition of the remaining genes did not result in significant 
changes in CHIKV infection (Figure 6.7c).  BST2, or tetherin, has been extensively studied 
upon recently, with earliest reports showing its IFNα-induced antiviral activity against HIV-I, 
inhibiting the latter’s release (Neil et al., 2008).  While microarray findings suggest a similar 
action by BST2 during CHIKV infection (Appendix F), siRNA knockdown of BST2 resulted 
in decreased, and not increased, CHIKV levels (Figure 6.7c).  However, given that it has been 
shown earlier that CHIKV undergoes a dual mode of egress from host cells (Section 4.5), it is 
therefore possible that CHIKV virions are able to be released via the primary but inefficient 
route of viral budding, instead of exocytosis. 
 
 Knockdown of viral egress genes were also performed to validate the microarray 
findings as well as to investigate their roles in CHIKV infection.  While siRNA knockdown of 
genes such as ANXA2, SNAP23, IL29 and RSAD2 did not lead to significant changes in 
CHIKV titres, ISG15 knockdown resulted in significantly reduced levels of CHIKV (Figure 
6.7d).  Okumura and colleagues (2008) found that ISG15 ubiquitin-like modifier (ISG15) 
inhibited Ebola virus budding by blocking the activity of NEDD4L.  The putative mechanism 
of action of ISG15 in CHIKV infection, however, may be similar to that of BST2.  With the 
increase in ISG15 levels upon CHIKV infection, as shown in the microarray findings 





mode of exocytosis.  However, with the knockdown of ISG15, CHIKV is then able to be 
released from host cells via viral budding, thus resulting in decreased CHIKV levels (Figure 
6.7d). 
 
 In general, while many of the selected genes did not result in significant changes in 
CHIKV titres upon siRNA-based gene knockdown, the siRNA knockdown results did, 
nevertheless, validate the microarray findings.  Furthermore, the putative roles of several 
genes were able to be postulated based on comparison between the microarray and siRNA 

















































































































































































































































































































































































































































































































 Recent studies on CHIKV have been extensive and wide-ranging.  Previously based on 
known literature on other related alphaviruses such as Sindbis virus (SINV) and Semliki 
Forest virus (SFV), CHIKV has now been on the forefront of the alphaviral research scene.  
For instance, crystal structures of CHIKV viral particles have recently been deduced (Voss et 
al., 2010), whilst previously structural assumptions were made based on its close relationship 
to SINV.   
 
 One of the main factors driving the extensive research being conducted on CHIKV is its 
similarity in clinical manifestations with dengue virus (DENV), albeit being classified in two 
different families, with the former in the Togaviridae family and the latter grouped in the 
Flaviviridae family.  Typical clinical symptoms of both CHIKV and DENV are highly 
similar, including high fever, nausea, rash and muscle and joint pains.  Furthermore, both 
diseases are transmitted to humans via mosquitoes, thus increasing the potential for co-
infection and/or misdiagnosis.  Nevertheless, with the recent advent of laboratory-based 
technology, misdiagnosis of CHIKV infection is less likely to occur, subsequently resulting in 
more chikungunya cases being reported.  Hence, the need for more effective and efficient 
management and prevention of the disease is enhanced.   
 
 Several studies have previously demonstrated susceptibility of various cell lines to 
CHIKV infection, with epithelial and endothelial cells, primary fibroblasts and monocyte-
derived macrophages found to be permissive to infection (Sourisseau et al., 2007).  Most 
recently, several mammalian and insect cell lines were assessed for CHIKV infection and host 
responses as a result of the infection.  Nevertheless, this study aimed to ascertain 
susceptibility of a wider panel of mammalian and insect cell lines to CHIKV infection than 




previously studied.  In addition, it also aimed to establish growth kinetics of various 
Singapore CHIKV isolates available and determine whether susceptibility of these cell lines 
to CHIKV infection is strain-specific (Chapter 3). 
 
 To this end, viral plaque assays, immunofluorescence studies and TEM analyses were 
performed.  A total of eight different human-based mammalian cell lines (HUH7, HUH7.5, 
HEK293FT, HEK293A, RD, HepG2, SK-N-SH and SJCRH30) (Section 3.3), four non-
human mammalian cell lines (BHK, CHO, Vero and C2C12) (Section 3.4) and one mosquito 
cell line (C6/36) (Section 3.5) were used throughout the cell susceptibility study.  While most 
of these cell lines have been previously shown to be either susceptible or non-susceptible to 
CHIKV infection, several others were performed on CHIKV for the first time.  Cell lines such 
as SK-N-SH, SJCRH30 and C2C12 have yet to be analysed on their susceptibility profiles 
upon CHIKV infection.  Indeed, CHIKV growth profiles for these cell lines were shown to be 
amongst the best across all three virus strains.  This is hardly surprising as SJCRH30 and 
C2C12 cells, in particular, are derived from muscle tissues and are fibroblastic and myoblastic 
in nature, respectively.  The use of SJCRH30 cells in relation to CHIKV infection was very 
recently demonstrated and published by fellow lab members (Issac et al., 2014). 
 
 In general, all cell lines tested in this study are shown to be susceptible to varying 
extents.  CHIKV-122508 appeared to be the most efficient of the three strains, resulting in 
high susceptibility profiles across all cell lines, while CHIKV-0708 and CHIKV-6708 
exhibited similar growth profiles across majority of the cell lines tested.  One possible reason 
for the similarity in growth profiles between CHIKV-0708 and CHIKV-6708 could be the 
periods of isolation of these two strains.  Although collected by different agencies in 




Singapore, they were isolated within months of each other during the CHIKV outbreak in 
Singapore in 2008.   
 
 Meanwhile, CHIKV-122508 was markedly different from the other two strains in its 
genetic sequence.  While CHIKV-6708 is found to be genetically similar to the prototypic 
CHIKV 37997 African reference strain, CHIKV-122508 closely resembles the E1-226V 
mutated CHIKV strain LR-OPY1 (Lee et al., 2013).  Previous research have shown enhanced 
CHIKV infectivity due to a single mutation in the E1 viral protein, with valine substituting for 
alanine at amino acid position 226 (Tsetsarkin et al., 2007).  More studies would need to be 
performed to ascertain whether similar reasoning can be applied to explain the more effective 
growth profiles of CHIKV-122508 as opposed to CHIKV-0708 and CHIKV-6708.  It should 
nevertheless be noted that several more amino acid differences were also observed amongst 
the three CHIKV strains (Section 3.2), which could potentially account for the varying growth 
profiles. 
 
        Although several human cell lines have previously been shown to be permissive to 
CHIKV infection, these cell lines do not, however, address the tissue tropism observed during 
the infection in humans.  While Chapter 3 discussed susceptibility profiles of immortal cell 
lines, human-originated or otherwise, upon CHIKV infection, Chapter 4 aimed to delve into 
establishing a human cellular model that is truly representative of the infection.  To this end, 
HSMM cells were identified and characterised as a novel human primary cell line that is 
highly permissive to CHIKV infection.  Morphological assessment of the cells during CHIKV 
infection showed that cytopathic effects can be observed by as early as 12 h.p.i., with almost 
complete destruction of the cell monolayer seen by 48 h.p.i. (Section 4.2).  CHIKV growth 
kinetics performed on HSMM cells also showed peak viral titres at 16 h.p.i. (Section 4.2).  




While these findings are consistent with earlier cell susceptibility results (Chapter 3) as well 
as various research done previously, the peak titres at a much earlier infection time-point 
suggest the high permissibility of HSMM cells to CHIKV infection. 
 
 Alphaviruses have long been known to undergo exit from host cells via viral budding 
(Kail et al., 1991; Strauss et al., 1995).  CHIKV exit, in particular, has however not been 
extensively studied, although a recent study by Jones and colleagues (2013) showed that 
tetherin-mediated inhibition of CHIKV budding could be counteracted by CHIKV nsP1.  This 
study discovered the possibility of CHIKV undergoing a dual mode of egress, with budding 
being the predominant mode during early infective phase and exocytosis during late infective 
stages (Section 4.5).  These findings can be clearly observed via TEM analysis, with 
individual virions budding from the cell surface by 12 h.p.i., as well as the formation of CPV-
Is during the early infection time-points.  Mature virions were later observed to accumulate in 
greater numbers into CPV-IIs, prior to exocytosis of the vacuoles at later infection time-
points. 
 
The significance of the dual mode of CHIKV egress remains to be seen, although it 
could provide an interesting clue as to the pathogenesis of CHIKV infection.  In the event 
whereby the host mounts an early immune response against CHIKV infection, releasing 
inhibitory host factors to block viral exit and subsequent replication, the virus may then adopt 
an alternative approach to counter and evade host responses and enable mature virions to be 
released.  This, in turn, allows the virus titres to be sustained throughout a chronic CHIKV 
infection, in which persistent clinical presentation of the disease, such as myalgia and 
arthralgia, has been widely documented. 
 




Sourisseau and co-workers (2007) first showed the replication characteristics of the 
reemerging CHIKV, describing the cytopathic effects of CHIKV replication and the induction 
of apoptosis in infected cells.  To investigate whether apoptosis is induced in CHIKV-infected 
HSMM cells, a TUNEL assay was performed across several infection time-points (Section 
4.6).  It was observed that the level of apoptosis increased with increasing CHIKV infection, 
as more cells were infected and subsequently succumbed to cell death as infection progressed.  
Cell nuclei were also seen to shrivel in response to CHIKV infection, indicating that apoptosis 
was indeed taking place.  Furthermore, TEM analysis of HSMM cells confirmed the role of 
apoptosis during CHIKV infection, with nuclear condensation and vacuolation observed at 4 
d.p.i. 
 
These findings suggest that HSMM cells are indeed a highly reliable cellular model for 
CHIKV infection.  However, due to the limited lifespan of each batch of these cells, extensive 
time and financial resources were required.  Unlike continuous cell lines, passaging of the 
cells took approximately 1-2 weeks to form confluent monolayers.  Experimentation with 
these cells was therefore greatly limited.  Variation among cell batches was also unavoidable, 
as is often the case for mortal cell lines.  Nevertheless, the infectivity of CHIKV in HSMM 
cells is undeniable, and initial data in each section of the study had been reliably consistent 
with downstream results. 
 
Similar to other alphaviruses, CHIKV infectious entry into host cells has been widely 
accepted to be dependent on clathrin-mediated endocytosis.  However, alternative 
mechanisms of alphaviral entry have also been reported.  For instance, SINV was shown to 
enter various types of cells in the absence of low pH, indicating non-reliance on clathrin 
(Hernandez et al., 2001).  Similar findings were also observed in SFV (Hase et al., 1989; 




Marsh and Bron, 1997) and CHIKV, with the latter’s entry into target cells found to be 
primarily mediated by a clathrin-independent, albeit Eps15-dependent endocytic pathway 
(Bernard et al., 2010).   
 
To investigate the endocytic pathways through which CHIKV enters HSMM cells, an 
siRNA-based library screening of membrane trafficking genes (Section 5.1).  Due to the 
highly fibroblastic nature of the HSMM cells, the criteria of percentage of viral antigen-
positive cells relative to the total number of cell nuclei, that is typically used in screening data 
analysis, was unable to be accounted for.  Instead, FITC-based fluorescence intensities of 
each screened well were measured against relevant controls.  Less stringent hits selection 
criteria was also used due to the inherent variation observed.  Nevertheless, the screening data 
achieved was subsequently validated with various methods in order to attain confidence in 
analysis. 
 
The screening data revealed genes associated with both clathrin-mediated endocytosis 
and macropinocytosis to be the main players in CHIKV infectious entry into HSMM cells 
(Section 5.2).  Several of these genes undoubtedly play essential roles in both pathways, such 
as genes from the dynamin and RAB families.  While these results showed that CHIKV can 
enter HSMM cells via these two pathways, it remained inconclusive as to which pathway is 
preferred or predominantly used by CHIKV for its entry.  Nevertheless, the use of the 
macropinocytic pathway by CHIKV for its infectious entry into host cells is a novel finding.  
 
Validation of the library screening data was performed via three different laboratory 
approaches, to ensure reliability and reproducibility of data (Section 5.3).  In Section 5.3.1, 
data validation via qRT rt-PCR analysis was conducted.  Two different infection time-points 




were selected for this purpose, namely 6 h.p.i. and 24 h.p.i.  Ideally, earlier infection time-
points would have been a better and more accurate indication of CHIKV infectious entry into 
host cells.  However, experience with handling HSMM cells suggested that minimal mRNA 
levels could be achieved at such early infective stages.  Hence, a 6 h.p.i. time-point was 
selected as the best time for collection of total RNA, with 24 h.p.i. time-point also selected as 
a precautionary measure. 
 
A total of twelve genes were randomly selected from the screening list of top hits.  
While majority of the clathrin-associated genes failed to exhibit differential expression upon 
CHIKV infection, mRNA expression levels of several macropinocytic-related genes were 
enhanced, including SNX9, PAK1 and RAC1.  These genes have yet to be extensively studied 
upon in alphaviral research, although the latter two have been shown to be involved in 
macropinocytic processes of other viruses, such as RSV (Krzyzaniak et al., 2013), African 
swine virus (Sanchez et al., 2012) and HIV-I (Carter et al., 2011).   
 
In particular, PAK1 has been greatly implicated in entry of viruses, such as lymphocytic 
choriomeningitis virus (LCMV) (Iwasaki et al., 2014), HBV (Xu et al., 2012) and influenza A 
virus (Pascua et al., 2011), into target cells.  Similarly, RAC1 has been shown to be 
associated with Coxsackievirus A9 (CVA9) (Huttunen et al., 2014) and HCV (Li et al., 2014) 
infectious entry.  While more downstream analyses would need to be performed to determine 
the role of these genes and their interactions with CHIKV viral proteins, it can nevertheless be 
concluded that CHIKV utilises macropinocytosis as a major entry pathway into HSMM cells. 
 
To further substantiate the novel findings, siRNA-based knockdown of several 
macropinocytosis-associated genes - namely SNX9, RAC1, PIK3CG and DNM2 - was 




performed (Section 5.3.2) and was determined to significantly result in the inhibition of 
CHIKV infection by between one- to 1.5-log units of viral titres.  While the results indicated 
the importance of these genes in CHIKV infection, the block in infection was partial.   
 
One possible reason could be that some of these genes form part of a bigger family of 
related genes that could have compensated for the loss in expression of the knocked-down 
gene.  For instance, SNX9 is one of numerous sorting nexins, several of which form a subset 
of the SNX family based on their lipid-binding (PX) and membrane curvature sensing (BAR) 
domain architecture (SNX-PX-BAR), including SNX5 (Wang et al., 2010).  Hence, the loss 
in SNX9 expression could have had minimal effect in inhibiting CHIKV entry.   
 
Another putative reason for the partial inhibition of CHIKV entry could be that CHIKV 
is able to hijack several endocytic pathways to penetrate into target cells, as already 
mentioned earlier.  It is highly possible for CHIKV to enter through an alternative pathway 
that does not require the action of macropinocytosis-related genes.  Indeed, upon siRNA 
knockdown of CLTC, a significant one-log unit decrease in CHIKV infection was observed, 
hence suggesting that clathrin-mediated endocytosis could also be an entry pathway for 
CHIKV into host cells.  Further analyses could include double siRNA knockdown of 
macropinocytic genes and/or a combination of macropinocytic and clathrin-dependent 
endocytic genes.  Should maximal inhibition of CHIKV infection be achieved, it can therefore 
be concluded that CHIKV entry into target cells occurs by these two pathways. 
 
In addition, drug treatment assays were conducted, with minimal and/or non-dose 
dependent inhibition of CHIKV infection observed upon pre-treatment with inhibitors 
commonly associated with clathrin- and cavaeloe-mediated endocytosis.  Conversely, pre-




treatment with EIPA, a specific inhibitor of macropinocytosis, was found to result in a four-
log reduction in CHIKV infection, thus indicating the major role played by the 
macropinocytic pathway in enabling CHIKV entry into host cells.   
 
Taken together, it can be concluded that CHIKV enters HSMM cells primarily via 
macropinocytosis.  These findings were later found to be consistent with the microarray data 
(Chapter 6), in which clathrin- and macropinocytosis-associated genes were found to be 
down-regulated upon CHIKV infection.  Conversely, caveolae-related genes were found to be 
non-differentially expressed.  
  
Hugely significant dose-dependent reductions in CHIKV levels were also observed 
upon pre-treatment with concanamycin A and bafilomycin A1, thus indicating that low pH 
levels in the lysosomal and endosomal compartments is crucial for CHIKV infection.  This 
finding is consistent with that of Gold and colleagues (2010), in which infection with the 
blue-tongued virus (BTV) is found to be dependent on low pH despite the non-reliance on 
clathrin.  Similarly, filamentous influenza virus was shown to enter cells via 
macropinocytosis, with low pH mediating the change in membrane curvature (Rossman et al., 
2012). 
 
In order to further understand the pathogenesis of CHIKV infection, the effect of 
CHIKV infection on host gene expression was analysed by performing human genomic 
microarray profiling (Chapter 6).  The Illumina HumanHT-12 v4 Expression BeadChip used 
targets more than 47,000 probes across the entire human transcriptome.  Although several 
CHIKV-based microarray studies have been conducted recently (Nakaya et al., 2012; Lee et 
al., 2013), no genome-wide analyses have been performed.  In the case of Nakaya and co-




workers (2012), only a consensus CHIKV arthritis gene expression signature in a mouse 
model was used while Lee and colleagues (2013) conducted microarray profiling targeting 
less than 19,000 transcripts across the mosquito genome.  This study demonstrates, for the 
first time, genome-wide profiling across the human transcriptome. 
 
Gene ontology analysis of the microarray expression data revealed host genes involved 
in a wide range of biological processes (Section 6.3).  Ten functional pathways with genes 
altered upon CHIKV infection were selected for downstream analyses.  Most of these 
pathways are typically observed in relation to host response upon viral infection.  They 
include host defence pathways - with genes involved in proinflammatory antiviral 
mechanisms and cellular survival - cellular function, including molecular transport and host 
metabolism, and viral replication.  A biological pathway associated with skeletal and 
muscular disorders was also chosen to demonstrate its relevance to the pathogenesis of 
CHIKV infection.  Also, it has to be mentioned that many of these genes are involved in 
overlapping biological pathways, as commonly observed in literature.  For instance, CXCL10 
is a gene known to be involved in various cellular processes such as cellular survival, 
molecular transport, calcium metabolism and lipid and carbohydrate metabolism. 
 
Similar to the library screening data, the microarray results were further validated and 
analysed via qRT rt-PCR and siRNA-based knockdown studies of selected genes.  Eight 
genes were randomly selected from the list of top putative hits for qRT rt-PCR validation 
analyses (Section 6.4.1).  With the exception of OAS1 and MYD88, which exhibited very 
similar upregulated trends across all infection time-points between both the microarray and 
qRT rt-PCR data sets, other genes chosen (RARRES3, GBP1, CXCL10, IFNβ1, CASP1 and 
RTP4) were particularly dissimilar at the 6 h.p.i. time-point.  One possible reason could be the 




relatively early infection time as opposed to other infection time-points of 12, 24 and 48 h.p.i., 
thus resulting in inaccurate mRNA levels being exhibited in either of the data sets.   
 
Nevertheless, general upregulated trends were demonstrated throughout all infection 
time-points, and were the primary observations to be made towards validating the microarray 
results.  Furthermore, the at-times drastic differences in fold changes between the microarray 
and qRT rt-PCR data sets could be explained by the fact that two very different laboratory 
techniques were being performed.  It would, hence, be inaccurate to compare absolute fold 
change values between both data sets. 
 
Majority of the genes selected for siRNA-based knockdown did not exhibit significant 
changes to CHIKV infection (Section 6.4.2).  Genetic compensation could yet be a possible 
reason for these unexpected discrepancies.  For instance, the loss of CASP1 expression could 
be compensated by other initiator caspase isoforms, such as CASP4, CASP8 and CASP9.  
Hence, minimal and/or no inhibition of CHIKV infection could be visibly observed upon 
siRNA knockdown of CASP1.  Similarly, TRIM22 is a member of the tripartite motif (TRIM) 
family and its loss of expression could be substituted with other TRIM members, particularly 
members in Group 2, which possess a C-terminal SPRY domain, including TRIM21, TRIM27 
and TRIM30. 
 
Knockdown results of BST2 and ISG15, both of which resulted in significant inhibition 
of CHIKV infection, are of particular interest, especially in relation to earlier findings.  As 
observed in Chapter 4, CHIKV was found to undergo a dual mode of egress from host cells.  
The actions of both BST2 and ISG15 could substantiate this novel finding, and provide an 
interesting outlook into the essential roles played by these genes in CHIKV exit. 





Microarray results, as shown in Appendix F, indicated that BST2 operates in a similar 
manner as have been previously described in literature (Neil et al., 2008), inhibiting the 
release of CHIKV from host cells.  However, knockdown of BST2 was found to decrease, and 
not increase, CHIKV infectious titres.  This finding suggested that while BST2 may have 
been able to block viral release by budding, it is unable to prevent subsequent release of 
mature CHIKV virions via massive exocytosis.  Its genetic knockdown therefore means that 
CHIKV is yet able to utilise its preferred albeit less efficient mode of viral budding, thereby 
reducing CHIKV infectious titres.  A similar mechanism of action may also be used to explain 
the findings of ISG15 knockdown.  Further analyses of these genes need, nevertheless, to be 
performed to confirm these interesting data. 
 
A proposed model displaying the stages of CHIKV infection and the various putative 
genes that were observed to be involved is shown in Figure 7.1.  While previous research has 
found that CHIKV infectious entry into host cells occurs via clathrin-mediated endocytosis, 
this study showed that macropinocytosis is the dominant entry pathway for CHIKV into 
HSMM cells, with PAK1, RAC1, SNX9 and DNM2 among associated genes observed to 
regulate CHIKV entry.  Similarly, budding has been previously established as the primary 
means of CHIKV egress from host cells.  However, this study found that CHIKV exits via a 
dual mode of egress, that is, viral budding at early infection time-points and massive 
exocytosis at latter stages of the infection.  Genes that were observed to result in exocytosis 


















Figure 7.1 Proposed Model of CHIKV Infection in Host Cells 
Several putative genes have been identified throughout the study as key players in 
regulating the various stages of CHIKV infection.  
 
In conclusion, novel findings have been established throughout the study in relation to 
the interactions between CHIKV and its host, as follows: 
 
1 In developing susceptibility profiles of various cell lines upon CHIKV infection, it 
was found that: 
 Various CHIKV strains contain essential amino acid differences 
 A wide range of mammalian and mosquito cell lines are found to be susceptible 
to CHIKV infection 
 Susceptibility of various cell lines to CHIKV infection is strain-specific 














































2 In establishing and characterising a novel primary human cellular model for 
CHIKV infection, it was observed that: 
 HSMM cells are permissive to CHIKV infection 
 HSMM cells maintain their myoblastic features and are transfectable 
 CHIKV undergoes a dual mode of egress (viral budding and exocytosis) from 
HSMM cells, with formation of CPV-Is and CPV-IIs 
 CHIKV infection induces apoptosis in HSMM cells 
 
3 In determining host factors that mediate the infectious entry processes of CHIKV 
in HSMM cells, the following observations were made: 
 Screening of the membrane trafficking library reveals CHIKV infectious entry 
via clathrin-mediated endocytosis and macropinocytosis 
 Downstream experiments suggest macropinocytosis to be the major entry 
pathway for CHIKV 
 CHIKV is dependent on cholesterol and acidic pH for its infectious entry into 
HSMM cells 
 Microtubule and actin polymerisation may not be necessary for CHIKV 
infectious entry 
 
4 In performing genomic profiling of host factors involved in CHIKV infection and 
investigating the interactions between CHIKV and its host, it was deduced that: 
 CHIKV infection regulates HSMM cell gene expression, altering the expression 
of host genes involved in various pathways such as skeletal and muscular 
disorders, host defence mechanisms, cellular function and virus replication 




     
Further studies are crucial to understanding the mechanisms of CHIKV pathogenesis.  
Future experiments should thus be performed with a focus on CHIKV entry and egress 
processes, and its interactions with host proteins.   
 
In particular, infectious entry processes of CHIKV can be further validated via the use 
of dominant negative mutants.  For instance, dominant negative mutants of Eps15 can be used 
to confirm CHIKV entry through clathrin-mediated endocytosis, while DNM2 and PAK1 
mutants can substantiate macropinocytic-mediated CHIKV entry.  In addition, transfection of 
selected host genes involved in CHIKV exit can be performed prior to downstream analyses 
such as immunofluorescence and TEM assays.   
 
Finally, the role of specific skeletal and muscular disorders-associated genes found to be 
differentially regulated upon CHIKV infection can be further established by performing 
histological studies.  It is possible that these genes may either assist or prevent chronic 
CHIKV infection through regulation of protein expression.  Identification of these host factors 
and their roles in chronic CHIKV infection will enable for targeted strategies towards 
controlling the persistent symptoms often witnessed in CHIKV patients.  Indeed, it is only 
through deep and thorough understanding of the pathogenesis of this virus infection that we 
will be able to develop effective therapeutics.     
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APPENDIX A: LIST OF REAGENTS USED 
 
1) MATERIALS FOR TISSUE CULTURE 
 
 All materials prepared for cell culture were either sterile or sterilised.  Ultrapure water 
(Milli-Q Integral water purification system, Millipore, Massachusetts, U.S.A.) was used for 
all dilutions. 
 
(a) 10x Phosphate Buffered Saline (PBS) 
ITEM AMOUNT SOURCE 
NaCl 80.0g Merck, Darmstadt, Germany 
KCl 2.0g Merck, Darmstadt, Germany 
KH2PO4 2.0g Merck, Darmstadt, Germany 
Na2HPO4 11.5g Merck, Darmstadt, Germany 
 
 The specified constituents were dissolved in 900mL Ultrapure water (Milli-Q Integral 
water purification system, Millipore, Massachusetts, U.S.A.) and the pH was adjusted to 7.4.  
The stock solution was topped up to 1L and then autoclaved at 121
o
C for 15 mins.  The stock 
solution was then stored at room temperature.  To prepare the working 1x PBS solution, the 









(b) 10x Trypsin-Versene Solution 
ITEM AMOUNT SOURCE 
NaCl 80.0g Merck, Darmstadt, Germany 
KCl 4.0g Merck, Darmstadt, Germany 
D-glucose 10.0g Analar, U.K. 
NaHCO3 5.8g Merck, Darmstadt, Germany 
Trypsin 5.0g 
Invitrogen, Carlsbad, California, 
U.S.A. 
Versene (EDTA) 2.0g 
Sigma Diagnostics, St. Louis, 
U.S.A. 
Ultrapure Water 1L 
Milli-Q Integral water 
purification system, Millipore, 
Massachusetts, U.S.A. 
 




) pressure through a 0.22µM filter unit 
(Corning, New York, U.S.A.).  To prepare the working 1x trypsin-versene solution, the 10x 
stock solution was diluted 1:10. 
 
(c) SkGM-2 Growth Medium for HSMM Cells 
ITEM AMOUNT SOURCE 
Skeletal Muscle Myoblast 
Cell Growth Medium 
(SkGM-2) 
500.0mL 
Clonetics, Lonza Group, 
Switzerland 
Dexamethasone 1 tube 
Clonetics, Lonza Group, 
Switzerland 
GA-1000 1 tube 
Clonetics, Lonza Group, 
Switzerland 
rhEGF 1 tube 
Clonetics, Lonza Group, 
Switzerland 
L-Glutamine 1 bottle 
Clonetics, Lonza Group, 
Switzerland 
Fetal Calf Serum (FCS) 50.0mL 
Clonetics, Lonza Group, 
Switzerland 
 
 All growth supplements were added to the culture medium together, as per 
manufacturer’s instructions. 





(d) DMEM Growth Medium 
ITEM AMOUNT SOURCE 
Dulbecco’s Modified 
Eagle’s Media (DMEM) 
16.4g 
Thermo Scientific, Hyclone, 
Rockford, U.S.A. 
NaHCO3 2.0g Merck, Darmstadt, Germany 
Fetal Calf Serum (FCS) 100.0mL 
Thermo Scientific, Hyclone, 
Rockford, U.S.A. 
Ultrapure Water 1L 
Milli-Q Integral water purification 
system, Millipore, Massachusetts, 
U.S.A. 
 
 DMEM powder and NaHCO3 were dissolved and the pH was adjusted to 7.3 using 





through a 0.22µM filter unit (Corning, New York, U.S.A.).  FCS was heat-inactivated at 60oC 
for 30 mins prior to addition to the culture medium. 
 
(e) RPMI-1640 Growth Medium 
ITEM AMOUNT SOURCE 
Roswell Park Memorial 
Institute- (RPMI-)1640 
16.4g 
Sigma Diagnostics, St. Louis, 
U.S.A. 
NaHCO3 2.0g Merck, Darmstadt, Germany 
Fetal Calf Serum (FCS) 100.0mL 
Thermo Scientific, Hyclone, 
Rockford, U.S.A. 
Ultrapure Water 1L 
Milli-Q Integral water purification 
system, Millipore, Massachusetts, 
U.S.A. 
 
 RPMI-1640 powder and NaHCO3 were dissolved and the pH was adjusted to 7.3 using 





through a 0.22µM filter unit (Corning, New York, U.S.A.).  FCS was heat-inactivated at 60oC 
for 30 mins prior to addition to the culture medium. 





(f) L-15 Growth Medium for C6/36 Cells 
ITEM AMOUNT SOURCE 
L-15 16.4g 
Sigma Diagnostics, St. Louis, 
U.S.A. 
Fetal Calf Serum (FCS) 100.0mL 
Thermo Scientific, Hyclone, 
Rockford, U.S.A. 
Ultrapure Water 1L 
Milli-Q Integral water purification 
system, Millipore, Massachusetts, 
U.S.A. 
 
 L-15 powder was dissolved and the pH was adjusted to 7.3 using either 1M HCl or 1M 




) pressure through a 0.22µM filter 
unit (Corning, New York, U.S.A.).  FCS was heat-inactivated at 60
o
C for 30 mins prior to 



















2) MATERIALS FOR VIRUS CULTURE 
 
 All materials prepared for virus infection, propagation and infectious plaque assay were 
either sterile or sterilised.  Ultrapure water (Milli-Q Integral water purification system, 
Millipore, Massachusetts, U.S.A.) was used for all dilutions. 
 
(a) Overlay Medium for BHK-21 Cells 
ITEM AMOUNT SOURCE 
RPMI-1640 16.4g 
Sigma Diagnostics, St. Louis, 
U.S.A. 
NaHCO3 2.0g Merck, Darmstadt, Germany 
Fetal Calf Serum (FCS) 20.0mL 





500.0mL Behring Diagnostic, U.S.A. 
 
 RPMI-1640 powder and NaHCO3 were dissolved in 480mL ultrapure water (Milli-Q 
Integral water purification system, Millipore, Massachusetts, U.S.A.) and the pH was adjusted 





pressure through a 0.22µM filter unit (Corning, New York, U.S.A.), prior to addition of FCS 
and CMC.   
 
(b) 0.5% Crystal Violet / 25% Formaldehyde 
ITEM AMOUNT SOURCE 
Crystal Violet 5.0g 




300.0mL Merck, Darmstadt, Germany 
PBS 200.0mL See Section 1a, Appendix A 
 





(c) DMEM Maintenance Medium 
ITEM AMOUNT SOURCE 
Dulbecco’s Modified 
Eagle’s Media (DMEM) 
16.4g 
Thermo Scientific, Hyclone, 
Rockford, U.S.A. 
NaHCO3 2.0g Merck, Darmstadt, Germany 
Fetal Calf Serum (FCS) 20.0mL 
Thermo Scientific, Hyclone, 
Rockford, U.S.A. 
Ultrapure Water 1L 
Milli-Q Integral water purification 
system, Millipore, Massachusetts, 
U.S.A. 
 
 DMEM powder and NaHCO3 were dissolved and the pH was adjusted to 7.3 using 





through a 0.22µM filter unit (Corning, New York, U.S.A.).  FCS was heat-inactivated at 60oC 
for 30 mins prior to addition to the culture medium. 
 
(d) RPMI-1640 Maintenance Medium 
ITEM AMOUNT SOURCE 
Roswell Park Memorial 
Institute- (RPMI-)1640 
16.4g 
Sigma Diagnostics, St. Louis, 
U.S.A. 
NaHCO3 2.0g Merck, Darmstadt, Germany 
Fetal Calf Serum (FCS) 20.0mL 
Thermo Scientific, Hyclone, 
Rockford, U.S.A. 
Ultrapure Water 1L 
Milli-Q Integral water purification 
system, Millipore, Massachusetts, 
U.S.A. 
 
 RPMI-1640 powder and NaHCO3 were dissolved and the pH was adjusted to 7.3 using 





through a 0.22µM filter unit (Corning, New York, U.S.A.).  FCS was heat-inactivated at 60oC 
for 30 mins prior to addition to the culture medium. 




APPENDIX B: SEQUENCES OF PRIMERS USED 


















































































































APPENDIX C: SEQUENCES OF CHIKV STRAINS  
 











































































































































































































































































































































































































































































































































































































































































































APPENDIX D: HUMAN GENES ASSOCIATED WITH 
MEMBRANE TRAFFICKING 
(RTF H-005500, DHARMACON) 
 
GENE SYMBOL LOCUS ID GENBANK ACCESSION NO. 
ACTR2 10097 NM_005722 
ACTR3 10096 NM_005721 
ADAM10 102 NM_001110 
AMPH 273 NM_001635 
AP1B1 162 NM_001127 
AP1M1 8907 NM_032493 
AP1M2 10053 NM_005498 
AP2A1 160 NM_014203 
AP2A2 161 NM_012305 
AP2B1 163 NM_001282 
AP2M1 1173 NM_004068 
ARF1 375 NM_001658 
ARF6 382 NM_001663 
ARFIP2 23647 NM_012402 
ARPC1B 10095 NM_005720 
ARPC2 10109 NM_005731 
ARPC3 10094 NM_005719 
ARPC4 10093 NM_005718 
ARPC5 10092 NM_005717 
ARRB1 408 NM_004041 
ARRB2 409 NM_004313 
ATM 472 NM_138293 
ATP6V0A1 535 NM_005177 
BIN1 274 NM_004305 
CAMK1 8536 NM_003656 
CAV1 857 NM_001753 
CAV2 858 NM_001233 
CAV3 859 NM_001234 




GENE SYMBOL LOCUS ID GENBANK ACCESSION NO. 
CBL 867 NM_005188 
CBLB 868 NM_170662 
CBLC 23624 NM_012116 
CDC42 998 NM_001791 
CFL1 1072 NM_005507 
CIB1 10519 NM_006384 
CIB2 10518 NM_006383 
CIB3 117286 NM_054113 
CLTA 1211 NM_001833 
CLTB 1212 NM_001834 
CLTC 1213 NM_004859 
CLTCL1 8218 NM_001835 
DAB2 1601 NM_001343 
DDEF2 8853 NM_003887 
DIAPH1 1729 NM_005219 
DNM1 1759 NM_004408 
DNM2 1785 NM_004945 
DNM3 26052 NM_015569 
EEA1 8411 NM_003566 
EFS 10278 NM_005864 
ELKS 23085 NM_015064 
ENTH 9685 NM_014666 
EPN1 29924 NM_013333 
EPN2 22905 NM_148921 
EPN3 55040 NM_017957 
EPS15 2060 NM_001981 
EPS15L1 58513 NM_021235 
FYN 2534 NM_002037 
GAF1 26056 NM_015470 
GIT1 28964 NM_014030 
GORASP1 64689 NM_031899 
GRB2 2885 NM_002086 
HIP1 3092 NM_005338 
HIP1R 9026 NM_003959 
IHPK3 117283 NM_054111 
ITSN1 6453 NM_003024 




GENE SYMBOL LOCUS ID GENBANK ACCESSION NO. 
ITSN2 50618 NM_006277 
LIMK1 3984 NM_002314 
MAP4K2 5871 NM_004579 
MAPK8IP1 9479 NM_005456 
MAPK8IP2 23542 NM_012324 
MAPK8IP3 23162 NM_015133 
NEDD4 4734 NM_006154 
NEDD4L 23327 NM_015277 
NSF 4905 NM_006178 
PACSIN1 29993 NM_020804 
PACSIN3 29763 NM_016223 
PAK1 5058 NM_002576 
PICALM 8301 NM_007166 
PIK3CG 5294 NM_002649 
PIK4CA 5297 NM_002650 
PIP5K1A 8394 NM_003557 
PSCD3 9265 NM_004227 
RAB11A 8766 NM_004663 
RAB11B 9230 NM_004218 
RAB3A 5864 NM_002866 
RAB3B 5865 NM_002867 
RAB3C 115827 NM_138453 
RAB3D 9545 NM_004283 
RAB4A 5867 NM_004578 
RAB4B 53916 NM_016154 
RAB5A 5868 NM_004162 
RAB5B 5869 NM_002868 
RAB5C 5878 NM_004583 
RAB6A 5870 NM_002869 
RAB6B 51560 NM_016577 
RAB7L1 8934 NM_003929 
RAB8A 4218 NM_005370 
RAB8B 51762 NM_016530 
RAC1 5879 NM_018890 
RHOA 387 NM_001664 
ROCK1 6093 NM_005406 




GENE SYMBOL LOCUS ID GENBANK ACCESSION NO. 
ROCK2 9475 NM_004850 
SH3GLB1 51100 NM_016009 
SH3GLB2 56904 NM_020145 
SNAP91 9892 NM_014841 
STAU 6780 NM_004602 
SYNJ1 8867 NM_003895 
SYNJ2 8871 NM_003898 
SYT1 6857 NM_005639 
SYT2 127833 NM_177402 
TNIK 23043 XM_039796 
VAMP1 6843 NM_014231 
VAMP2 6844 NM_014232 
VAPA 9218 NM_003574 
VAPB 9217 NM_004738 
VAV2 7410 NM_003371 
VIL2 7430 NM_003379 
WAS 7454 NM_000377 
WASF1 8936 NM_003931 
WASF2 10163 NM_006990 
WASF3 10810 NM_006646 
PIK3C2G 5288 NM_004570 
MGC9726 338382 NM_177403 
   
Controls   
siCONTROL™ Non-Targeting siRNA pool   
siCONTROL RISC-free™ siRNA   
siCONTROL siGLO Risc-free™ siRNA   
GAPDH SMARTpool™ siRNA   
siCONTROL™ Cyclo B duplex   











APPENDIX E: MEMBRANE TRAFFICKING GENES 










ARRB2 41.2 SH3GLB2 35.4 
DDEF2 53.7 VAPA 17.1 
AMPH 37.2 PACSIN1 29.8 
BIN1 30.5 RAB3A 28.1 
DNM1 59.5 RAB6B 31.6 
AP1B1 27.9 SNAP91 41.8 
CAMK1 56.3 VAPB 22.4 
DNM2 46.4 RAB7L1 39.5 
EPS15L1 62.8 PAK1 30.2 
AP1M1 36.0 RAB3C 28.5 
ARPC2 49.5 SYNJ1 49.0 
DNM3 32.0 VIL2 31.9 
AP2A2 24.8 PICALM 35.6 
VAMP1 39.6 PIK3CG 33.1 
RAB11A 39.6 RAB4A 36.3 
RAB5C 27.7 RAC1 31.7 
VAMP2 20.0 SYT1 34.7 













APPENDIX F: MICROARRAY GENOME PROFILING 
DIFFERENTIALLY EXPRESSED GENES 
 
GENE p-value 
FOLD CHANGE (INFECTED VS MOCK) 
6H 12H 24H 48H ALL 
MX1 0.0111913 119.585 83.7658 92.9999 184.017 114.425 
CXCL10 4.19E-09 241.449 49.9858 72.0782 117.478 100.545 
IFIT2 0.00051374 109.742 64.6844 66.5057 99.7303 82.8351 
HERC5 0.000486369 58.5343 80.7972 80.5397 53.2425 67.1072 
IFIT1 0.00237235 71.3181 45.2379 48.4289 86.0906 60.5606 
IFITM1 8.13E-12 47.1423 29.6011 52.7079 158.834 58.4634 
CCL5 2.87E-13 54.6798 28.2303 45.5577 125.855 54.5436 
RSAD2 2.20E-05 69.0507 33.1524 51.3873 54.4445 50.3064 
OASL 2.19E-05 71.1116 39.4207 46.9837 42.7535 48.7131 
IFNB1 5.63E-08 94.909 35.5492 43.3711 21.2862 42.0106 
IFIT3 2.58E-05 46.4258 36.226 32.268 57.0001 41.9379 
EPSTI1 0.000903909 51.6709 30.2975 37.6762 50.9794 41.6417 
IFIH1 8.16E-05 59.3526 28.4231 28.7656 45.0406 38.4501 
TNFSF10 1.33E-11 66.7383 15.6661 21.148 56.3151 33.4047 
ISG20 1.22E-05 23.8831 38.1099 45.1198 27.4285 32.578 
MX2 1.09E-07 33.7018 22.9378 25.8625 56.1332 32.548 
IFI27 1.94E-17 45.9647 6.09631 10.8888 301.379 30.9668 
OAS2 7.41E-11 25.6061 20.3834 22.7943 56.5085 28.6345 
BST2 2.47E-09 16.916 17.2357 34.5498 66.0178 28.5567 
OAS1 1.71E-07 22.3619 21.6986 23.8821 44.2637 26.7618 
GBP4 1.36E-10 64.6269 15.0207 20.1885 22.1637 25.6722 
ISG15 4.64E-07 24.6116 16.1027 20.9576 35.2927 23.2684 
LOC100129681 2.80E-08 11.5749 12.7653 27.2229 54.8755 21.6753 
IFI44L 5.47E-08 17.0143 11.7971 16.0746 38.8237 18.8129 
HERC6 0.000644415 19.7405 14.7349 17.4515 22.1004 18.3014 
TNFSF13B 9.75E-05 26.2146 12.7935 16.1012 16.0858 17.1676 
GBP5 5.85E-13 53.0382 9.70877 9.09077 15.3261 16.3661 
PARP14 0.000240422 22.2603 14.4743 15.1355 12.9984 15.8673 





FOLD CHANGE (INFECTED VS MOCK) 
6H 12H 24H 48H ALL 
INDO 1.62E-11 73.5741 6.3341 6.45619 19.605 15.5843 
CFB 2.54E-05 12.5005 12.2481 23.4904 14.1561 15.0213 
RARRES3 1.08E-12 26.6021 7.40254 10.6769 19.4668 14.2236 
IFI35 1.21E-06 11.6305 10.5389 14.1537 20.8761 13.7952 
OAS3 0.000568321 10.8689 9.85989 15.1047 20.4118 13.4823 
DDX58 2.83E-11 29.6852 7.3594 8.03523 18.4746 13.4196 
IDO1 4.93E-11 61.4036 5.3079 5.65405 16.6176 13.2285 
PARP12 0.000381019 16.1152 9.80553 10.8471 16.9008 13.0461 
SLC15A3 2.50E-05 10.0371 9.98255 14.6791 19.0495 12.9377 
RTP4 0.000118985 17.9505 9.75478 9.51122 16.7924 12.9318 
GBP1 4.76E-06 22.8132 10.2864 9.84733 9.84435 12.2812 
PRIC285 0.000453626 19.8281 9.38162 10.2153 10.0451 11.7542 
SAMD9 8.51E-06 12.7343 7.44534 9.39377 18.42 11.3174 
PARP9 0.00207275 10.1303 8.88218 10.8917 14.5791 10.9331 
CCL3L3 9.92E-11 25.5793 6.23489 12.2949 7.16046 10.8854 
IFI44 1.08E-09 15.8655 5.72641 7.25786 19.6289 10.6662 
CXCL11 3.60E-07 22.4677 4.48928 6.48592 19.193 10.5855 
USP18 0.00343295 15.8697 10.4124 10.8829 6.58279 10.4308 
HES4 5.69E-06 14.3371 10.6607 12.9051 5.82162 10.3517 
PSMB9 0.000400849 9.60585 7.80917 9.30544 12.7652 9.71574 
TMEM140 4.31E-09 17.8109 6.09794 5.31001 13.7298 9.43316 
XAF1 1.37E-09 11.057 5.54711 7.25988 16.606 9.27309 
SAMD9L 2.62E-07 15.7147 5.60922 5.39973 13.6161 8.97239 
BATF2 0.000198553 14.7901 6.48525 8.23642 8.19036 8.96881 
TAP1 0.178141 8.44365 7.99214 9.35163 8.23822 8.49138 
IRF7 0.0010422 8.88247 7.16879 9.66989 7.81356 8.32842 
DDX60L 3.22E-06 13.9962 5.8379 5.40778 10.7433 8.30054 
IL29 6.07E-13 29.2069 4.54052 7.13969 4.38256 8.02601 
DHX58 0.000113053 12.776 5.88038 6.41015 7.40652 7.72806 
CXCL9 1.05E-11 42.2781 5.28597 4.3959 3.2174 7.49805 
DDX60 5.89E-05 8.96247 4.69021 4.95842 11.1578 6.94441 
IL6 3.45E-14 27.3998 2.84706 4.43507 6.70284 6.93947 
CASP1 1.45E-08 9.53458 3.94558 4.50294 12.7527 6.81753 
CCNA1 0.00282785 9.01887 5.98639 6.9619 5.70116 6.80381 





FOLD CHANGE (INFECTED VS MOCK) 
6H 12H 24H 48H ALL 
CLDN23 2.32E-06 9.84222 5.14817 5.29938 7.73311 6.75043 
NCOA7 0.000540804 10.2918 4.75029 5.27629 7.27184 6.58106 
LOC400759 1.66E-08 17.9372 3.68413 3.81825 6.87891 6.45458 
SP110 3.25E-07 8.62491 4.56939 4.55688 9.38068 6.40662 
APOBEC3G 0.028335 7.46463 6.87845 6.13795 5.25943 6.38065 
KIAA1618 8.23E-06 6.07276 4.50806 6.54756 8.86049 6.31289 
LOC728835 1.25E-11 26.4135 2.98869 5.26824 3.67719 6.25349 
C19orf66 0.00015192 7.49807 5.68186 5.59489 5.11198 5.9082 
PMAIP1 0.00174984 8.54731 4.19832 4.94865 6.65198 5.86254 
IL18BP 5.05E-11 6.08829 3.49285 4.21689 12.3672 5.77078 
GMPR 1.10E-09 10.1152 5.91389 5.51905 3.26391 5.72945 
UBA7 0.0104157 7.12358 5.49595 5.56198 4.66537 5.64565 
APOL3 2.11E-07 9.51099 4.0896 4.37039 5.3062 5.48028 
GCA 1.73E-07 3.50455 4.8225 6.11253 8.48111 5.44057 
TDRD7 0.0190588 6.58606 4.18771 4.95027 5.79005 5.30247 
TNFAIP6 0.00369878 3.49252 4.58595 7.42609 6.38187 5.24891 
STAT1 1.80E-11 7.16268 2.8096 3.2382 10.5685 5.12282 
WARS 2.15E-08 9.02298 3.11963 3.87789 5.84076 5.02492 
TLR3 0.000197497 5.24401 3.90763 3.87937 6.82124 4.82559 
CCL3 9.39E-10 10.7484 2.87344 5.42621 3.17952 4.80454 
IRF1 2.81E-08 8.12391 3.65491 3.04284 5.62885 4.74881 
UBE2L6 0.00365106 4.00083 4.65927 4.99415 5.3215 4.71782 
RASGRP3 7.59E-10 9.4118 4.0199 4.32979 2.67989 4.57739 
CMPK2 0.0324648 5.56593 3.26419 4.42218 5.3357 4.55025 
MYD88 0.00728699 5.22148 3.87537 4.15931 5.05566 4.54179 
TRIM21 0.00776584 5.44006 3.94707 3.68811 5.36138 4.53931 
PDGFRL 1.85E-07 4.44379 2.93994 4.07044 7.70674 4.49936 
PLSCR1 6.29E-05 4.57686 3.90137 3.23947 6.97824 4.4823 
CCL3L1 2.57E-09 9.01256 2.84773 5.52353 2.83831 4.47874 
IL28A 2.04E-10 13.7671 2.85922 3.81701 2.55876 4.42803 
PSMB8 0.00261455 4.27422 3.84652 4.20978 5.17074 4.34945 
ZMYND15 4.95E-08 9.42494 3.72167 3.19655 2.89145 4.2433 
TRIM25 1.70E-05 6.88424 4.05878 4.00413 2.84229 4.22286 
ZBP1 8.55E-05 2.83523 3.79612 5.20947 5.49943 4.19044 





FOLD CHANGE (INFECTED VS MOCK) 
6H 12H 24H 48H ALL 
PLEKHA4 0.0118807 5.35399 4.063 4.51761 3.12943 4.18769 
CCL4L1 1.38E-10 15.3783 2.27092 3.61419 2.36735 4.15764 
MT1F 6.56E-11 15.3947 2.78866 2.33635 2.97032 4.15458 
CD83 3.06E-10 2.93073 3.79808 8.32332 3.0863 4.11215 
HRASLS2 0.00202041 3.22238 3.17927 5.45369 4.80338 4.04749 
LOC100128274 3.08E-06 6.59398 2.57004 4.05722 3.62152 3.97239 
TMEM62 8.83E-09 4.80269 2.39459 3.04767 6.98626 3.95578 
HCP5 1.22E-09 2.07074 2.24549 3.49038 14.7418 3.93292 
LAP3 5.25E-05 3.44388 2.92981 3.54198 6.57383 3.91505 
IRF9 2.44E-05 5.16798 2.63202 2.81781 5.43307 3.79876 
IFI30 7.75E-10 2.53684 2.21964 4.01636 8.9453 3.77138 
NT5C3 1.63E-05 2.58477 2.9079 3.74387 6.43003 3.66761 
GSDMD 0.0172791 3.25842 3.94782 4.46738 3.11565 3.65798 
APOL2 7.09E-09 7.52487 2.65187 3.32886 2.68633 3.65491 
NFE2L3 4.24E-09 3.04338 2.00406 2.71511 10.6344 3.64285 
GBP2 5.08E-08 5.29635 3.54423 3.77778 2.45462 3.63229 
NKX3-1 0.00356606 3.5317 3.40929 5.00451 2.86672 3.62534 
DTX3L 0.958159 3.67676 3.50665 3.59144 3.7001 3.61793 
ECGF1 4.98E-07 2.51584 2.71187 5.52324 4.48373 3.60534 
CTGLF7 3.34E-10 7.65652 2.02817 2.49166 3.91316 3.50783 
MLKL 0.000646212 4.63772 2.95897 2.95116 3.58736 3.47179 
PARP10 0.22144 3.8251 2.9908 3.23698 3.83149 3.45131 
TRIM22 2.72E-05 3.33729 2.88906 2.74231 5.30188 3.44092 
ZNFX1 0.00188119 4.84636 2.79049 2.82526 3.54781 3.41215 
LOC389386 8.64E-05 3.11821 2.65388 3.25949 5.00087 3.40797 
EIF2AK2 0.000113674 3.79886 2.34085 2.72962 5.00264 3.31957 
HLA-DOB 1.98E-09 6.80284 2.14769 2.44013 3.24511 3.27964 
SLC25A28 0.000367207 4.43848 2.88833 2.56534 3.39992 3.2518 
TAC3 1.03E-06 3.25124 2.39119 2.43992 5.6766 3.2213 
FBXO6 0.289105 3.20303 3.45692 3.50828 2.7693 3.22054 
TAP2 0.00264223 3.68464 2.61516 3.5232 3.01553 3.18089 
TRIM5 0.000137216 4.62198 2.67621 2.48259 3.29503 3.1716 
LITAF 0.00047216 3.81772 3.20045 3.43826 2.03814 3.04191 
BIRC3 0.00190661 3.60727 2.10283 3.13589 3.54742 3.03085 





FOLD CHANGE (INFECTED VS MOCK) 
6H 12H 24H 48H ALL 
TNFAIP3 4.92E-05 3.25639 2.26947 4.31829 2.54873 3.00313 
BTC 0.000107821 3.83224 2.19926 2.26409 3.78023 2.9143 
IFI16 6.62E-06 3.07396 2.30079 2.38858 4.00425 2.86787 
MOV10 0.00354184 3.78256 2.32943 2.60734 2.88721 2.85383 
STAT2 2.40E-05 3.9194 2.23004 2.25752 3.01836 2.77801 
CCDC109B 0.0134795 3.48148 2.31185 2.2624 2.91787 2.69985 
CXCL16 0.000563131 2.72185 2.20366 2.5141 3.44132 2.68398 
PHACTR4 0.00037075 3.47706 2.24091 2.30883 2.52908 2.59715 
TRIM69 0.305414 2.37752 2.63355 2.72409 2.34337 2.51438 
EHD4 0.000295644 3.68013 2.11719 2.19408 2.06081 2.43629 
RALGDS 0.30302 -2.48745 -2.05079 -2.16265 -2.48846 -2.28901 
HNRPA1L-2 0.00861644 -2.12024 -2.36869 -2.85939 -3.09278 -2.58154 
TNFRSF10D 0.0103901 -2.87696 -2.85337 -3.71374 -2.00015 -2.79442 
MEF2D 0.0274319 -3.20512 -2.97668 -3.84321 -2.71633 -3.1591 
PLEKHA6 1.26E-06 -2.52499 -4.84036 -4.5159 -2.02062 -3.24969 
 
 
 
 
 
 
 
